WO2019083024A1 - Gene analysis method, gene analyzer, management server, gene analysis system, program and recording medium - Google Patents

Gene analysis method, gene analyzer, management server, gene analysis system, program and recording medium

Info

Publication number
WO2019083024A1
WO2019083024A1 PCT/JP2018/039963 JP2018039963W WO2019083024A1 WO 2019083024 A1 WO2019083024 A1 WO 2019083024A1 JP 2018039963 W JP2018039963 W JP 2018039963W WO 2019083024 A1 WO2019083024 A1 WO 2019083024A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
information
analysis
panel
sequence
Prior art date
Application number
PCT/JP2018/039963
Other languages
French (fr)
Japanese (ja)
Inventor
二三夫 井上
誓吾 鈴木
鈴木 健一郎
Original Assignee
シスメックス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2018201317A external-priority patent/JP7320345B2/en
Application filed by シスメックス株式会社 filed Critical シスメックス株式会社
Priority to EP18869832.8A priority Critical patent/EP3702473A4/en
Priority to CN201880069344.4A priority patent/CN111263964A/en
Publication of WO2019083024A1 publication Critical patent/WO2019083024A1/en
Priority to US16/855,239 priority patent/US20200350035A1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00Apparatus for enzymology or microbiology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00Subject matter not provided for in other groups of this subclass

Definitions

  • the present invention relates to a gene analysis method, a gene analysis device, a management server, a gene analysis system, a program, and a recording medium implemented by a computer to analyze gene mutations.
  • a panel test which analyzes an abnormality in a specific gene associated with a specific disease or an abnormality in an exon region translated into a protein at high throughput using a next-generation sequencer There is.
  • Patent Document 1 it is determined whether a gene or the like is abnormal as compared to a reference sequence, and a drug therapy used corresponding to the gene or the like showing an abnormality is identified, and treatment is performed according to the subject. A system for determining the method is described.
  • the user performing the panel test needs to prepare a dedicated analysis program to be used for gene analysis by the sequencer for each panel according to the gene to be tested and the request, and perform gene analysis.
  • One aspect of the present invention is a user-friendly gene analysis method, a gene analysis device, a management server, a gene analysis system, etc. which can be applied to various gene panels when analyzing genes to be analyzed using the gene panel Aims to achieve
  • a gene analysis method for analyzing sequence information of a gene, comprising: lead sequence information read by a sequencer (2); And information on a gene panel including a plurality of genes, and an analysis result of lead sequence information is output based on the acquired information on the gene panel.
  • the analysis result of the lead sequence information is output based on the acquired information on the gene panel.
  • the output according to the gene panel can be obtained, thereby improving user convenience. Do.
  • the “gene” includes a sequence on the genome from the start codon to the stop codon, an mRNA generated from the sequence on the genome, a promoter region on the genome, and the like. Genes to be analyzed include mRNA transcribed from genes on the genome. mRNA includes pre-mRNA.
  • the “lead sequence” means a polynucleotide sequence obtained by sequencing, and the “lead sequence information” refers to the information of the lead sequence outputted by the sequencer 2.
  • the "gene panel” means a reagent kit for analyzing a plurality of analysis objects by performing a series of analysis processes once (one run). Gene panels often contain a complete set of reagents such as primers and probes.
  • a plurality of analysis targets may be a plurality of gene sequences or a plurality of exons of a certain gene.
  • a reagent kit for analyzing the sequence of gene A and the sequence of gene B a reagent kit for analyzing the sequence of exon 1 of gene A and the sequence of exon 2 of the same gene, and the like are included.
  • a more specific example of the gene panel includes a reagent kit for analyzing a plurality of gene sequences related to a specific disease.
  • the gene panel When this gene panel is used, amplification of one or more genes that are important for medical treatment, substitution of sequences, deletion, insertion, methylation of promoter region, fusion genes, and the like can be analyzed.
  • the gene panel contains a plurality of genes to be analyzed. As the gene panel, for example, a large panel of 100 or more genes to be analyzed can be used.
  • the “information on gene panel” may be any information that can be used to specify a gene panel, and may be, for example, a gene panel name and a name of a gene to be analyzed in panel inspection.
  • the target gene of the analysis result may be changed based on the information on the acquired gene panel.
  • an analysis algorithm for analyzing a gene as an output target of the analysis result may be changed.
  • an analysis program used for analysis may not be set for each gene.
  • An input screen for inputting information in which a plurality of genes are associated as information on a gene panel may be displayed on the display unit (16).
  • An input screen for selecting at least one piece of information from a plurality of gene panels may be displayed on the display unit (16).
  • An input screen for inputting the reagent kit name as information on the gene panel may be displayed on the display unit (16).
  • An input screen for inputting a plurality of genes to be analyzed as information on a gene panel may be displayed on the display unit (16).
  • An input screen for inputting a disease to be analyzed as information on a gene panel may be displayed on the display unit (16).
  • reference sequence information to be compared with the read sequence information may be selected, and an analysis result based on a comparison between the read sequence information and the selected reference sequence information may be output.
  • the “reference sequence” is a sequence to which the lead sequence is to be mapped in order to determine which region on the gene the lead sequence corresponds to, which mutation the lead sequence corresponds to the gene, etc. .
  • “mapping” means a process of aligning each read sequence to a target reference sequence. Specifically, it is intended to find a region having the same or similar sequence as the read sequence read in the genome sequence to be referred, and assign the read sequence to the region.
  • the reference sequence information to be compared with the lead sequence information is selected from a plurality of reference sequence information including the mutant sequence, and the analysis result based on the selected reference sequence is You may output it.
  • “Mutation” means polymorphism, substitution and / or mutation such as InDel of a gene.
  • InDel Insertion and / or Deletion
  • “Polymorphism” of a gene includes SNV (Single Nucleotide Variant, single nucleotide polymorphism), VNTR (Variable Nucleotide of Tandem Repeat, repeat sequence polymorphism), STRP (Short Tandem Repeat Polymorphism, microsatellite polymorphism), etc. .
  • the analysis result of the lead sequence information may be output using a gene panel related information database (121) that stores information on genes to be analyzed in the gene panel for each gene panel.
  • Alignment may be performed by reading the selected reference sequence from the reference sequence database (122) and mapping the read sequence information to the read reference sequence.
  • the selected reference sequence may be read from the reference sequence database, the position of the read sequence information may be determined based on the degree of matching between the reference sequence and the read sequence information, and the mutations included in the read sequence information may be identified.
  • an analysis result including information on the mutations associated with the acquired information on the gene panel may be output.
  • drug information related to the mutation identified by the analysis of the lead sequence information may be output as the analysis result of the lead sequence information.
  • a drug database (124) may be searched in which mutations of genes to be analyzed and drugs related to the gene panel are associated and stored.
  • a list of agents associated with the mutations identified by analysis of the lead sequence information, extracted in a search of the agent database (124) may be generated.
  • a list of agents associated with the mutations identified by analysis of the lead sequence information, extracted in a search of the agent database (124) may be generated.
  • drug information including the approval status of the drug may be output.
  • a reference database (125) may be searched, which stores the mutations of the gene to be analyzed and the reference information related to the mutations in association.
  • a report is prepared, and the report may include information on mutations among the mutations identified by the analysis of the lead sequence information, which correspond to the information related to the acquired gene panel. Good.
  • a mutation corresponding to the information on the acquired gene panel is selected based on the information on the gene panel, and information associated with the selected mutation is obtained as an analysis result of the lead sequence information. You may output it.
  • the report may include information related to the gene panel.
  • the report may include at least one of a drug list and reference information.
  • Information on the analysis status of gene sequence information may be transmitted to the management server (3).
  • Information on the analysis status of gene sequence information may be transmitted to the management server (3) for each information on the gene panel.
  • the number of gene sequence analyzes may be transmitted to the management server (3) for each information on the gene panel.
  • the number of analyzed genes may be transmitted to the management server (3) for each information on the gene panel.
  • Information on the amount of data processed in gene sequence analysis may be sent to the management server (3) for each information on the gene panel.
  • a comparison result of comparison between the lead sequence information and the sequence information of the gene to be analyzed by the gene panel associated with the acquired information on the gene panel may be output as an analysis result of the lead sequence information.
  • An error may be displayed if the acquired information on the gene panel is not registered.
  • An error may be displayed if the information on the acquired gene panel is not specified from the medical institution (210).
  • analysis of the gene panel may be permitted if the user inputs permission to use the gene panel.
  • Analysis of the gene panel may be prohibited if the acquired information on the gene panel is not registered.
  • the analysis of the gene panel may be prohibited if the information on the acquired gene panel is not specified from the medical institution (210).
  • any of the plurality of modes may be selectable.
  • An error may be displayed when the number of pieces of lead sequence information including the sequences of genes not to be analyzed among the pieces of lead sequence information indicated by the information on the acquired gene panel is equal to or more than a predetermined number.
  • the lead sequence information may include an index sequence associated with the information on the gene panel.
  • the index sequence may be different for each information on the gene panel.
  • An error may be displayed when the information on the gene panel associated with the index sequence included in the lead sequence information is different from the information on the acquired gene panel.
  • first read sequence information read using the first gene panel for analyzing the first analysis target gene group is analyzed
  • second analysis target gene group is analyzed
  • the result and the analysis result obtained by analyzing the second read sequence information may be output based on the information on the selected gene panel.
  • sample can also be used as a specimen or a sample, and is used in the same sense as a specimen or preparation in the art, and a biological material as a source (eg, an individual, a body fluid, a cell line, a tissue culture or a tissue section) Any preparations or preparations obtained from) are contemplated.
  • a biological material eg, an individual, a body fluid, a cell line, a tissue culture or a tissue section
  • the method may further include the step of evaluating the quality of the gene panel test, and in the step of outputting the analysis result, the evaluation result of quality may be output based on the information on the acquired gene panel.
  • the “quality evaluation index” is an index for evaluating the quality of gene panel test, and, for example, the reading quality included in the lead sequence information output by the sequencer (2) and the bases among the genes included in the plurality of genes to be analyzed was the ratio of bases read by the sequencer (2), the read depth of the read sequence information (depth), the variation of the read depth of the read sequence information (depth), or all mutations of each standard gene included in the quality control sample detected? Indicators such as whether or not.
  • a quality control index to be used in evaluating the quality may be selected based on the acquired information on the gene panel.
  • the evaluation criteria of the quality control index used in evaluating the quality may be selected.
  • the number of quality control indicators to be used in evaluating the quality may be selected based on the acquired information on the gene panel.
  • a gene analysis device (1) is a gene analysis device (1) for analyzing sequence information of a gene, and a read by a sequencer (2)
  • the gene analysis device (1) outputs the analysis result of the lead sequence information based on the acquired information on the gene panel. According to this aspect, when the user performing the panel test analyzes the gene using various gene panels, the output according to the gene panel to be used can be obtained, thereby improving the convenience of the user.
  • the control unit (11) selects reference sequence information to be compared with the read sequence information based on the acquired information on the gene panel, and analyzes based on comparison between the read sequence information and the selected reference sequence information. The result may be output to the output unit (13).
  • control unit (11) outputs, to the output unit (13), an analysis result including information on the mutations associated with the acquired information on the gene panel. Good.
  • the control unit (11) outputs the drug information related to the mutation identified by the analysis of the lead sequence information to the output unit (13) as an analysis result of the lead sequence information based on the acquired information on the gene panel. May be
  • the control unit (11) may output the evaluation result of the quality of the gene panel test to the output unit (13) based on the acquired information on the gene panel.
  • the management server (3) is information for specifying a user who performs gene sequence analysis, information on a gene panel used, and analysis status of the sequence information And information including the information on the information from the gene analysis device (1).
  • the “information regarding the analysis status of sequence information” may be, for example, the number of times of sequence analysis in which analysis using a predetermined gene panel is performed in the gene analysis device 1, or the number of analyzed genes. It may be a total such as the number of mutations identified. Alternatively, it may be information on the amount of data processed in the analysis.
  • the management server (3) may receive, from the gene analysis device (1), information on the analysis state of the sequence information of the gene.
  • the management server (3) may receive, from the gene analysis device (1), information on the analysis status of the sequence information of the gene for each information on the gene panel.
  • the management server (3) may receive the number of times of sequence analysis of the gene from the gene analysis device (1) for each information on the gene panel.
  • the management server (3) may receive the number of analyzed genes from the gene analysis device (1) for each information related to the gene panel.
  • the management server (3) may receive information on the amount of data processed in the sequence analysis of the gene from the gene analysis device (1) for each information on the gene panel.
  • the management server (3) may calculate the value when the user performs sequence analysis using the gene analysis device (1), based on the information on the analysis status of the gene sequence information.
  • the management server (3) may receive an update request for information on the gene panel from the gene analysis device (1).
  • a gene analysis system (100) comprises: information on a gene panel including lead sequence information read by a sequencer (2) and a plurality of genes to be analyzed
  • a gene analysis device (1) comprising: a control unit (11) for acquiring data; and an output unit (13) for outputting an analysis result of lead sequence information based on the information on the gene panel acquired by the control unit (11)
  • the information from the gene analyzer (1) to the network (4) including information specifying the user performing gene sequence analysis, information on the gene panel used, and information on the analysis status of gene sequences.
  • a management server (3) to receive the information.
  • the gene analysis device (1) outputs the analysis result of the lead sequence information based on the acquired information on the gene panel.
  • the management server (3) includes, from the gene analysis device (1), information specifying the user performing gene sequence analysis, information on the gene panel used, and information on the analysis status of the gene sequence Receive information
  • the management server (3) can confirm and manage the analysis result of the analysis performed by the user using the gene analysis device (1). Therefore, for example, consideration such as the fee for using the gene analysis system (100) can be appropriately determined and charged to the user.
  • the value when the user performs sequence analysis using the gene analysis device may be calculated based on the information on the analysis status of the sequence information of the gene.
  • the gene analysis device (1) may be realized by a computer, and in this case, the gene analysis is performed by operating the computer as each portion (software element) included in the gene analysis device (1).
  • a program for realizing the device (1) by a computer, and a computer readable recording medium recording the same also fall within the scope of the present invention.
  • a program is a program for analyzing sequence information of a gene, and a computer is provided with read sequence information read by a sequencer and a plurality of analysis targets. It is a program for executing a step of acquiring information on a gene panel including a gene and a step of outputting an analysis result of lead sequence information based on the acquired information on the gene panel.
  • a recording medium according to an aspect of the present invention is a computer readable recording medium on which a program according to an aspect of the present invention is recorded.
  • a gene analysis method acquires read sequence information read by a sequencer (2) and information on a gene panel including a plurality of genes to be analyzed, and the acquired information on the gene panel According to the gene analysis method for analyzing the sequence information of a gene, the analysis result of the lead sequence information is output, and an error is displayed when the acquired information on the gene panel is not registered.
  • a gene analysis method acquires read sequence information read by a sequencer (2) and information on a gene panel including a plurality of genes to be analyzed, and the acquired information on the gene panel It is a gene analysis method for analyzing sequence information of a gene which outputs analysis result of lead sequence information based on the case where information on the acquired gene panel is not designated from a medical institution (210), Display an error.
  • FIG. 1 is a view showing an application example of a gene analysis system according to an embodiment of the present invention.
  • FIG. 2 is a sequence diagram showing an example of main processing performed in the gene analysis system.
  • FIG. 3 is a diagram showing an example of the data structure of data stored in the management server.
  • FIG. 4 is a diagram showing an example of the configuration of a gene analysis device.
  • FIG. 5 is a flow chart showing an example of the flow of processing for receiving input of information on a gene panel.
  • FIG. 6 is a diagram showing an example of a GUI used to input information on a gene panel.
  • FIG. 7 is a diagram showing an example of the data structure of a gene panel related information database.
  • FIG. 8 is a diagram showing an example of a GUI used when the user updates information on a gene panel.
  • FIG. 1 is a view showing an application example of a gene analysis system according to an embodiment of the present invention.
  • FIG. 2 is a sequence diagram showing an example of main processing performed in the gene analysis system.
  • FIG. 9 is a flow chart for explaining an example of a procedure from pretreatment to sequencing for analyzing the base sequence of sample DNA by a sequencer.
  • FIG. 10 is a view for explaining an example of the step (a) of fragmentation of a sample, and the step (b) of application of an index sequence and an adapter sequence.
  • FIG. 11 is a view for explaining an example of the step of hybridization.
  • FIG. 12 is a diagram for explaining an example of a process of recovering a DNA fragment to be analyzed.
  • FIG. 13 is a figure explaining an example of the process of providing a DNA fragment to a flow cell.
  • FIG. 14 is a diagram for explaining an example of a process of amplifying a DNA fragment to be analyzed.
  • FIG. 15 is a diagram for explaining an example of the sequencing process.
  • FIG. 10 is a view for explaining an example of the step (a) of fragmentation of a sample, and the step (b) of application of an index sequence and an adapter sequence.
  • FIG. 11
  • FIG. 16 is a flow chart for explaining an example of the flow of analysis by the gene analysis device.
  • FIG. 17 is a diagram showing an example of a file format of read sequence information.
  • (A) of FIG. 18 is a figure explaining the alignment by a data adjustment part
  • (b) is a figure which shows an example of the format of the alignment result of a data adjustment part.
  • FIG. 19 shows an example of the structure of a reference sequence database.
  • FIG. 20 shows an example of a known mutation incorporated into a reference sequence (not showing a wild-type sequence) contained in a reference sequence database.
  • FIG. 21 is a flowchart for explaining an example of a detailed process of alignment. (A) of FIG.
  • FIG. 22 is a figure which shows an example of score calculation
  • (b) is a figure which shows the other example of score calculation.
  • FIG. 23 is a diagram showing an example of the format of the result file generated by the mutation identification unit.
  • FIG. 24 is a diagram showing an example of the structure of a mutation database.
  • FIG. 25 is a diagram showing a detailed example of the structure of mutation information in the mutation database.
  • (A) of FIG. 26 is a table showing the correspondence between a gene to be analyzed and position information
  • (b) is a diagram showing a state in which a mutation not corresponding to the information on the gene panel is excluded from the result file is there.
  • FIG. 27 is a diagram showing another example of the configuration of the gene analysis device.
  • FIG. 27 is a diagram showing another example of the configuration of the gene analysis device.
  • FIG. 28 is a flowchart showing an example of a process in which the drug search unit generates a list of drugs related to mutation.
  • FIG. 29 shows an example of the data structure of a drug database.
  • FIG. 30 shows an example of the data structure of a drug database.
  • FIG. 31 is a flowchart showing an example of a process in which the drug search unit generates a list including information on drugs related to mutation.
  • FIG. 32 is a flowchart showing an example of a process of determining the presence or absence of a drug that may be used outside the application based on the information obtained by searching the drug database by the drug search unit, and generating a list including the determination result. It is.
  • FIG. 33 is a diagram showing an example of the data structure of a drug database.
  • FIG. 34 is a flowchart showing an example of a process in which the drug search unit generates a list including information on drug trials.
  • FIG. 35 is a diagram showing another example of the configuration of the gene analysis device.
  • FIG. 36 shows an example of the data structure of the reference database.
  • FIG. 37 is a diagram showing an example of a created report.
  • FIG. 38 is a diagram showing another example of the configuration of the gene analysis device.
  • FIG. 39 is a diagram showing an example of the data structure of a gene panel related information database.
  • FIG. 40 is a diagram showing another example of a GUI used to input information on a gene panel.
  • FIG. 41 is a diagram showing another example of a GUI used to input information on a gene panel.
  • FIG. 40 is a diagram showing another example of a GUI used to input information on a gene panel.
  • FIG. 42 is a flowchart illustrating another example of the flow of processing for receiving input of information on a gene panel.
  • FIG. 43 is a diagram showing another example of the gene analysis device.
  • FIG. 44 is a flow chart showing an example of the flow of processing for analyzing gene sequences.
  • FIG. 45 is a diagram showing an example of the quality evaluation index.
  • FIG. 46 is a diagram showing an example of a report to be created.
  • Embodiment 1 Hereinafter, an embodiment of the present invention will be described in detail.
  • a gene analysis method acquires information on a gene panel, and outputs an analysis result of a lead sequence read by a sequencer based on the acquired information on the gene panel.
  • FIG. 1 is a view showing an application example of a gene analysis system 100 according to an embodiment of the present invention.
  • the gene analysis system 100 is a system that analyzes gene sequence information, and includes at least a gene analysis device 1 and a management server 3.
  • the gene analysis system 100 shown in FIG. 1 analyzes and analyzes the provided sample in response to an analysis request from the analysis system management organization 130 that manages the entire analysis performed in the examination organization 120 and the medical institution 210. It is applied in the inspection organization 120 which provides the result to the medical institution 210.
  • the gene analysis device 1 is installed at the inspection organization 120, and the management server 3 is installed at the analysis system management organization 130.
  • the gene analysis device 100 and the management server 3 constitute a gene analysis system 100.
  • the inspection organization 120 is an organization which inspects and analyzes the sample provided from the medical institution 210, creates a report based on the analysis result, and provides the medical institution 210 with the report.
  • the sequencer 2 and the gene analyzer 1 and the like are installed in the inspection organization 120, the present invention is not limited to this.
  • the analysis system management organization 130 is an organization that manages the entire analysis performed in each inspection organization 120 using the gene analysis system 100.
  • the analysis system management organization 130 is an enterprise that installs the gene analysis device 1 at the inspection organization 120 and provides gene analysis services corresponding to various gene panels.
  • the analysis system management organization 130 updates the information stored in the database of the gene analyzer 1 and manages the gene analysis system 100 so that gene analysis is performed based on the latest information.
  • the analysis system management organization 130 may acquire the status of the gene analysis in the gene analysis device 1 and may receive a reward from the inspection organization 120 according to the result of the gene analysis.
  • the medical institution 210 is an institution where a doctor, a nurse, a pharmacist or the like performs medical operations such as diagnosis, treatment, dispensing for the patient, and examples thereof include a hospital, a clinic, a pharmacy and the like.
  • FIG. 2 is a sequence diagram showing an example of main processing performed in the gene analysis system 100.
  • the process shown in FIG. 2 is only a part of the process performed by each organization.
  • the inspection organization 120 that desires to use the gene analysis system 100 introduces the gene analysis device 1. Then, the application for use of the gene analysis system 100 is applied to the analysis system management organization 130 (step S101).
  • the inspection organization 120 and the analysis system management organization 130 can conclude a desired contract in advance regarding the use of the gene analysis system 100 among a plurality of contract types.
  • the service contents provided from the analysis system management organization 130 to the inspection organization 120, the method of determining the system usage fee charged to the inspection organization 120 by the analysis system management organization 130, and the method of paying the system usage fee differ. It may be selected from the contract types of
  • the management server 3 of the analysis system management organization 130 specifies the contents of the contract concluded with the inspection organization 120 in response to the application from the inspection organization 120 (step S102).
  • the management server 3 managed by the analysis system management organization 130 assigns an examination organization ID to the gene analysis device 1 of the examination organization 120 which has made a contract, and starts provision of various services (steps S103).
  • the gene analysis device 1 receives various services from the management server 3.
  • the various services include analysis results of gene sequences that can be output from the gene analysis device 1, and provision of programs and information for controlling reports based on the analysis results. Thereby, the gene analysis device 1 can output an analysis result, a report, and the like that conform to the information on the input gene panel.
  • a doctor or the like collects samples such as tissue and blood of a lesion site of a subject as needed.
  • an analysis request is transmitted from the communication terminal 5 provided in the medical institution 210 (step S105).
  • the medical institution 210 provides the examination organization 120 with the sample ID assigned to each sample together with the transmission of the analysis request.
  • the sample ID given to each sample is to associate information on the subject from which each sample is collected with each sample.
  • subject refers to human subjects as well as non-human subjects such as mammals, invertebrates, vertebrates, fungi, yeasts, bacteria, viruses and plants.
  • examples herein relate to human subjects, the concepts of the present invention are applicable to genomes from organisms other than humans, such as animals or plants, and are useful in the fields of medicine, veterinary medicine and animal science, etc. is there.
  • Panel inspection is not limited to clinical examinations, but includes examinations for research applications.
  • the analysis request transmitted from the medical institution 210 in step S105 of FIG. 2 may include information on the gene panel.
  • the information on the gene panel may be any information that can be used to specify the gene panel, and may be, for example, the gene panel name and the name of the gene to be analyzed in the panel test.
  • the gene analysis device 1 receives an analysis request from the medical institution 210 (S106). Furthermore, the gene analysis device 1 receives a sample from the medical institution 210 that is the transmission source of the analysis request.
  • the inspection organization 120 receives a request from the medical institution 210, and a gene group to be analyzed is determined for each gene panel.
  • the inspection organization 120 can also use a plurality of gene panels according to the purpose of analysis. That is, the first gene panel is used to analyze the first analysis target gene group for the first sample provided from the medical institution 210, and the second analysis target gene group is analyzed for the second sample. For this purpose, a second gene panel can be used.
  • the gene analysis device 1 receives an input of information on a gene panel used to analyze a sample from the user (step S107).
  • pretreatment of the received sample is performed, and sequencing using the sequencer 2 is performed (step S108).
  • the pretreatment may include a process of fragmenting a gene such as DNA contained in a sample and recovering the fragmented gene. Sequencing also includes a process of reading the sequence of one or more DNA fragments to be analyzed collected in the pretreatment. Sequence information read by sequencing by the sequencer 2 is output to the gene analysis device 1 as read sequence information.
  • the gene analysis device 1 acquires the read sequence information from the sequencer 2 and analyzes the gene sequence (step S109).
  • the gene analysis device 1 creates a report based on the analysis result in step S109 (step S110), and transmits the created report to the communication terminal 5 (step S111).
  • the sample in response to an analysis request from the medical institution 210, the sample is analyzed, and a report based on the analysis result is created.
  • the medical institution 210 receives a report from the inspection institution 120 (step S112).
  • the laboratory 120 may analyze the sample and charge the medical institution 210 for an analysis fee as a compensation for providing the medical institution 210 as the analysis request source with a report based on the analysis result.
  • the analysis system management organization 130 may, as described above, provide various information and services according to the contents of a contract with the inspection organization 120, and may also request each inspection organization 120 for compensation such as a system usage fee. .
  • the gene analysis device 1 of the inspection organization 120 using the gene analysis system 100 notifies the management server 3 of the information on the gene panel used for the analysis, the information on the analyzed gene, the analysis result and the like (step S113). Specifically, the gene analysis device 1 sends the inspection organization ID, the gene panel ID, the gene ID, the analysis result, and the like to the management server 3.
  • the management server 3 stores the acquired examination organization ID, the gene panel ID, the gene ID, the analysis result, and the like in association with each other (step S114).
  • the examination institution ID is information for specifying a user who performs sequence analysis of a gene, and may be a user ID which is identification information assigned to each user who uses the gene analysis device 1.
  • Gene panel ID is identification information provided to identify a gene panel used for analysis of a gene of interest.
  • the gene panel ID assigned to the gene panel is associated with the gene panel name and the name of the company providing the gene panel.
  • the gene ID is identification information provided for each gene in order to specify the gene to be analyzed.
  • the analysis result is information on the analysis status of the gene sequence information.
  • the analysis result may be, for example, the number of times of sequence analysis for which analysis using a predetermined gene panel was performed in the gene analysis apparatus 1, or the number of analyzed genes, or the identified mutation It may be a total such as a number. Alternatively, it may be information on the amount of data processed in the analysis.
  • the management server 3 tabulates the analysis results in a predetermined period (for example, any period such as day, week, month, year) for each inspection organization 120, and determines the system usage fee according to the tabulation result and the contract type ( Step S115).
  • the analysis system management organization 130 may charge the determined system usage fee to the inspection organization 120 and request the analysis system management organization 130 to pay the system usage fee.
  • the gene analysis system 100 is a system that analyzes gene sequence information, and includes at least a gene analysis device 1 and a management server 3.
  • the gene analysis device 1 is connected to the management server 3 via a network 4 such as an intranet and the Internet.
  • the sequencer 2 is a base sequence analyzer used to read the base sequence of a gene contained in a sample.
  • the sequencer 2 is preferably a next generation sequencer that performs sequencing using a next generation sequencing technology, or a third generation sequencer.
  • the next-generation sequencer is a group of base sequence analyzers that has been developed in recent years, and has dramatically improved by performing parallel processing of clonally amplified DNA templates or single DNA molecules in large quantities in a flow cell. It has analysis ability.
  • the sequencing technology that can be used in the present embodiment may be a sequencing technology that acquires multiple leads by reading the same region redundantly (deep sequencing).
  • sequencing techniques examples include ionic semiconductor sequencing, pyrosequencing, sequencing-by-synthesis using a reversible dye terminator, sequencing Sequencing technology that can obtain multiple reads per run based on sequencing principles other than the Sanger method, such as sequencing-by-ligation and sequencing by probe ligation of oligonucleotides .
  • the sequencing primer used for sequencing is not particularly limited, and is appropriately set based on a sequence suitable for amplifying a region of interest. Further, as a reagent used for sequencing, a suitable reagent may be selected according to the sequencing technology and sequencer 2 used. The procedure from pre-processing to sequencing will be described later with specific examples.
  • FIG. 3 is a view showing an example of the data structure of data stored in the management server 3.
  • the analysis system management organization 130 determines the system usage fee charged to each inspection organization based on each data shown in FIG. 3.
  • the management server 3 includes information (for example, a laboratory ID) for specifying a user who performs gene sequence analysis, information on a gene panel used, and information on analysis status of gene sequences (for example, analysis results). Information to be included is received from the gene analyzer 1 via the network 4.
  • the name of the testing organization using the gene analysis system 100 and the testing organization ID assigned to each testing organization are associated.
  • the type of contract that the analysis system management organization 130 concludes with the inspection organization 120 and the service provided to the inspection organization that has made each contract (for example, available gene panel ) And the system usage fee are associated.
  • the analysis system management organization 130 uses the inspection organization P according to the number of operations. Charge a fee.
  • the “number of operations” is, for example, the number of panel tests performed by the gene analyzer 1.
  • the data 3C to 3E shown in FIG. 3 were respectively identified by the number of operations performed by a laboratory using the gene analysis system 100 during the period from August 1, 2017 to August 31, 2017, the analyzed genes, and It is an analysis result about the total number of mutations. These analysis results are transmitted from the gene analyzer 1 to the management server 3 and stored in the management server 3.
  • the analysis system management organization 130 determines the system usage fee charged to each inspection organization based on the data of these analysis results.
  • the actual aggregation period is not limited to the above, and may be aggregated in any period such as day, week, month, year.
  • the system usage fee is determined depending on whether it is provided by a company that provides (for example, manufacturing or selling) the gene panel used for the test. You may change it.
  • data 3F shown in FIG. 3 may be stored in the management server 3.
  • the company name providing gene panels such as "company A” and "company B”, gene panel ID, and agreement on system usage fee (for example, necessity of system usage fee, etc.) And are associated.
  • the case where the “P organization” concludes a contract of “plan 1” with the analysis system management organization 130 and the analysis result is as shown in FIG. 3 will be described as an example.
  • the P organization conducts five tests using the gene panel (gene panel ID "AAA”) provided by company A, and tests using the gene panel (gene panel ID "BBB”) provided by company B. It has been done 10 times. According to the data shown in FIG. 3, no system fee is required for 5 batches using the gene panel provided by Company A. Therefore, the analysis system management organization 130 determines the system usage fee to the P organization excluding the number of examinations using the gene panel provided by the company A.
  • FIG. 4 is an example of the configuration of the gene analysis device 1.
  • the gene analysis device 1 is based on the control unit 11 for acquiring the read sequence information read by the sequencer 2 and the information on the gene panel including a plurality of genes to be analyzed, and the information on the gene panel acquired by the control unit 11 And an output unit 13 for outputting an analysis result of the lead arrangement information.
  • the gene analysis device 1 can be configured using a computer.
  • the control unit 11 is a processor such as a CPU
  • the storage unit 12 is a hard disk drive.
  • the storage unit 12 also stores a program for sequence analysis, a program for generating a single reference sequence, and the like.
  • the output unit 13 includes a display, a printer, a speaker, and the like.
  • the input unit 17 includes a keyboard, a mouse, a touch sensor, and the like. Alternatively, a device having both an input unit and an output unit function, such as a touch panel in which a touch sensor and a display are integrated, may be used.
  • the communication unit 14 is an interface for the control unit 11 to communicate with an external device.
  • the gene analysis device 1 controls the units included in the gene analysis device 1 to control all units, the first storage unit 12 that stores various data used by the analysis execution unit 110, the output unit 13, the communication unit 14, the display A unit 16 and an input unit 17 are provided.
  • the control unit 11 includes an analysis execution unit 110 and a management unit 116.
  • the analysis execution unit 110 includes a sequence data reading unit 111, an information selection unit 112, a data adjustment unit 113, a mutation identification unit 114, and a report creation unit 115.
  • a gene panel related information database 121, a reference sequence database 122, a mutation database 123, and an analysis result log 151 are stored.
  • the gene analysis device 1 creates a report including analysis results corresponding to the used gene panel.
  • a user who uses the gene analysis system 100 can analyze the result of panel inspection with a common analysis program regardless of the type of gene panel, and create a report. Therefore, when performing panel inspection, the trouble that the analysis program used for every gene panel is properly used or special settings for each gene panel used for the analysis program are eliminated is eliminated. User convenience is improved.
  • the information selection unit 112 refers to the gene panel related information database 121, and the analysis program receives the information on the input gene panel.
  • An algorithm of an analysis program is controlled to execute analysis of a gene to be analyzed. That is, the gene analysis device 1 changes the analysis algorithm according to the input information on the gene panel.
  • the information on the gene panel may be any information that specifies the gene panel used for measurement by the sequencer 2.
  • gene panel name gene name targeted for analysis of gene panel, gene panel ID, etc. It is.
  • the information selection unit 112 changes the analysis algorithm for performing analysis corresponding to the gene to be analyzed of the gene panel indicated by the information on the gene panel based on the information on the gene panel input from the input unit 17.
  • the changes of the specific analysis algorithm in the present embodiment include (1) change of reference sequence, and (2) change of region of mutation database 123 which is referred to identify mutations.
  • the information selection unit 112 outputs an instruction based on the information on the gene panel to at least one of the data adjustment unit 113, the mutation identification unit 114, and the report creation unit 115.
  • the gene analysis device 1 can output the analysis result of the lead sequence information based on the input information on the gene panel.
  • the information selection unit 112 acquires information on a gene panel including a plurality of genes to be analyzed, and based on the acquired information on the gene panel, the analysis result of the lead sequence information is output from the output unit 13 Is a functional block to control the
  • genes contained in various samples are analyzed by the user performing panel inspection, various gene panels are used according to a group of genes to be analyzed for each sample.
  • the gene analysis device 1 reads the first read sequence information read from the first sample using the first gene panel for analyzing the first analysis target gene group, and the second analysis target from the second sample
  • a second gene panel for analyzing gene groups can be used to obtain second read sequence information read.
  • the gene analysis apparatus 1 includes the information selection unit 112 to appropriately analyze the analysis result of the lead sequence information. It can be output.
  • the user can select the information on the gene panel without setting the analysis program used for the analysis of the lead sequence information for each analysis target gene or performing the analysis, and It is possible to output an analysis result appropriately.
  • the data adjustment unit 113 performs an alignment process or the like reflecting the information on the gene panel.
  • the information selection unit 112 uses the reference sequence (the wild type genomic sequence and the reference sequence into which the mutant sequence is integrated) used by the data adjustment unit 113 to map the lead sequence information according to the information on the gene panel as information on the gene panel. It is instructed to limit only to the reference sequence for the gene corresponding to
  • the information selection unit 112 instructs the mutation identification unit 114 to perform processing after the processing by the data adjustment unit 113. It is not necessary to output an instruction based on information on the gene panel.
  • the mutation identification unit 114 performs a process reflecting the information on the gene panel.
  • the information selecting unit 112 instructs to limit the region of the mutation database 123 to which the mutation identifying unit 114 refers to only the mutation on the gene corresponding to the information on the gene panel. Thereby, the information on the gene panel is reflected in the result of the processing by the mutation identifying unit 114.
  • FIG. 5 is a flow chart showing an example of the flow of processing for receiving input of information on a gene panel.
  • control unit 11 causes the display unit 16 to display a GUI for inputting information related to the gene panel and allows the user to input information related to the gene panel.
  • the input unit 17 may be a device (for example, a mouse and a keyboard) capable of performing an input operation on the GUI presented to the user.
  • the display unit 16 has a function as the input unit 17. That is, when a touch panel is used as the display unit 16, the display unit 16 also functions as the input unit 17.
  • control unit 11 of the gene analysis device 1 causes the display unit 16 to display a GUI for causing the user to select information on a gene panel.
  • Information on the gene panel is acquired based on the user's input operation on the GUI (step S201).
  • the information selection unit 112 searches the gene panel related information database 121 based on the information selected by the user among the information displayed as a GUI, and reads out information on a gene panel corresponding to the selected information.
  • the gene analysis device 1 reads out information on the gene panel included in the analysis request received from the medical institution 210.
  • the gene panel corresponding to the selected information is registered in the gene panel related information database 121 (YES in step S 202), and the gene panel is one of the gene panels included in the analysis request received from the medical institution 210. If the user has made a decision (YES in step S203), the information selection unit 112 accepts the input. Then, the information selection unit 112 displays a message indicating that the gene panel input to the display unit 16 is usable (step S204).
  • information selector 112 causes the display unit 16 to display a message indicating that the input gene panel can not be used (step S205), and prohibits analysis by the gene analysis device 1.
  • a message indicating an error may be displayed instead of the message that the gene panel is not usable.
  • a message may be, for example, the message "The selected gene panel has not been registered.” Or "Please re-enter information on the gene panel”. It may be one that adds a prompting message.
  • the information selection unit 112 displays the display unit 16 A message indicating that the input gene panel is not available is displayed (step S205), and analysis by the gene analysis device 1 is prohibited.
  • a message may be displayed to notify an error.
  • a message may be, for example, a message such as "The selected gene panel is different from the order.”, Or "Re-enter information on the gene panel", etc. It may be a message.
  • Such processing prevents sequencing using an inappropriate gene panel and execution of unnecessary analysis operations, and wasteful use of the gene panel and useless movement of the gene analysis system 100. It can be eliminated.
  • FIG. 6 is a diagram showing an example of a GUI used to input information on a gene panel.
  • a list of gene panel names such as "xxxxx” and "yyyyy” is displayed on the GUI as information on the gene panel, and a desired gene panel for the user is selected from the gene panels shown in the list. You may
  • the list of gene panel names displayed on the GUI is displayed based on the gene panel name of the gene panel to which the gene panel ID is assigned, which is registered in the gene panel related information database 121.
  • the GUI shown in FIG. 6 shows that “gene panel 2 (gene panel name:“ yyyy ”)” is selected by the user.
  • the information selection unit 112 searches the gene panel related information database 121 using the gene panel ID associated with the selected gene panel name “yyyyy” as a key, and relates to the gene panel corresponding to the input gene panel name Get information.
  • FIG. 7 is a view showing an example of the data structure of the gene panel related information database 121. As shown in FIG.
  • the names of genes that can be analyzed and the gene ID assigned to each gene are stored for each gene panel.
  • genes related information database 121 as in the data 121B shown in FIG. 7, names of selectable gene panels, gene panel IDs assigned to each gene panel, and genes targeted by each gene panel are analyzed. Gene ID (related gene ID) is associated and stored. In addition, about each gene panel, the information regarding whether the use is approved by the public organization (for example, the Ministry of Health, etc. of Japan) may also be matched.
  • the information selection unit 112 refers to the gene panel related information database 121 to select the selected gene panel. Extract gene panel ID and related gene ID associated with the name.
  • the information selection unit 112 refers to the gene panel related information database 121 and associates it with the selected gene name.
  • the gene ID of the gene panel including the identified gene ID and the gene ID of the related gene ID is extracted.
  • the names of gene panels related to diseases and the gene names (or gene IDs) to be analyzed in each gene panel are stored in association with each other. May be
  • the information selection unit 112 selects the gene panel related information database 121.
  • the gene panel ID of the gene panel including those gene IDs and their gene IDs in the related gene ID is extracted from the gene name associated with the gene panel name for the selected disease, with reference to FIG.
  • FIG. 8 is a diagram showing an example of a GUI used when the user updates the gene panel related information database 121. As shown in FIG.
  • the update of the information stored in the gene panel related information database 121 may be performed by an update patch provided from the analysis system management organization 130 to the inspection organization 120. For example, when a gene to be analyzed in the gene panel is changed, or a new gene panel is added, the information stored in the gene panel related information database 121 is updated to the latest one.
  • the provision of the update patch from the analysis system management organization 130 may be performed on the inspection organization 120 for which the system usage fee has been paid.
  • the analysis system management organization 130 may notify the inspection organization 120 that there is an available update patch and that it is a condition of providing the update patch that the system usage fee is paid. By notifying in this manner, payment of the system usage fee can be appropriately urged to the inspection agency 120.
  • a field for inputting "registered file name” is displayed, and in that field, genes such as "gene panel target gene .csv", etc. You may enter a file name in which the name is written.
  • the “gene panel target gene. Csv” includes a plurality of gene names such as RET, CHEK2, PTEN and MEK1.
  • an update request for information on the gene corresponding to the gene name contained in the file is associated with the examination organization ID, and the communication unit 14 And sent to the management server 3.
  • the generation of the update request and the association with the inspection organization ID may be performed by, for example, the control unit 11 in FIG. 4.
  • the analysis system management organization 130 includes information including the gene ID given to the gene name included in the update request received by the management server 3 and the gene panel ID given to the gene panel for analysis of the gene.
  • the gene analyzer 1 permits downloading.
  • an update request for information on the gene corresponding to the gene name is associated with the examination organization ID, and is transmitted to the management server 3 via the communication unit 14 Be done.
  • the analysis system management organization 130 includes information including the gene ID given to the gene name included in the update request received by the management server 3 and the gene panel ID given to the gene panel for analysis of the gene.
  • the gene analyzer 1 permits downloading.
  • information of input candidates to be displayed is provided in advance from the management server 3 to the gene analysis device 1 and stored in the first storage unit 12. Then, when a click operation on the GUI of the field to be input is detected, all updatable gene names are presented as input candidates, allowing the user to select from among them, or updating possible matching the character string input by the user
  • the gene name may be presented as an input candidate.
  • a list of updatable gene names such as “EGFR” and “ESR” is displayed. Alternatively, the user may select one from the list.
  • each gene name, the gene ID of the gene, and the protein name encoded by the gene may be stored in association with each other.
  • the information selection unit 112 refers to the gene panel related information database 121 and the input protein name.
  • the gene name and gene ID associated with can be obtained.
  • the management unit 116 associates the analysis record including the number of times the analysis execution unit 110 has been operated, the number of analyzed genes, the total number of identified authorities, etc. with the gene panel ID and the gene ID, and analyzes the analysis record log 151 as needed.
  • the management unit 116 reads data including analysis results from the analysis result log 151 at an arbitrary frequency (for example, every day, every week, every month), associates the data with the inspection organization ID, and communicates the communication unit 14 Send to the management server via
  • the communication unit 14 is for the gene analysis device 1 to communicate with the management server 3 via the network 4.
  • the data transmitted from the communication unit 14 to the management server 3 may include a laboratory ID, a gene panel ID, a gene ID, an analysis record, an update request, and the like.
  • the data received from the management server 3 may include information on gene panels, gene names that can be updated, and the like.
  • FIG. 9 is a flow chart for explaining an example of a procedure from pretreatment to sequencing for analyzing the base sequence of sample DNA by the sequencer 2.
  • sequencer 2 that can be used in the present embodiment is not particularly limited, and a sequencer that can analyze a plurality of analysis targets in a single run can be suitably used.
  • a device for example, MySeq, HiSeq, NextSeq, etc.
  • Illumina San Diego, Calif.
  • a device adopting the same system as Illumina's sequencer is used.
  • Illumina's sequencer can perform sequencing while synthesizing and synthesizing a large number of target DNAs on a flow cell by a combination of Bridge PCR method and a technique called Sequencing-by-synthesis.
  • the sample (DNA) is fragmented into a length for reading the sequence by the sequencer 2 (step S301 of FIG. 9).
  • Fragmentation of sample DNA can be performed by known methods such as, for example, ultrasonication, and treatment with a reagent that fragments nucleic acid.
  • the resulting DNA fragment (nucleic acid fragment) may be, for example, tens to hundreds of bp in length.
  • the gene to be analyzed is DNA is described as an example, but the gene to be analyzed may be RNA.
  • step S302 in FIG. 9 adapter sequences corresponding to the type of sequencer 2 and the sequencing protocol to be used at both ends (3 'end and 5' end) of the DNA fragment obtained in step S301.
  • Step S302 in FIG. 9 this step is an essential step when the sequencer 2 is a device that adopts the same method as Illumina's sequencer or Illumina's sequencer, but when using other types of sequencer 2 May be omitted.
  • the adapter sequence is a sequence used to perform sequencing in a later step, and in one embodiment may be a sequence for hybridizing to oligo DNA immobilized on a flow cell in Bridge PCR method.
  • adapter sequences may be added directly to both ends of the DNA fragment. Addition of adapter sequences to DNA fragments can be carried out using techniques known in the art. For example, DNA sequences may be blunted and adapter sequences may be ligated.
  • an index sequence may be inserted between both ends of the DNA fragment and the adapter sequence.
  • the index sequence is a sequence unique to each sample, each gene panel, and each company providing a gene panel to distinguish data of each sample.
  • the base sequence used as the index sequence is not limited to this, for example, a sequence in which 10 to 14 consecutive adenine, 5 to 7 consecutive adenine and 5 to 7 consecutive guanine, etc. And have a given length.
  • the index sequence is based on the sequence pattern and length, and for which sequence of the DNA fragment the DNA sequence to which the index sequence is added, what sample lead sequence information, what gene panel was used, the gene panel used It can be used to identify information on which company providing the company, etc. A configuration for identifying information on a panel using an index array will be described in detail later (see Embodiment 4).
  • the index sequence in analysis using gene panel A is a sequence pattern in which adenine is 14 consecutive
  • the index sequence in analysis using gene panel B is a sequence pattern in which guanine is 7 consecutive after 7 adenine is continuous Good.
  • the index sequence in analysis using gene panel A is a sequence in which adenine is 14 consecutive (that is, the length of the index sequence is 14)
  • the index sequence in analysis using gene panel C is 10 consecutive adenines It may be an array (ie, the length of the index array is 10).
  • index sequences and adapter sequences can be carried out using techniques known in the art. For example, after blunting a DNA fragment and ligating an index sequence, an adapter sequence may be further ligated.
  • RNA bait library is hybridized to the DNA fragment to which the adapter sequence is attached (Step S303 in FIG. 9).
  • the biotinylated RNA bait library is composed of biotinylated RNA (hereinafter referred to as RNA bait) that hybridizes to a gene to be analyzed.
  • RNA bait biotinylated RNA
  • the length of the RNA bait is arbitrary, for example, a long oligo RNA bait of about 120 bp may be used to enhance the specificity.
  • a large number of genes (for example, 100 or more) are genes to be analyzed.
  • the reagents used in the panel test include a set of RNA bait corresponding to each of the large number of genes. Since different panels have different numbers and types of genes to be tested, the set of RNA bait contained in the reagent used in the panel test is also different.
  • the DNA fragment to be analyzed is recovered (step S304 in FIG. 9). Specifically, as shown in the upper part of FIG. 12, Streptavidin magnetic beads in which streptavidin and magnetic beads are bound are mixed with the DNA fragment hybridized with the biotinylated RNA bait library. As a result, as shown in the middle of FIG. 12, the streptavidin portion of the streptavidin magnetic beads and the biotin portion of the RNA bait are bound.
  • the streptavidin magnetic beads are collected with a magnet, and fragments not hybridized with the RNA bait (ie, DNA fragments not to be analyzed) are removed by washing.
  • the DNA fragment hybridized with the RNA bait that is, the DNA fragment to be analyzed can be selected and concentrated.
  • the sequencer 2 obtains a plurality of lead sequences by reading the nucleic acid sequence of the DNA fragment thus selected using a plurality of RNA baits.
  • the streptavidin magnetic beads and RNA bait are removed from the concentrated DNA fragment, and the pretreatment is completed by amplification by the PCR method.
  • the DNA fragment to be analyzed has two different adapter sequences (for example, adapter 1 sequence and adapter 2 sequence in FIG. 14) at both ends by the above-described pretreatment. Is added (“1” in FIG. 14), this DNA fragment is rendered single stranded, and the adapter 1 sequence on the 5 ′ end side is immobilized on the flow cell (“2” in FIG. 14).
  • the adapter 2 sequence at the 5 'end is fixed in advance on the flow cell, and the adapter 2 sequence at the 3' end of the DNA fragment is bridged by binding to the adapter 2 sequence at the 5 'end on the flow cell.
  • the bridge is formed (“3” in FIG. 14).
  • the DNA elongation reaction is carried out by DNA polymerase ("4" in FIG. 14), and when it is denatured, two single-stranded DNA fragments are obtained ("5" in FIG. 14).
  • DNA polymerase DNA polymerase
  • two single-stranded DNA fragments are obtained ("5" in FIG. 14).
  • a large number of single-stranded DNA fragments can be locally amplified and fixed to form clusters (FIG. 14 “6” to "10").
  • the sequence is read by sequencing-by-synthesis using single-stranded DNA forming a cluster as a template (step S307 in FIG. 9).
  • sequence primer may be designed, for example, to hybridize to a portion of the adapter sequence.
  • the sequence primer may be designed to amplify the DNA fragment derived from the sample DNA, and may be designed to further amplify the index sequence when the index sequence is added.
  • DNA polymerase After addition of the sequence primer, DNA polymerase performs single base extension reaction of 3 'end-blocked fluorescent dNTP. In order to use dNTP blocked at the 3 'end side, the polymerase reaction is stopped when it is extended by one base. Then, the DNA polymerase is removed (the middle right column in FIG. 15) and the fluorescent substance bound to the base is excited by laser light to the single-stranded extended single-stranded DNA (lower right column in FIG. 15). The light emission occurring at that time is recorded as a picture (lower left column in FIG. 15). Photographs are taken for each of the fluorescent colors corresponding to A, C, G, and T, respectively, while changing the wavelength filter in order to determine four types of bases using a fluorescence microscope.
  • the fluorescent substance and the protecting group blocking the 3 'end are removed to proceed to the next polymerase reaction.
  • the entire length can be sequenced by repeating this flow as one cycle and the second cycle and the third cycle.
  • the chain length that can be analyzed is up to 150 bases ⁇ 2, and analysis is possible in units much smaller than the picotiter plate, so by densifying, in one analysis A huge amount of sequence information of 40 to 200 Gb can be obtained.
  • the gene panel used for reading a lead sequence by the sequencer 2 means an analysis kit for analyzing a plurality of analysis objects in a single run, as described above, and in one embodiment, a plurality of genes related to a specific disease It can be an analysis kit for analyzing sequences.
  • kit is intended for packaging comprising a container (eg, a bottle, a plate, a tube, a dish, etc.) containing the particular material. Preferably, instructions for using each material are provided.
  • a container eg, a bottle, a plate, a tube, a dish, etc.
  • instructions for using each material are provided.
  • "provided” is intended to be contained within any of the individual containers that make up the kit.
  • the kit may be a package in which a plurality of different compositions are packaged together, wherein the form of the composition may be as described above, and in the case of a solution form it may be enclosed in a container It is also good.
  • the kit may be prepared by mixing substance A and substance B in the same container or in separate containers.
  • the "instructions” indicate procedures for applying each component in the kit to treatment and / or diagnosis.
  • the “instruction manual” may be written or printed on paper or other medium, or attached to an electronic medium such as magnetic tape, computer readable disc or tape, CD-ROM, etc. It is also good.
  • the kit can also include a container containing a diluent, solvent, wash solution or other reagent. Furthermore, the kit may be provided with the necessary equipment for therapeutic and / or diagnostic applications.
  • the gene panel comprises one or more of the above-described reagents for fragmenting nucleic acids, reagents for ligation, reagents for washing, reagents such as PCR reagents (dNTP, DNA polymerase etc.), and magnetic beads. It is also good. Also, the gene panel may be provided with one or more of an oligonucleotide for adding an adapter sequence to fragmented DNA, an oligonucleotide for adding an index sequence to fragmented DNA, an RNA bait library, etc. Good.
  • each gene panel may be a sequence unique to the gene panel for identifying the gene panel.
  • the RNA bait library provided in each gene panel may be a library unique to the gene panel, including RNA bait corresponding to each test gene of the gene panel.
  • sequence data reading unit 111 (Sequence data reading unit 111, data adjustment unit 113, mutation identification unit 114) Subsequently, the processing of sequence data reading unit 111, data adjustment unit 113, and mutation identification unit 114 of analysis execution unit 110 will be described along the flow of processing shown in FIG. 16 with reference to FIGS. 17 to 26 as appropriate. Do.
  • FIG. 16 is a flow chart for explaining an example of the flow of analysis by the gene analysis device 1. The process shown in FIG. 16 corresponds to step S109 shown in FIG.
  • step S11 of FIG. 16 the array data reading unit 111 reads the read array information provided from the sequencer 2.
  • the read sequence information is data indicating the base sequence read by the sequencer 2.
  • the sequencer 2 sequences a large number of nucleic acid fragments obtained using a specific gene panel, reads their sequence information, and provides the information to the gene analyzer 1 as lead sequence information.
  • the read sequence information may include the quality score of each base in the sequence, as well as the read sequence. Further, both of the lead sequence information obtained by applying the FFPE sample collected from the lesion site of the subject to the sequencer 2 and the lead sequence information obtained by applying the blood sample of the subject to the sequencer 2 are It is input to the gene analyzer 1.
  • FIG. 17 is a diagram showing an example of a file format of read sequence information.
  • the read sequence information includes the sequence name, the sequence, and the quality score.
  • the sequence name may be a sequence ID assigned to the read sequence information output from the sequencer 2 or the like.
  • the sequence shows the base sequence read by sequencer 2.
  • the quality score indicates the probability that the base 2 assignment by the sequencer 2 is not correctly performed.
  • E represents an estimated value of the probability that base assignment is not correctly performed.
  • the higher the Q value the lower the probability of error.
  • the lower the Q value the larger the unusable part of the lead.
  • false positive mutation assignments may also increase, which may reduce the accuracy of the results.
  • False positive means that although the lead sequence has no true mutation to be judged, it is judged to have a mutation.
  • “Positive” means that the lead sequence has a true mutation to be determined, and “negative” means that the lead sequence does not have a targeted mutation.
  • step S12 of FIG. 16 the data adjustment unit 113 executes alignment of the lead sequence of each of the nucleic acid fragments contained in the read sequence information based on the read sequence information read by the sequence data reading unit 111.
  • (A) of FIG. 18 is a diagram for explaining alignment by the data adjustment unit 113.
  • the data adjustment unit 113 executes alignment by referring to the reference sequence stored in the reference sequence database 122 and mapping the lead sequence of each nucleic acid fragment to the reference sequence to be compared with the read sequence information. Do.
  • the reference sequence database 122 stores a plurality of types of reference sequences corresponding to the genes to be analyzed.
  • the data adjustment unit 113 also provides the read sequence information obtained by applying the FFPE sample collected from the lesion site of the subject to the sequencer 2 and the read sequence obtained by applying the blood sample of the subject to the sequencer 2 Perform an alignment, both with the information.
  • FIG. 18 is a diagram illustrating an example of the format of the alignment result of the data adjustment unit 113.
  • the format of the alignment result is not particularly limited as long as it can identify the read sequence, reference sequence and mapping position, but as shown in FIG. 18 (b), reference sequence information, read sequence name, position information, map It may include quality and alignment.
  • the reference sequence information is information indicating the reference sequence name (reference sequence ID) in the reference sequence database 122, the sequence length of the reference sequence, and the like.
  • the reference sequence information is preferably capable of identifying the reference sequence, and includes, for example, a reference sequence name and a reference sequence ID.
  • the read sequence name is information indicating the name (read sequence ID) of each read sequence that has become the alignment target.
  • the position information is information indicating a position (Leftmost mapping position) on the reference sequence to which the leftmost base of the read sequence is mapped.
  • the map quality is information indicating the mapping quality corresponding to the lead arrangement.
  • the sequence is information indicating a nucleotide sequence (eg, ... GTAAGGCACGTCATA ...) corresponding to each read sequence.
  • FIG. 19 shows an example of the structure of the reference sequence database 122.
  • the reference sequence database 122 incorporates a reference sequence (for example, the genomic sequence of chromosomes # 1 to 23) representing a wild-type sequence and a known displacement relative to the wild-type sequence.
  • a reference sequence is stored.
  • each reference sequence in the reference sequence database 122 is provided with metadata indicating information on a gene panel.
  • the information on the gene panel provided to each reference sequence may be, for example, one directly or indirectly indicating the gene to be analyzed to which each reference sequence corresponds.
  • the information selection unit 112 when the data adjustment unit 113 acquires the reference sequence from the reference sequence database 122, the information selection unit 112 refers to the input information on the gene panel and the metadata of each reference sequence. Control may be performed to select a reference sequence corresponding to the information on the gene panel. For example, in one aspect, the information selection unit 112 may control the data adjustment unit 113 to select a reference sequence corresponding to a gene to be analyzed identified by the input information on the gene panel. As a result, the data adjustment unit 113 may perform mapping only to the reference sequences related to the used gene panel, so that the analysis efficiency can be improved.
  • the information selection unit 112 may not perform the above control. In that case, the information selection unit 112 may control the mutation identification unit 114 or the report creation unit 115 as described later.
  • FIG. 20 shows an example of a known mutation incorporated into the reference sequence (not showing the wild-type sequence) contained in the reference sequence database 122.
  • Known mutations are mutations registered in an external database (for example, COSMIC, ClinVar, etc.), and as shown in FIG. 20, chromosomal positions, gene names and mutations are identified.
  • mutations of amino acids are identified, but mutations of nucleic acids may be identified.
  • the type of mutation is not particularly limited, and may be various mutations such as substitution, insertion, deletion and the like, or may be a mutation to which a partial sequence of another chromosome or a reverse complementary sequence is bound.
  • FIG. 21 is a flow chart for explaining an example of a detailed process of alignment in step S12 of FIG.
  • the alignment in step S12 of FIG. 16 is performed by steps S401 to S405 shown in FIG.
  • step S401 in FIG. 21 the data adjustment unit 113 selects one of the read sequences of each of the nucleic acid fragments contained in the read sequence information acquired by the sequence data reading unit 111 that has not been aligned, and uses the reference sequence database. Compare with the reference sequence obtained from 122. Then, in step S402, the data adjustment unit 113 identifies the position on the reference array where the degree of coincidence with the read array satisfies a predetermined reference.
  • the degree of coincidence is a value indicating how much the acquired read sequence information and the reference sequence are in agreement, and, for example, the number and ratio of coincident bases can be mentioned as an example.
  • the data adjustment unit 113 calculates a score indicating the degree of matching between the read sequence and the reference sequence.
  • the score indicating the degree of identity can be, for example, the percentage identity between the two sequences.
  • the data adjustment unit 113 identifies the number of positions where the base of the read sequence and the base of the reference sequence are identical, obtains the number of matched positions, and reads the number of matched positions compared with the reference sequence. The percentage is calculated by dividing by the number of bases in the sequence (number of bases in comparison window).
  • (A) of FIG. 22 is a figure which shows an example of score calculation.
  • the score of the degree of coincidence between the lead sequence R1 and the reference sequence is 100% because 13 bases out of the 13 bases of the lead sequence are identical, and The score of the degree of coincidence with the reference sequence is 92.3% because 12 bases out of the 13 bases of the lead sequence are coincident.
  • the data adjustment unit 113 determines that the lead sequence has a predetermined mutation (for example, insertion / deletion (InDel: Insertion / Deletion)) with respect to the reference sequence. If it is included, it may be calculated to have a lower score than the normal calculation.
  • a predetermined mutation for example, insertion / deletion (InDel: Insertion / Deletion)
  • the data adjustment unit 113 inserts or deletes, for example, a score calculated by the usual calculation as described above, for a sequence in which the lead sequence includes at least one of an insertion and a deletion relative to the reference sequence.
  • the score may be corrected by multiplying by a weighting factor according to the corresponding number of bases.
  • FIG. 22 (B) of FIG. 22 is a figure which shows the other example of score calculation.
  • the data adjustment unit 113 specifies the position on the reference sequence that satisfies the predetermined criteria by calculating the score of the matching degree while changing the mapping position of the reading sequence to each reference sequence.
  • algorithms known in the art such as dynamic programming, FASTA, BLAST may be used.
  • step S403 when the position on the reference array where the degree of coincidence with the read array satisfies the predetermined reference is a single position (NO in step S403), the data adjustment unit 113 If the read sequence is aligned at the corresponding position, and the position on the reference sequence at which the degree of coincidence with the read sequence satisfies the predetermined reference is a plurality of positions (YES in step S403), the data adjustment unit 113 The lead array is aligned at the position with the highest degree of coincidence (step S404).
  • step S405 when the data adjustment unit 113 does not align all the read sequences included in the read sequence information acquired by the sequence data reading unit 111 (NO in step S405), the process returns to step S401, and If all the included read sequences are aligned (YES in step S405), the process of step S12 is completed.
  • the data adjustment unit 113 outputs, as an analysis result of the lead sequence information, a comparison result of comparison between the lead sequence information and the sequence information of the gene to be analyzed by the gene panel associated with the acquired information about the gene panel. You may
  • the sequence information of the gene to be analyzed by the gene panel may include the sequence of the gene (eg, exon) to be analyzed and the index sequence added to the sequence of the gene to be analyzed.
  • the data adjustment unit 113 may cause the display unit 16 to display an error as an analysis result of the lead arrangement information.
  • the index sequence included in the read sequence information read by the sequence data reading unit 111 corresponds to the information corresponding to the information on the gene panel acquired by the information selection unit 112 (for example, FIG. (See 39).
  • the gene array corresponding to the information on the gene panel acquired by the information selection unit 112 includes a predetermined number or more of sequences of genes that are not to be analyzed.
  • the lead sequence information contains less than a predetermined number of sequences of genes to be analyzed by the gene panel indicated by the gene panel acquired by the information selection unit.
  • the data adjustment unit 113 may display on the display unit 16 errors such as “the analysis can not be performed” and “the information on the gene panel is incorrect”.
  • the data adjustment unit 113 further displays a message such as “Please enter information on the gene panel again” on the display unit 16, and the user may input the gene panel name and the gene name to be analyzed again. You may
  • the error may be displayed on the display unit 16 only when the number of pieces of lead sequence information including sequences of genes not to be analyzed is equal to or more than a predetermined number.
  • an error is displayed only when the number of pieces of lead sequence information mapped to genes not to be analyzed by the gene panel corresponding to the information on the gene panel among the lead sequence information is a predetermined number or more. May be
  • the aspect which outputs an error is not limited to this.
  • the error content may be output by voice from a speaker.
  • the user may be notified of an error by lighting or blinking a lamp or the like.
  • step S13 the mutation identification unit 114 supplies the sample obtained from the lesion site of the subject and the sequence of the reference sequence to which the lead sequence obtained is aligned (alignment sequence); A blood sample of the same subject is provided, and the lead sequence obtained is compared with the sequence of the aligned reference sequence.
  • step S14 of FIG. 16 the difference between both alignment sequences is extracted as a mutation.
  • the mutation identification unit 114 extracts the difference between G and C as a mutation. Do.
  • the mutation identification unit 114 generates a result file based on the extracted mutations.
  • FIG. 23 is a diagram showing an example of the format of the result file generated by the mutation identifying unit 114. As shown in FIG. The format may be based on, for example, Variant Call Format (VCF).
  • VCF Variant Call Format
  • the positional information indicates the position on the reference genome, and includes, for example, the chromosome number and the position on the chromosome.
  • the reference base indicates a reference base (A, T, C, G, etc.) at the position indicated by the position information.
  • the mutated base indicates the base after mutation of the reference base.
  • the reference base is a base on the alignment sequence derived from the blood sample, and the variant base is a base on the alignment sequence derived from the tumor tissue.
  • a mutation in which the reference base is C and the mutant base is G is an example of substitution mutation
  • a mutation in which the reference base is C and the mutant base is CTAG is an example of insertion mutation
  • a mutation in which the reference base is TCG and the mutant base is T is an example of a deletion mutation.
  • mutations whose mutant bases are G! 17: 198982], 13: 123456] T, C [2: 321682 [or, [17: 198983 [A] are sequences of other parts of chromosomes or reverse complements It is an example of a mutation bound to a sequence.
  • step S15 the mutation identification unit 114 searches the mutation database 123. Then, in step S16, the mutation identifying unit 114 refers to the mutation information in the mutation database 123, and annotates the mutation included in the result file to identify the mutation.
  • FIG. 24 shows an example of the structure of mutation database 123.
  • the mutation database 123 is constructed, for example, based on an external database such as COSMIC or ClinVar.
  • each mutation information in the database is provided with metadata about information on a gene panel.
  • the gene ID of the gene to be analyzed is attached as metadata to each piece of mutation information in the database.
  • FIG. 25 is a diagram showing a detailed example of the structure of mutation information in the mutation database 123.
  • mutation information included in mutation database 123 includes mutation ID, positional information of mutation (eg, “CHROM” and “POS”), “REF”, “ALT”, “Annotation” may be included.
  • Mutation ID is an identifier for identifying a mutation.
  • positional information of mutations "CHROM” indicates a chromosome number
  • POS indicates a position on the chromosome number
  • REF indicates a base in wild type (Wild type)
  • ALT indicates a base after mutation.
  • “Annotation” indicates information on mutation. “Annotation” may be information indicating a mutation of an amino acid such as “EGFR C2573G” or “EGFR L858R”, for example.
  • EGFR C2573G indicates that the cysteine at residue 2573 of the protein "EGFR” is a mutation substituted with glycine.
  • "Annotation" of mutation information may be information for converting a mutation based on base information into a mutation based on amino acid information.
  • the mutation identification unit 114 can convert a mutation based on base information into a mutation based on amino acid information based on the referenced “Annotation” information.
  • the mutation identification unit 114 searches the mutation database 123 using information (for example, positional information on the mutation and base information corresponding to the mutation) specifying the mutation included in the result file as a key. For example, the mutation identification unit 114 may search the mutation database 123 using any of the information of “CHROM”, “POS”, “REF” and “ALT” as a key.
  • the mutation identification unit 114 detects the mutation existing in the sample. And assign annotations (eg, “EGFR L858R”, “BRAF V600E”, etc.) to the mutations included in the result file.
  • the information selection unit 112 causes the mutation identification unit 114 to search for mutations that do not correspond to the information on the gene panel input to the mutation identification unit 114 before searching the mutation database 123 based on the result file. You may mask (exclude) from the result file.
  • the mutation identification unit 114 notified of the information on the gene panel from the information selection unit 112 is a gene to be analyzed and position information (for example, “CHROM” and “ The position of the mutation corresponding to the gene to be analyzed identified by the information on the notified gene panel is identified with reference to the table showing the correspondence with “POS”), and as shown in FIG. The mutation at the position of may be masked (excluded) from the result file.
  • the mutation identification unit 114 only needs to annotate the mutations associated with the used gene panel in the result file, so that the efficiency of mutation identification can be improved.
  • the information identifying unit 114 when the information identifying unit 114 refers to the mutation information in the mutation database 123 in order to add the annotation, the information identifying unit 114 receives information on the input gene panel and each mutation.
  • the mutation identification unit 114 may control to select and refer to mutation information corresponding to information on the gene panel with reference to information metadata.
  • the information selection unit 112 may control the mutation identification unit 114 to refer to mutation information corresponding to the gene to be analyzed identified by the information on the input gene panel.
  • the mutation identification unit 114 only needs to refer to the mutation information related to the used gene panel in the mutation database 123, so that the efficiency of the annotation can be improved.
  • a mutation corresponding to the information on the input gene panel is selected based on the information on the gene panel, and as a result of analysis of the lead sequence information, a mutation associated with the selected mutation is selected.
  • Information may be output.
  • the mutation identification unit 114 refers to the information on the gene panel from the information selection unit 112 and the metadata of each mutation information, and among all the mutations identified, the information on the gene panel It may be controlled to select only mutation information corresponding to For example, although different gene panels analyze genes of the same gene ID, there may be cases where mutations to be analyzed are different from one another.
  • the mutation identification unit 114 can output only the mutation information corresponding to the information on the gene panel input by the user to the report generation unit 115.
  • the mutation information may be output from the output unit 13 or displayed on the display unit 16 as the analysis result of the lead sequence information.
  • the report creation unit 115 creates a report based on the information output from the mutation identification unit 114 and the information on the gene panel provided from the information selection unit 112 (corresponding to step S110 in FIG. 2).
  • the information contained in the generated report includes information on the gene panel and information on the identified mutations.
  • the report creation unit 115 causes the information selection unit 112 to select the target to be included in the report based on the information on the gene panel from the information selection unit 112, and deletes the information not selected from the report.
  • the information selection unit 112 selects the information related to the gene corresponding to the information on the gene panel input through the input unit 17 as a target to be included in the report, and the information not selected is deleted from the report. May be configured to control the report generation unit 115.
  • the report created by the report creation unit 115 may be data transmitted from the output unit 13 to the terminal device 5 installed in the medical institution 210 as an analysis result of the lead arrangement information (corresponding to step S111 in FIG. 2) . Alternatively, it may be sent to a printer (not shown) connected to the gene analysis device 1 and printed by the printer, and then sent from the examination institution 120 to the medical institution 210 as a paper medium.
  • FIG. 27 is a diagram showing another example of the configuration of the gene analysis device 1a.
  • the analysis execution unit 110a of the gene analysis apparatus 1a further includes a drug search unit 117, and the first storage unit 12a is different from the gene analysis apparatus 1 illustrated in FIG. 4 in that the first storage unit 12a further includes a drug database 124.
  • FIG. 28 is a flowchart showing an example of a process in which the drug search unit 117 generates a drug list related to mutation.
  • the drug search unit 117 searches the drug database 124 using the mutation ID assigned to the mutation identified by the mutation identification unit 114 as a key (step S15a). Based on the search results, the drug search unit 117 generates a list including information on drugs related to mutation (step S16a). The generated list is incorporated into the report generated by the report generation unit 115.
  • FIG. 29 shows an example of the data structure of the medicine database 124. As shown in FIG.
  • a mutation ID given for each mutation is stored in association with each other. It should be noted that a plurality of related drugs may be associated with each mutation ID so that “drug A” and “drug B” are associated with the mutation ID “# 3” in FIG.
  • each mutation ID of the drug database 124 may be provided with “metadata related to gene panel related information” which is metadata related to information related to a gene panel.
  • the drug search unit 117 refers to the "metadata related to gene panel related information”.
  • the drug search unit 117 changes the range in which the drug database 124 is searched to the range indicated in the metadata.
  • the drug search unit 117 can narrow down the drugs to be referred to in the drug database according to the information on the gene panel input as "metadata on gene panel related information" given to each drug.
  • a list can be generated that contains information about the drug depending on the information about the gene panel.
  • the drug search unit 117 may search the drug database 124 having the data structure shown in FIG. 30 and generate a list including other information on the drug related to the mutation. Specifically, in addition to the list of drugs associated with mutations generated in Embodiment 2, drug approval information is added. This will be described with reference to FIG. FIG. 31 is a flowchart showing an example of a process in which the drug search unit 117 generates a list including information on drugs related to mutation.
  • the drug search unit 117 searches the drug database 124 storing the data shown in FIG. 30 to see if the relevant drug has been approved by the authority (FDA, PMDA, etc.). Specifically, the drug search unit 117 uses, for example, information on a mutation such as a “mutation ID” as a key, and indicates “approval status” indicating whether the related drug corresponding to the mutation is approved by the authority, Search for "approved country” indicating whether or not it is approved in (step S15b).
  • the drug search unit 117 generates a list including the mutation, the related drug corresponding to the mutation, information on approval of the related drug, and the like based on the search result (step S16b).
  • the drug search unit 117 may search the drug database 124 having the data structure shown in FIG. 30 and generate a list including further information on drugs related to the mutation. Specifically, in addition to the list of agents associated with mutations generated in Embodiment 2, information of agents corresponding to the disease of the subject is added. This will be described with reference to FIG. FIG. 32 determines the presence or absence of a drug having a possibility of Off-label use based on the information obtained by the drug search unit 117 searching the drug database 124, and a list including the determination result is displayed. It is a flow chart which shows an example of processing to generate.
  • the drug search unit 117 searches the drug database 124 storing the data 124B shown in FIG. 30 to see if the relevant drug is approved by the authority (FDA, PMDA, etc.) (step S15 b). If the searched drug is unapproved (NO in step S21), the drug search unit 117 associates the drug as a non-approved drug with the mutation (step S23), and generates a report of the drug related to the mutation (step S23). Step S16a).
  • the drug retrieval unit 117 determines the disease of the subject from which the sample was collected and the disease corresponding to the related drug retrieved from the drug database 124 (for example, It is determined whether or not “the target disease” shown in FIG. 30 matches (step S22).
  • step S22 When the disease of the subject and the "target disease” coincide (YES in step S22), the drug of the search result is associated with the mutation as an approved drug (step S24), the mutation, the related drug corresponding to the mutation, And a list including information related to the approval of the related drug (step S16a).
  • Step S22 when the disease of the subject and the "target disease" are different (NO in step S22), it is determined that the related drug retrieved is a drug having the possibility of off-label use (use outside application), The determination result is associated with the mutation (Step S25), and a list including the mutation, the related drug corresponding to the mutation, and information on approval of the related drug is generated (Step S16a).
  • the information on the disease of the subject may be input from the input unit 17 by the operator or the like, for example, when performing the gene analysis.
  • the header area of the lead arrangement information may include a disease ID which is identification information corresponding to a disease of a subject.
  • the drug search unit 117 may search the drug database 124 having the data structure shown in FIG. 33 and generate a list including information on trials of drugs related to mutation. Specifically, in addition to the list of drugs related to mutations generated in Embodiment 2, drug trial information is added. This will be described with reference to FIG. FIG. 34 is a flowchart showing an example of a process in which the drug search unit 117 generates a list including information on clinical trials of drugs.
  • the drug search unit 117 searches the drug database 124 storing the data 124C shown in FIG. 33 for information such as the progress of the clinical trial of the related drug. Specifically, the drug search unit 117 uses the mutation ID or the like as a key, and information on the trial of the mutation, for example, the “trial / clinical test status” shown in FIG. 33, the “implementation country” performing the trial, Search for "implementing agency” and the like (step S15c in FIG. 34). The drug search unit 117 generates a list including the mutation, the related drug corresponding to the mutation, information on the trial of the related drug, and the like based on the search result (step S16c in FIG. 34).
  • the data 124A shown in FIG. 29, the data 124B shown in FIG. 30, and the data 124C shown in FIG. 33 may be integrated into one and stored in the medicine database 124, and a plurality of medicine databases 124 are included. It may be distributed and stored in a database.
  • FIG. 35 is a diagram showing another example of the configuration of the gene analysis device 1b.
  • the analysis execution unit 110b of the gene analysis apparatus 1b further includes a reference search unit 118, and the first storage unit 12b is different from the gene analysis apparatus 1 illustrated in FIG. 4 in that the first storage unit 12b further includes a reference database 125.
  • the reference search unit 118 searches the reference database 125 using the mutation ID assigned to the mutation identified by the mutation identification unit 114 as a key. Based on the search result, the reference search unit 118 extracts reference information on the mutation. The extracted reference information is incorporated into the report created by the report creation unit 115.
  • FIG. 36 is a diagram showing an example of the data structure of the reference database 125. As shown in FIG.
  • a mutation ID information on the biological background of the mutation, molecular function information, clinical information, and literature information such as a book and a scientific article on the mutation are mutually associated. Are stored.
  • each mutation ID of the reference database 125 may be provided with “metadata related to gene panel related information” which is metadata related to information related to a gene panel (not shown).
  • the reference search unit 118 refers to the “metadata related to gene panel related information” according to the instruction from the information selection unit 112, and the range for searching the reference database 125 is indicated by the metadata. Change to a range.
  • the reference search unit 118 narrows down the reference information to be referred to in the drug database according to the "metadata related to gene panel related information" associated with each mutation and the information related to the input gene panel. It is possible to extract reference information according to the information on the gene panel.
  • the report creation unit 115 may create a report based on the information output by the drug search unit 117 or may create a report based on the information output by the reference search unit 118. Furthermore, the report creation unit 115 may create a report based on the information output from both the drug search unit 117 and the reference search unit 118.
  • the report created by the report creation unit 115 includes information on the identified mutation, information on the drug related to the mutation, a reference on the mutation (for example, information on molecular biological knowledge and documents on each mutation, etc. Or any combination of these information may be posted.
  • the information selection unit 112 selects, for example, information related to the target gene corresponding to the input information on the gene panel as a target to be included in the report, and the report generation unit 115 creates a report on which the selected information is posted. Control to
  • FIG. 37 is a diagram showing an example of a report created by the report creation unit 115.
  • “patient ID” indicating “subject ID”, “patient's gender”, “patient's disease name”, and the name of the doctor in charge of the subject at the medical institution 210 “ The name of the doctor in charge and the name of the institution showing the name of the medical institution are described.
  • the gene panel name "A panel” is also included as information on the gene panel.
  • information on the mutation identified by the mutation identification unit 114 and the drug search unit 117 search the drug database 124 in the column of “Detected gene mutation and related drug”, and are generated based on the search result. List is included.
  • the column of “clinical test list” includes a list of information on clinical trials of drugs generated by the drug search unit 117 by searching the drug database 124 and based on the search results.
  • Embodiment 4 Other embodiments of the present invention are described below. In addition, about the member which has the same function as the member demonstrated in the said embodiment for convenience of explanation, the same code
  • FIG. 38 is a functional block diagram showing another example of the configuration of the gene analysis device 1c.
  • an index sequence for identifying the read sequence information may be inserted for each sample or each type of gene panel.
  • the index sequence may be inserted only into the sequence of a specific gene among the genes to be analyzed by the gene panel. If it is the read sequence information in which the index sequence is not inserted, it is sufficient to allow the user to input information on the gene panel as shown in FIG.
  • FIG. 39 is a diagram showing an example of the data structure of the gene panel related information database 121 c.
  • names of selectable gene panels, gene panel IDs assigned to the respective gene panels, and index sequence information to be inserted are stored in association with each other.
  • the lead sequence information analyzed using the gene panel "A panel” having the gene panel ID "AAA” includes the index sequence "ppppppppppp", and the gene panel ID is "
  • the reading sequence information analyzed using the gene panel "B panel” which is BBB indicates data indicating that the index sequence” qqqqqqqqqqqq "is included.
  • "p" and "q” have shown the base.
  • the data adjustment unit 113c analyzes the read sequence information read by the sequence data reading unit 111, and the sequence includes the index sequences “ppppppppppp”, “qqqqqqqqq”, etc. stored in the gene panel related information database 121c. It is determined whether the If the index array is not included, the data adjustment unit 113c notifies the information selection unit 112c to that effect. On the other hand, when the index arrangement is included, the data adjustment unit 113 c outputs the detected index arrangement (for example, “ppppppppppp”) to the information selection unit 112 c.
  • the information selection unit 112c when notified by the data adjustment unit 113c that the index array is not included, displays the GUI shown in FIG. 6 together with a message such as "Please enter information about gene panel". Display on 16
  • the gene panel related information database 121c is searched using the index sequence as a key, and gene panel related information such as gene panel name and gene panel ID corresponding to the index sequence. Identify For example, when the index sequence received from the data adjustment unit 113c is "qqqqqqqqqqqqqqqqqq", the information selection unit 112c searches the gene panel related information database 121c, and specifies that "B panel” is used as a gene panel. And obtain gene panel related information of the gene panel. The acquired gene panel related information is applied to control of the data adjustment unit 113c, the mutation identification unit 114, the report creation unit 115, and the like as described above.
  • the index sequence when the index sequence is inserted into the read sequence information, it is possible to specify the gene panel related information without having the user input the gene panel related information. Thus, further convenience can be provided to the user.
  • FIG. 1 shows one medical institution 210 and one laboratory 120, it is not limited thereto. That is, the medical institution 210 may request the analysis to a plurality of inspection institutions 120, and the inspection institution 120 may receive an analysis request from a plurality of medical institutions 210. That is, each of the medical institution 210 and the examination institution 120 may be plural.
  • FIG. 1 and FIG. 2 show the sequencer 2 and the gene analysis device 1 of the inspection organization 120 one by one, it is not limited thereto. That is, the inspection organization 120 may be provided with a plurality of sequencers 2 and a plurality of gene analysis devices 1.
  • the genetic analysis system 100 should preferably be applied also to an institution having functions of both the medical institution 210 and the examination institution 120 (for example, a research institute which combines a clinical institution and an examination institution, and a university hospital). Is possible.
  • the present invention is not limited to the gene analysis system 100, and a gene analysis method executed by the gene analysis device 1, a program for controlling the gene analysis device 1 having a computer realized the gene analysis method, and a computer reading the same
  • a possible recording medium may also be suitably applied to an organization having the functions of both the medical institution 210 and the inspection institution 120.
  • Analysis using a gene panel may be used for analysis of polymorphisms such as single nucleotide polymorphism (SNP, Single Nucleotide Polymorphism) and copy number polymorphism (CNV, Copy Number Polymorphism).
  • the gene panel may be used for the output of information (also referred to as Tumor Mutation Burden etc.) regarding the amount of mutation or the like of the entire analysis target gene, and for calculation of the methylation frequency.
  • the input unit 17 may be a barcode reader, and the user may read the barcode. If a barcode is indicated on the label of the container of each reagent of each gene panel and on the surface of a box containing a set of reagents of the gene panel, the barcode is read using a barcode reader. Thus, information on the gene panel is input.
  • the control unit 11 When the control unit 11 causes the display unit 16 to display a GUI for inputting information related to the gene panel, the user may select a gene to be analyzed. In this case, as shown in FIG. 40, a list of candidate genes may be displayed on the GUI, and the user may select a gene to be analyzed by the gene panel.
  • the gene name displayed on the GUI is displayed based on the gene name of the gene assigned with the gene ID registered in the gene panel related information database 121.
  • the gene name in the list displayed as a selection branch is displayed based on the information regarding the gene panel registered in the gene panel related information database 121.
  • FIG. 40 shows a list including a plurality of gene names (for example, “AKT1” and “APC” etc.) to be analyzed, and an example in which a check box is provided on the left side of each gene name is shown .
  • gene names such as “AKT1” and “APC” are selected, and gene names such as “EML4” and “JAK3” are not selected.
  • the information selection unit 112 specifies gene panel IDs associated with the selected gene names from the selected gene names, searches the gene panel related information database 121, and selects a gene panel corresponding to the input gene panel name. Get information about
  • a list of gene panel names is displayed on the GUI for each disease such as “lung cancer panel” or “colorectal cancer panel”, and a desired disease for the user from among the gene panels shown in the list. You may select the gene panel regarding.
  • a list of disease names such as “lung cancer” and “colorectal cancer” may be displayed on the GUI, and the user may select a desired disease from among the disease names shown in the list.
  • the information selection unit 112 specifies the gene panel ID associated with the disease name from the selected disease name, searches the gene panel related information database 121, and selects the gene corresponding to the selected disease name. Get information about the panel.
  • the gene name displayed on the GUI as a selection branch for selecting a gene panel associated with the selected disease is displayed based on the information registered in the gene panel related information database 121.
  • the gene panel name of the gene panel regarding disease may be a reagent kit name.
  • the gene panel includes a set of reagents such as various buffers, enzymes, and primers used for target sequencing, which are performed to read the sequence of the gene to be analyzed by the sequencer 2.
  • the reagent kit name or gene panel name is given to the entire set of reagents.
  • the flow of the process shown in FIG. 5 assumes, for example, a case where a panel inspection using a gene panel designated from the medical institution 210 is performed in the inspection institution 120 which has received an analysis request from the medical institution 210.
  • the present invention is not limited to this, and analysis may be performed using a gene panel other than the gene panel designated by the sample provider.
  • samples are obtained from medical institution 210 and, in addition to analysis using a designated gene panel, Panel testing with different gene panels may also be performed.
  • the information selection unit 112 causes the display unit 16 to Along with the fact that the input gene panel is different from the designated gene panel, a message is displayed asking whether to use the input gene panel (step S206).
  • the information selection unit 112 receives the input. Then, the information selection unit 112 displays a message indicating that the gene panel input to the display unit 16 is usable (step S204).
  • the information selection unit 112 causes the information selection unit 112 to display the input gene in the display unit 16. A message indicating that the panel can not be used is displayed (step S205), and analysis by the gene analysis device 1 is prohibited.
  • the gene analyzer 1 when the gene analyzer 1 receives the input of the information regarding a gene panel, it may be the structure which can select either the input mode shown in FIG. 5 or the input mode shown in FIG.
  • the input mode shown in FIG. 5 in the case of performing a panel test using a gene panel designated by the medical institution 210, it is preferable to select the input mode shown in FIG. 5, and analysis is performed using a gene panel other than the designated gene panel
  • the user using the gene analysis apparatus 1 can select the input mode according to the application.
  • the gene analysis method acquires information on a gene panel, and changes an analysis algorithm for evaluating the quality of panel inspection based on the acquired information on the gene panel.
  • an analysis algorithm for evaluating the quality of panel inspection based on the acquired information on the gene panel.
  • the quality evaluation index for example, the reading quality included in the read sequence information output by the sequencer 2, the ratio of the bases read by the sequencer 2 to the bases included in the plurality of genes to be analyzed, the reading of the read sequence information There are indicators such as the depth (depth), the variation in the reading depth of the lead sequence information (depth), and whether or not all mutations of each standard gene contained in the quality control sample are detected.
  • FIG. 43 is a view showing another example of the configuration of the gene analysis device 1d.
  • the gene analysis device 1d can create a report including the evaluation result of the quality of the panel test.
  • the flow of data is indicated by arrows.
  • the analysis execution unit 110 d of the gene analysis apparatus 1 d further includes a quality control unit 119, and the storage unit 12 d is different from the gene analysis apparatus 1 illustrated in FIG. 4 in that the storage unit 12 d further includes a quality evaluation reference database 126.
  • the quality evaluation standard database 126 stores reference values that define whether the reliability of the analysis result in the panel inspection has reached a certain standard.
  • the certain standard is used, for example, to determine whether or not it has the reliability required to apply the analysis result of the panel test to treatment or diagnosis.
  • the information selection unit 112 changes the reference value of the quality evaluation index based on the information on the gene panel input from the input unit 17.
  • Quality evaluation index As a quality evaluation index generated by the quality control unit 119 for measurement, for example, read quality included in the read sequence information output by the sequencer 2, read by the sequencer 2 among bases contained in a plurality of genes to be analyzed
  • the index such as the ratio of the identified bases, the reading depth of the read sequence information (depth), the variation in the reading depth of the read sequence information (depth), and whether all mutations of each standard gene contained in the quality control sample were detected It can be mentioned.
  • Quality Evaluation Index (1) Quality Score The quality score is an index indicating the accuracy of each base in the gene sequence read by sequencer 2.
  • the quality score is included in the read sequence information (see FIG. 17).
  • the details of the quality score are described in the first embodiment, and thus the description thereof is omitted here.
  • the cluster concentration is an indicator indicating the read quality included in the read sequence information output by the sequencer 2.
  • the sequencer 2 locally amplifies and fixes a large number of single-stranded DNA fragments on the flow cell to form a cluster (see 9 in FIG. 14). Then, the cluster group on the flow cell is imaged using a fluorescence microscope, and the sequence is read by detecting fluorescence of different wavelengths corresponding to A, C, G, and T, respectively.
  • the cluster density is an index showing how closely the clusters of each gene formed on the flow cell are close to each other.
  • Quality evaluation index (3) an index indicating the ratio of the base sequence of the target area read by the sequencer 2 to the base sequence read by the sequencer 2 This index is a base of other than the target area read by the sequencer 2 Among them, it is an index indicating how many bases in the target area have been read, and is calculated as the ratio between the total number of bases read and the total number of bases in the target area.
  • Quality evaluation index (4) index indicating the reading depth (depth) of lead sequence information This index is an index based on the total number of lead sequences from which the bases have been read for each base contained in the gene to be analyzed, Of the read bases, the ratio is calculated as the ratio between the total number of bases whose depth is greater than or equal to a predetermined value and the total number of read bases.
  • the reading depth (depth) means the total number of pieces of read sequence information read for the same base, and is also called coverage, coverage, or depth of coverage.
  • FIG. 45 shows a graph showing the depth of each base when the full length of the gene to be analyzed (“target gene” in the figure) is L bases and the base of the read region is t1 base. ing.
  • the horizontal axis of the graph in FIG. 45 is the position of the base, and the vertical axis is the depth of each base.
  • the total number of bases in the area having a depth of a predetermined value (for example, 100) or more is (t2 + t3) bases.
  • the quality evaluation index (4) is generated as a value of (t2 + t3) / t1.
  • Quality evaluation index (5) index showing variation in reading depth (depth) of lead arrangement information This index is an index showing uniformity of depth. If the read sequence information obtained by reading a part of the read area is extremely large, the uniformity of the depth is low. On the other hand, when the read arrangement information is present all over the read area, the uniformity of the depth is high. Depth uniformity can be quantified, for example, using the interquartile range (IQR). The higher the IQR, the lower the uniformity, and the lower the IQR, the higher the uniformity.
  • IQR interquartile range
  • Quality evaluation index (6) Index indicating whether or not all mutations possessed by each standard gene contained in the quality control sample have been detected This index is used when the quality control sample is measured in combination with the sample collected from the subject , An indicator showing whether mutations possessed by each standard gene contained in the quality control sample were detected and correctly identified. For example, it is used as a quality evaluation index whether or not the position of a known mutation possessed by each standard gene contained in the quality control sample, the type of mutation, etc. were correctly identified. Quality control samples are prepared by mixing multiple standard genes.
  • FIG. 44 is a flow chart showing an example of the flow of processing for analyzing gene sequences.
  • preprocessing for analyzing gene sequences is performed.
  • the pretreatment includes a process of fragmenting a gene such as DNA contained in the sample and recovering the fragmented gene.
  • the analysis target in the panel inspection for quality evaluation may be a sample collected from a subject, or a quality control sample prepared by mixing a plurality of standard genes.
  • the quality control sample contains at least two of a standard gene including SNV, a standard gene including Insertion, a standard gene including Deletion, a standard gene including CNV, and a standard gene including Fusion.
  • the quality control sample contains, as standard genes, a partial sequence of gene A containing "SNV" to wild type and a partial sequence of gene B containing "Insertion" to wild type.
  • step S32 the sequencer 2 reads the base sequence of DNA contained in the pretreated sample.
  • step S33 the control unit 11d of the gene analysis device 1d causes the input unit 17 to display a GUI for causing the user to select information on the gene panel.
  • Information on the gene panel is acquired based on the user's input operation to the GUI.
  • the acquisition of the information on the gene panel is not limited to the user's input by the GUI, but may be acquired by an identifier such as a barcode attached to the gene panel, or may be identified by reading the index sequence.
  • the control unit 11 d of the gene analysis device 1 d determines the type of gene panel based on the acquired information on the gene panel.
  • the gene analysis device 1 d changes the analysis algorithm so as to execute the quality control of the panel inspection according to the type of the acquired gene panel.
  • the gene analysis device 1d analyzes the gene sequence according to the type of gene panel, and specifies the presence or absence of a mutation in the base sequence, the position of the mutation, the type of mutation, and the like. By analyzing the read gene sequences, the detected mutations are identified.
  • the gene analysis device 1d evaluates the quality of the panel inspection based on the generated quality evaluation index.
  • the quality management unit 119 acquires the quality score (quality evaluation index 1) and the cluster concentration (quality evaluation index 2) from the array data reading unit 111.
  • quality evaluation index 3 the ratio of bases in the target area read by the sequencer 2
  • quality evaluation index 4 the reading depth of the read sequence information
  • quality evaluation index 5 the variation of the reading depth of the read sequence information
  • the quality control unit 119 does not need to acquire all of these quality evaluation indicators, and may acquire one or more arbitrary indicators.
  • the quality management unit 119 compares the acquired quality evaluation index with the reference value of the quality evaluation index stored in the quality evaluation standard database 126, and determines whether the analysis result has sufficient reliability.
  • the quality evaluation standard database 126 stores the standard value of the quality evaluation index in association with the information specifying the gene panel.
  • the quality evaluation index A is determined using the reference value a
  • the quality evaluation index B is determined using the reference value b.
  • the quality evaluation index A is determined using the reference value c
  • the quality evaluation index B is determined using the reference value b.
  • the quality evaluation index D is determined using the reference value e.
  • the quality evaluation is performed based on the two indexes of the quality evaluation indicators A and B, but in the analysis of the C panel, the quality evaluation is performed using only the quality evaluation indicator D. Is going.
  • the number of quality evaluation indexes to be used may be changed.
  • the gene analysis device 1d creates a report including the evaluation result of the identified mutation and the quality of the panel test determined in step S34.
  • FIG. 46 is a diagram showing an example of a report created by the report creation unit 115. As shown in FIG. In the upper left part of the report shown in this example, “patient ID” indicating “subject ID”, “patient's gender”, “patient's disease name”, and the name of the doctor in charge of the subject at the medical institution 210 “ The name of the doctor in charge and the name of the institution showing the name of the medical institution are described.
  • the gene panel name "A panel” is also included as information on the gene panel. Furthermore, a quality evaluation index "QC index”, which is information on the quality of panel inspection, is output in the report.

Abstract

To improve user convenience in analyzing gene sequences using various gene panels. A gene analyzer (1) for analyzing gene sequence information comprises: a control unit (11) acquiring read sequence information read out by a sequencer (2) and information relating to a plurality of analyte gene-containing panels; and an output unit (13) outputting analysis results of the read sequence information based on the information relating to the panels acquired by the control unit (11).

Description

遺伝子解析方法、遺伝子解析装置、管理サーバ、遺伝子解析システム、プログラム、および記録媒体Gene analysis method, gene analysis device, management server, gene analysis system, program, and recording medium
 本発明は、遺伝子の変異を解析するためにコンピュータによって実施される遺伝子解析方法、遺伝子解析装置、管理サーバ、遺伝子解析システム、プログラム、および記録媒体に関する。 The present invention relates to a gene analysis method, a gene analysis device, a management server, a gene analysis system, a program, and a recording medium implemented by a computer to analyze gene mutations.
 近年の遺伝子検査技術の進展の中、被検体の遺伝子配列を解析し、被検体の特性に応じた治療法や薬剤を適切に選択する個別化医療への期待が高まっている。遺伝子配列の解析には、例えば、特定の疾患に関連する特定の遺伝子における異常や、タンパク質に翻訳されるエクソン領域における異常を、次世代シーケンサーを用いてハイスループットに解析するパネル検査が知られている。 With recent advances in genetic testing technology, there is increasing hope for personalized medicine that analyzes the gene sequence of a subject and appropriately selects a therapeutic method or drug according to the subject's characteristics. For the analysis of gene sequences, for example, a panel test is known which analyzes an abnormality in a specific gene associated with a specific disease or an abnormality in an exon region translated into a protein at high throughput using a next-generation sequencer There is.
 特許文献1には、遺伝子等が参照となる配列と比べて異常があるかを判定し、異常を示した遺伝子等に対応して使用される薬物療法を同定して、被検体に合わせて治療方法を決定するシステムが記載されている。 In Patent Document 1, it is determined whether a gene or the like is abnormal as compared to a reference sequence, and a drug therapy used corresponding to the gene or the like showing an abnormality is identified, and treatment is performed according to the subject. A system for determining the method is described.
特表2015-200678号公報JP-A-2015-200678
 遺伝子検査では、解析対象となる遺伝子ごとに異なる解析が必要となる。例えば、次世代シーケンサーを用いたパネル検査では、断片化した遺伝子を同時並列的に読み取り、読み取った各断片の塩基配列であるリード配列情報を参照配列にマッピングすることで、塩基配列の解析が行われる。ここで、遺伝子パネル毎に解析対象となる遺伝子が異なる場合、測定対象遺伝子パネルごとに異なる解析プログラムが必要となる場合がある。よって、パネル検査を実施する場合に、遺伝子パネル毎に使用する解析プログラムを使い分けなければならないという煩わしさがあった。 In genetic testing, different analyzes are required for each gene to be analyzed. For example, in panel inspection using a next-generation sequencer, analysis of the base sequence is performed by reading fragmented genes in parallel and mapping read sequence information, which is the base sequence of each read fragment, to a reference sequence. It will be. Here, when the genes to be analyzed differ from one gene panel to another, a different analysis program may be required for each gene panel to be measured. Therefore, when performing panel test, there was an inconvenience that it was necessary to use properly an analysis program to be used for each gene panel.
 また、遺伝子検査において、エクソン領域全体を解析した場合には、被検体の遺伝子において多くの変異が検出される。ここで、変異の中にはその変異の臨床的意義や治療に有効な薬剤が確立しておらず、医師が実際の治療に活用できる情報以外のものも含まれる。医師が遺伝子検査の結果を被検体の実際の治療に適用しようとする場合には、検出した多くの変異の中から実際の治療に活用可能となる変異を選択的に知りたいという要望がある。 In addition, in genetic testing, when the entire exon region is analyzed, many mutations are detected in the gene of the subject. Here, among the mutations, clinical significance of the mutation and an effective drug for treatment have not been established, and include information other than information that the doctor can use for actual treatment. When a doctor intends to apply the result of a genetic test to the actual treatment of a subject, there is a demand to selectively know which mutations can be used for the actual treatment among many detected mutations.
 このような状況の中、パネル検査を実施するユーザは、検査対象遺伝子や要望に応じてパネルごとにシーケンサーによる遺伝子解析に用いる専用解析プログラムを準備し、遺伝子解析を行う必要があった。 Under such circumstances, the user performing the panel test needs to prepare a dedicated analysis program to be used for gene analysis by the sequencer for each panel according to the gene to be tested and the request, and perform gene analysis.
 本発明の一態様は、遺伝子パネルを用いて解析対象遺伝子を解析するにあたり、さまざまな遺伝子パネルに適用可能なユーザの利便性の高い遺伝子解析方法、遺伝子解析装置、管理サーバ、および遺伝子解析システムなどを実現することを目的とする。 One aspect of the present invention is a user-friendly gene analysis method, a gene analysis device, a management server, a gene analysis system, etc. which can be applied to various gene panels when analyzing genes to be analyzed using the gene panel Aims to achieve
 上記の課題を解決するために、本発明の一態様に係る遺伝子解析方法は、遺伝子の配列情報を解析する遺伝子解析方法であって、シーケンサー(2)により読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得し、取得した遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果を出力する。 In order to solve the above problems, a gene analysis method according to an aspect of the present invention is a gene analysis method for analyzing sequence information of a gene, comprising: lead sequence information read by a sequencer (2); And information on a gene panel including a plurality of genes, and an analysis result of lead sequence information is output based on the acquired information on the gene panel.
 この態様によれば、リード配列情報の解析結果を、取得した遺伝子パネルに関する情報に基づいて出力する。この態様により、例えば、パネル検査を実施するユーザは、さまざまな遺伝子パネルを用いて種々の組合せの解析対象遺伝子を解析するにあたり、遺伝子パネルに応じた出力が得られるため、ユーザの利便性が向上する。 According to this aspect, the analysis result of the lead sequence information is output based on the acquired information on the gene panel. According to this aspect, for example, when the user who performs panel inspection analyzes various target genes of analysis using various gene panels, the output according to the gene panel can be obtained, thereby improving user convenience. Do.
 「遺伝子」とは、スタートコドンからストップコドンまでのゲノム上の配列、ゲノム上の配列から生成されたmRNA、およびゲノム上のプロモータ領域などを含む。解析対象となる遺伝子は、ゲノム上の遺伝子から転写されたmRNAを含む。mRNAは、pre-mRNAを含む。 The "gene" includes a sequence on the genome from the start codon to the stop codon, an mRNA generated from the sequence on the genome, a promoter region on the genome, and the like. Genes to be analyzed include mRNA transcribed from genes on the genome. mRNA includes pre-mRNA.
 「リード配列」とは、シーケンシングによって得られたポリヌクレオチド配列を意味しており、「リード配列情報」はシーケンサー2により出力されるリード配列の情報を指している。 The “lead sequence” means a polynucleotide sequence obtained by sequencing, and the “lead sequence information” refers to the information of the lead sequence outputted by the sequencer 2.
 「遺伝子パネル」とは、複数の解析対象を一連の解析処理を1回実行(1ラン)することによって解析するための試薬キットを意味する。遺伝子パネルは、多くの場合、プライマーやプローブなどの一揃いの試薬を含んでいる。ここで、「複数の解析対象」とは、複数の遺伝子配列であってもよいし、ある遺伝子の複数のエクソンであってもよい。たとえば、遺伝子Aの配列および遺伝子Bの配列を解析するための試薬キット、遺伝子Aのエクソン1の配列および同遺伝子のエクソン2の配列を解析するための試薬キットなどが含まれる。遺伝子パネルのより具体的な例として、特定の疾病に関する複数の遺伝子配列を解析するための試薬キットが挙げられる。この遺伝子パネルを用いた場合、診療上重要となる1または複数の遺伝子の増幅、配列の置換、欠損、挿入、プロモータ領域のメチル化、および融合遺伝子などを解析することができる。遺伝子パネルは、解析対象として複数の遺伝子を含んでいる。遺伝子パネルとしては、例えば、解析対象となる遺伝子が100以上のラージパネルを用いることができる。 The "gene panel" means a reagent kit for analyzing a plurality of analysis objects by performing a series of analysis processes once (one run). Gene panels often contain a complete set of reagents such as primers and probes. Here, “a plurality of analysis targets” may be a plurality of gene sequences or a plurality of exons of a certain gene. For example, a reagent kit for analyzing the sequence of gene A and the sequence of gene B, a reagent kit for analyzing the sequence of exon 1 of gene A and the sequence of exon 2 of the same gene, and the like are included. A more specific example of the gene panel includes a reagent kit for analyzing a plurality of gene sequences related to a specific disease. When this gene panel is used, amplification of one or more genes that are important for medical treatment, substitution of sequences, deletion, insertion, methylation of promoter region, fusion genes, and the like can be analyzed. The gene panel contains a plurality of genes to be analyzed. As the gene panel, for example, a large panel of 100 or more genes to be analyzed can be used.
 「遺伝子パネルに関する情報」とは、遺伝子パネルを特定するために用いられ得る情報であればよく、例えば、遺伝子パネル名、およびパネル検査における解析対象となる遺伝子の名などであってよい。 The “information on gene panel” may be any information that can be used to specify a gene panel, and may be, for example, a gene panel name and a name of a gene to be analyzed in panel inspection.
 取得された遺伝子パネルに関する情報に基づいて、解析結果の出力対象となる遺伝子を変更してもよい。 The target gene of the analysis result may be changed based on the information on the acquired gene panel.
 この態様により、遺伝子パネルが解析対象とする遺伝子についての解析結果を出力することができる。 According to this aspect, it is possible to output an analysis result of a gene to be analyzed by the gene panel.
 取得された遺伝子パネルに関する情報に基づいて、解析結果の出力対象となる遺伝子を解析するための解析アルゴリズムを変更してもよい。 Based on the information on the acquired gene panel, an analysis algorithm for analyzing a gene as an output target of the analysis result may be changed.
 この態様により、遺伝子パネルが対象とする遺伝子を解析する場合に、解析に用いる解析プログラムを遺伝子毎に設定しなくてもよい。 According to this aspect, when analyzing a gene targeted by the gene panel, an analysis program used for analysis may not be set for each gene.
 複数の遺伝子が対応付けられた情報を、遺伝子パネルに関する情報として入力させるための入力画面を表示部(16)に表示してもよい。 An input screen for inputting information in which a plurality of genes are associated as information on a gene panel may be displayed on the display unit (16).
 複数の遺伝子パネルに関する情報から少なくとも1つの情報を選択させるための入力画面を表示部(16)に表示してもよい。 An input screen for selecting at least one piece of information from a plurality of gene panels may be displayed on the display unit (16).
 試薬キット名を遺伝子パネルに関する情報として入力させるための入力画面を表示部(16)に表示してもよい。 An input screen for inputting the reagent kit name as information on the gene panel may be displayed on the display unit (16).
 解析対象となる複数の遺伝子を遺伝子パネルに関する情報として入力させるための入力画面を表示部(16)に表示してもよい。 An input screen for inputting a plurality of genes to be analyzed as information on a gene panel may be displayed on the display unit (16).
 解析対象となる疾患を遺伝子パネルに関する情報として入力させるための入力画面を表示部(16)に表示してもよい。 An input screen for inputting a disease to be analyzed as information on a gene panel may be displayed on the display unit (16).
 取得した遺伝子パネルに関する情報に基づいて、リード配列情報の比較対象とすべき参照配列情報を選択し、リード配列情報と、選択された参照配列情報との比較に基づく解析結果を出力してもよい。 Based on the information on the acquired gene panel, reference sequence information to be compared with the read sequence information may be selected, and an analysis result based on a comparison between the read sequence information and the selected reference sequence information may be output. .
 「参照配列」は、リード配列が遺伝子上のどの領域に対応するか、およびリード配列が遺伝子上のどの変異に対応するかなどを判定するために、リード配列をマッピングする対象となる配列である。また、「マッピング」は、対象となる参照配列に各リード配列を整列させる処理を意味している。具体的には、参照するゲノム配列中に、読み取ったリード配列と同一または類似する配列を有する領域を見いだして、該領域にリード配列を帰属させることを意図している。 The “reference sequence” is a sequence to which the lead sequence is to be mapped in order to determine which region on the gene the lead sequence corresponds to, which mutation the lead sequence corresponds to the gene, etc. . Also, “mapping” means a process of aligning each read sequence to a target reference sequence. Specifically, it is intended to find a region having the same or similar sequence as the read sequence read in the genome sequence to be referred, and assign the read sequence to the region.
 取得された遺伝子パネルに関する情報に基づいて、変異配列が含まれた複数の参照配列情報から、リード配列情報の比較対象とすべき参照配列情報を選択し、選択された参照配列に基づく解析結果を出力してもよい。 Based on the information on the acquired gene panel, the reference sequence information to be compared with the lead sequence information is selected from a plurality of reference sequence information including the mutant sequence, and the analysis result based on the selected reference sequence is You may output it.
 「変異」とは、遺伝子の多型、置換およびInDelなどの変異のうちの少なくともいずれかを意味する。「InDel(Insertion and/or Deletion)」は、挿入、欠失、または、挿入および欠失の両方が含まれた変異を意味している。遺伝子の「多型」は、SNV(Single Nucleotide Variant、一塩基多型)、VNTR(Variable Nucleotide of Tandem Repeat、反復配列多型)、およびSTRP(Short Tandem Repeat Polymorphism、マイクロサテライト多型)などを含む。 “Mutation” means polymorphism, substitution and / or mutation such as InDel of a gene. "InDel (Insertion and / or Deletion)" means a mutation that includes an insertion, a deletion, or both an insertion and a deletion. "Polymorphism" of a gene includes SNV (Single Nucleotide Variant, single nucleotide polymorphism), VNTR (Variable Nucleotide of Tandem Repeat, repeat sequence polymorphism), STRP (Short Tandem Repeat Polymorphism, microsatellite polymorphism), etc. .
 遺伝子パネルの解析対象とする遺伝子に関する情報を遺伝子パネル毎に記憶する遺伝子パネル関連情報データベース(121)を用いて、リード配列情報の解析結果を出力してもよい。 The analysis result of the lead sequence information may be output using a gene panel related information database (121) that stores information on genes to be analyzed in the gene panel for each gene panel.
 選択された参照配列を参照配列データベース(122)から読み出して、読み出した参照配列に対してリード配列情報をマッピングすることによりアライメントを行ってもよい。 Alignment may be performed by reading the selected reference sequence from the reference sequence database (122) and mapping the read sequence information to the read reference sequence.
 選択された参照配列を参照配列データベースから読み出して、参照配列とリード配列情報との一致度に基づいて、リード配列情報の位置を決定し、リード配列情報に含まれる変異を同定してもよい。 The selected reference sequence may be read from the reference sequence database, the position of the read sequence information may be determined based on the degree of matching between the reference sequence and the read sequence information, and the mutations included in the read sequence information may be identified.
 リード配列情報の解析によって同定された変異のうち、取得された遺伝子パネルに関する情報に対応付けられた変異に関する情報を含む解析結果を出力してもよい。 Among the mutations identified by the analysis of the lead sequence information, an analysis result including information on the mutations associated with the acquired information on the gene panel may be output.
 取得された遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果として、リード配列情報の解析によって同定された変異に関連する薬剤情報を出力してもよい。 Based on the information on the acquired gene panel, drug information related to the mutation identified by the analysis of the lead sequence information may be output as the analysis result of the lead sequence information.
 リード配列情報の解析によって同定された変異に基づいて、解析対象とする遺伝子の変異と、遺伝子パネルに関連する薬剤とを対応付けて記憶する薬剤データベース(124)を検索してもよい。 Based on the mutations identified by the analysis of the lead sequence information, a drug database (124) may be searched in which mutations of genes to be analyzed and drugs related to the gene panel are associated and stored.
 薬剤データベース(124)の検索において抽出された、リード配列情報の解析によって同定された変異に関連する薬剤のリストを生成してもよい。 A list of agents associated with the mutations identified by analysis of the lead sequence information, extracted in a search of the agent database (124) may be generated.
 薬剤データベース(124)の検索において抽出された、リード配列情報の解析によって同定された変異に関連する薬剤のリストを生成してもよい。 A list of agents associated with the mutations identified by analysis of the lead sequence information, extracted in a search of the agent database (124) may be generated.
 リード配列情報の解析結果として、薬剤の承認状況を含む薬剤情報を出力してもよい。 As the analysis result of lead sequence information, drug information including the approval status of the drug may be output.
 リード配列情報の解析によって同定された変異に基づいて、解析対象とする遺伝子の変異と、変異に関連する参照情報とを対応付けて記憶するリファレンスデータベース(125)を検索してもよい。 Based on the mutations identified by the analysis of the lead sequence information, a reference database (125) may be searched, which stores the mutations of the gene to be analyzed and the reference information related to the mutations in association.
 リード配列情報の解析結果に基づいてレポートを作成し、レポートは、リード配列情報の解析によって同定された変異のうち、取得された遺伝子パネルに関連する情報に対応する変異に関する情報を含んでいてもよい。 Based on the analysis result of the lead sequence information, a report is prepared, and the report may include information on mutations among the mutations identified by the analysis of the lead sequence information, which correspond to the information related to the acquired gene panel. Good.
 同定されたすべての変異の中から、取得された遺伝子パネルに関する情報に対応する変異を、遺伝子パネルに関する情報に基づいて選択し、リード配列情報の解析結果として、選択された変異に関連する情報を出力してもよい。 Among all the identified mutations, a mutation corresponding to the information on the acquired gene panel is selected based on the information on the gene panel, and information associated with the selected mutation is obtained as an analysis result of the lead sequence information. You may output it.
 レポートは、遺伝子パネルに関連する情報を含んでいてもよい。 The report may include information related to the gene panel.
 レポートは、薬剤のリストおよび参照情報との少なくともいずれか一方を含んでいてもよい。 The report may include at least one of a drug list and reference information.
 遺伝子の配列情報の解析状況に関する情報を管理サーバ(3)に送信してもよい。 Information on the analysis status of gene sequence information may be transmitted to the management server (3).
 遺伝子の配列情報の解析状況に関する情報を、遺伝子パネルに関する情報毎に、管理サーバ(3)に送信してもよい。 Information on the analysis status of gene sequence information may be transmitted to the management server (3) for each information on the gene panel.
 遺伝子の配列解析回数を、遺伝子パネルに関する情報毎に、管理サーバ(3)に送信してもよい。 The number of gene sequence analyzes may be transmitted to the management server (3) for each information on the gene panel.
 解析された遺伝子の数を、遺伝子パネルに関する情報毎に、管理サーバ(3)に送信してもよい。 The number of analyzed genes may be transmitted to the management server (3) for each information on the gene panel.
 遺伝子の配列解析において処理されたデータ量に関する情報を、遺伝子パネルに関する情報毎に、管理サーバ(3)に送信してもよい。 Information on the amount of data processed in gene sequence analysis may be sent to the management server (3) for each information on the gene panel.
 リード配列情報と、取得した遺伝子パネルに関する情報に関連付けられた遺伝子パネルが解析対象とする遺伝子の配列情報とを比較した比較結果を、リード配列情報の解析結果として出力してもよい。 A comparison result of comparison between the lead sequence information and the sequence information of the gene to be analyzed by the gene panel associated with the acquired information on the gene panel may be output as an analysis result of the lead sequence information.
 取得した遺伝子パネルに関する情報が登録済のものでなかった場合に、エラーを表示させてもよい。 An error may be displayed if the acquired information on the gene panel is not registered.
 例えば、取得した遺伝子パネルに関する情報が、遺伝子パネル関連情報データベース(121)等に登録されていないとき、当該遺伝子パネルを用いて解析を行った場合には不適切な解析結果となる可能性がある。この態様によれば、未登録の遺伝子パネルを使用して不適切な結果を出力することや、不要な解析を実行したりすることを防止することができる。 For example, when the information about the acquired gene panel is not registered in the gene panel related information database (121) etc., there is a possibility that the analysis result will be inappropriate when the analysis is performed using the gene panel . According to this aspect, it is possible to prevent outputting an inappropriate result using an unregistered gene panel or performing unnecessary analysis.
 取得した遺伝子パネルに関する情報が医療機関(210)から指定されたものでなかった場合に、エラーを表示させてもよい。 An error may be displayed if the information on the acquired gene panel is not specified from the medical institution (210).
 エラーが表示された後に、ユーザから入力された遺伝子パネルの使用の許可を求める入力がされた場合に、遺伝子パネルの解析を許可してもよい。 After the error is displayed, analysis of the gene panel may be permitted if the user inputs permission to use the gene panel.
 取得した遺伝子パネルに関する情報が登録済のものでなかった場合に、遺伝子パネルの解析を禁止してもよい。 Analysis of the gene panel may be prohibited if the acquired information on the gene panel is not registered.
 取得した遺伝子パネルに関する情報が医療機関(210)から指定されたものでなかった場合に、遺伝子パネルの解析を禁止してもよい。 The analysis of the gene panel may be prohibited if the information on the acquired gene panel is not specified from the medical institution (210).
 遺伝子パネルに関する情報を取得する工程には複数のモードがあり、複数のモードのうちのいずれかを選択可能であってもよい。 There is a plurality of modes in the step of acquiring information on the gene panel, and any of the plurality of modes may be selectable.
 リード配列情報のうち、取得した遺伝子パネルに関する情報が示す遺伝子パネルが解析対象としない遺伝子の配列を含むリード配列情報が所定数以上である場合に、エラーを表示させてもよい。 An error may be displayed when the number of pieces of lead sequence information including the sequences of genes not to be analyzed among the pieces of lead sequence information indicated by the information on the acquired gene panel is equal to or more than a predetermined number.
 リード配列情報には、遺伝子パネルに関する情報に関連付けられたインデックス配列が含まれていてもよい。 The lead sequence information may include an index sequence associated with the information on the gene panel.
 インデックス配列は、遺伝子パネルに関する情報毎に異なっていてもよい。 The index sequence may be different for each information on the gene panel.
 リード配列情報に含まれるインデックス配列と関連付けられた遺伝子パネルに関する情報が、取得した遺伝子パネルに関する情報と異なる場合に、エラーを表示させてもよい。 An error may be displayed when the information on the gene panel associated with the index sequence included in the lead sequence information is different from the information on the acquired gene panel.
 第1試料について、第1の解析対象遺伝子群を解析するための第1遺伝子パネルを用いて読み取られた第1リード配列情報を解析し、第2試料について、第2の解析対象遺伝子群を解析するための第2遺伝子パネルを用いて読み取られた第2リード配列情報を解析し、遺伝子パネルを特定する情報の選択を受け付けて遺伝子パネルに関する情報を取得し、第1リード配列情報を解析した解析結果、および第2リード配列情報を解析した解析結果を、選択された遺伝子パネルに関する情報に基づいて出力してもよい。 For the first sample, first read sequence information read using the first gene panel for analyzing the first analysis target gene group is analyzed, and for the second sample, the second analysis target gene group is analyzed To analyze the second read sequence information read using the second gene panel to receive the selection of the information specifying the gene panel, obtain information on the gene panel, and analyze the first read sequence information The result and the analysis result obtained by analyzing the second read sequence information may be output based on the information on the selected gene panel.
 ここで、「試料」は、検体またはサンプルとも換言でき、当該分野において標本、調製物と同義で用いられ、供給源としての生物材料(例えば、個体、体液、細胞株、組織培養物もしくは組織切片)から得られる、任意の標本や調製物が意図される。 Here, “sample” can also be used as a specimen or a sample, and is used in the same sense as a specimen or preparation in the art, and a biological material as a source (eg, an individual, a body fluid, a cell line, a tissue culture or a tissue section) Any preparations or preparations obtained from) are contemplated.
 遺伝子パネル検査の品質を評価する工程をさらに含み、解析結果を出力する工程では、取得した遺伝子パネルに関する情報に基づいて、品質の評価結果を出力してもよい。 The method may further include the step of evaluating the quality of the gene panel test, and in the step of outputting the analysis result, the evaluation result of quality may be output based on the information on the acquired gene panel.
 この態様により、さまざまな遺伝子パネルを用いて種々の組合せの解析対象遺伝子を解析するにあたり、遺伝子パネルに応じた適切な品質管理を行うことができる。 According to this aspect, when analyzing various combinations of analysis target genes using various gene panels, appropriate quality control can be performed according to the gene panels.
 「品質評価指標」は、遺伝子パネル検査の品質を評価する指標であり、例えば、シーケンサー(2)が出力するリード配列情報に含まれる読み取り品質、複数の解析対象となる遺伝子に含まれる塩基のうちシーケンサー(2)で読み取られた塩基の割合、リード配列情報の読み取り深度(デプス)、リード配列情報の読み取り深度(デプス)のばらつき、品質管理試料に含まれる各標準遺伝子の変異が全て検出されたか否か、等の指標が挙げられる。 The “quality evaluation index” is an index for evaluating the quality of gene panel test, and, for example, the reading quality included in the lead sequence information output by the sequencer (2) and the bases among the genes included in the plurality of genes to be analyzed Was the ratio of bases read by the sequencer (2), the read depth of the read sequence information (depth), the variation of the read depth of the read sequence information (depth), or all mutations of each standard gene included in the quality control sample detected? Indicators such as whether or not.
 遺伝子パネル検査の品質を評価する工程において、取得した遺伝子パネルに関する情報に基づいて、品質を評価する際に用いる品質管理指標を選択してもよい。 In the step of evaluating the quality of the gene panel test, a quality control index to be used in evaluating the quality may be selected based on the acquired information on the gene panel.
 遺伝子パネル検査の品質を評価する工程において、取得した遺伝子パネルに関する情報に基づいて、品質を評価する際に用いる品質管理指標の評価基準を選択してもよい。 In the step of evaluating the quality of the gene panel test, based on the acquired information on the gene panel, the evaluation criteria of the quality control index used in evaluating the quality may be selected.
 遺伝子パネル検査の品質を評価する工程において、取得した遺伝子パネルに関する情報に基づいて、品質を評価する際に用いる品質管理指標の数を選択してもよい。 In the step of evaluating the quality of the gene panel test, the number of quality control indicators to be used in evaluating the quality may be selected based on the acquired information on the gene panel.
 上記の課題を解決するために、本発明の一態様に係る遺伝子解析装置(1)は、遺伝子の配列情報を解析する遺伝子解析装置(1)であって、シーケンサー(2)により読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得する制御部(11)と、出力部(13)と、を備え、制御部(11)は、取得した遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果を出力部(13)に出力する。 In order to solve the above problems, a gene analysis device (1) according to an aspect of the present invention is a gene analysis device (1) for analyzing sequence information of a gene, and a read by a sequencer (2) A control unit (11) for acquiring sequence information and information on a gene panel including a plurality of genes to be analyzed, and an output unit (13), the control unit (11) relates to the acquired gene panel Based on the information, the analysis result of the read sequence information is output to the output unit (13).
 この態様によれば、遺伝子解析装置(1)は、リード配列情報の解析結果を、取得した遺伝子パネルに関する情報に基づいて出力する。この態様により、パネル検査を実施するユーザは、さまざまな遺伝子パネルを用いて遺伝子を解析するにあたり、用いる遺伝子パネルに応じた出力が得られるため、ユーザの利便性が向上する。 According to this aspect, the gene analysis device (1) outputs the analysis result of the lead sequence information based on the acquired information on the gene panel. According to this aspect, when the user performing the panel test analyzes the gene using various gene panels, the output according to the gene panel to be used can be obtained, thereby improving the convenience of the user.
 制御部(11)は、取得した遺伝子パネルに関する情報に基づいて、リード配列情報の比較対象とすべき参照配列情報を選択し、リード配列情報と、選択された参照配列情報との比較に基づく解析結果を出力部(13)に出力してもよい。 The control unit (11) selects reference sequence information to be compared with the read sequence information based on the acquired information on the gene panel, and analyzes based on comparison between the read sequence information and the selected reference sequence information. The result may be output to the output unit (13).
 制御部(11)は、リード配列情報の解析によって同定された変異のうち、取得された遺伝子パネルに関する情報に対応付けられた変異に関する情報を含む解析結果を出力部(13)に出力してもよい。 Among the mutations identified by the analysis of the lead sequence information, the control unit (11) outputs, to the output unit (13), an analysis result including information on the mutations associated with the acquired information on the gene panel. Good.
 制御部(11)は、取得された遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果として、リード配列情報の解析によって同定された変異に関連する薬剤情報を出力部(13)に出力してもよい。 The control unit (11) outputs the drug information related to the mutation identified by the analysis of the lead sequence information to the output unit (13) as an analysis result of the lead sequence information based on the acquired information on the gene panel. May be
 制御部(11)は、取得した前記遺伝子パネルに関する情報に基づいて、遺伝子パネル検査の品質の評価結果を出力部(13)に出力してもよい。 The control unit (11) may output the evaluation result of the quality of the gene panel test to the output unit (13) based on the acquired information on the gene panel.
 上記の課題を解決するために、本発明の一態様に係る管理サーバ(3)は、遺伝子の配列解析を行うユーザを特定する情報と、使用された遺伝子パネルに関する情報と、配列情報の解析状況に関する情報とを含む情報とを、遺伝子解析装置(1)から受信する。 In order to solve the above problems, the management server (3) according to one aspect of the present invention is information for specifying a user who performs gene sequence analysis, information on a gene panel used, and analysis status of the sequence information And information including the information on the information from the gene analysis device (1).
 「配列情報の解析状況に関する情報」は、例えば、遺伝子解析装置1において所定の遺伝子パネルを用いた解析が実行された配列解析回数であってもよいし、解析された遺伝子数であってもよいし、同定された変異の数などの累計であってもよい。あるいは、解析において処理されたデータ量に関する情報であってもよい。 The “information regarding the analysis status of sequence information” may be, for example, the number of times of sequence analysis in which analysis using a predetermined gene panel is performed in the gene analysis device 1, or the number of analyzed genes. It may be a total such as the number of mutations identified. Alternatively, it may be information on the amount of data processed in the analysis.
 管理サーバ(3)は、遺伝子の配列情報の解析状況に関する情報を、遺伝子解析装置(1)から受信してもよい。 The management server (3) may receive, from the gene analysis device (1), information on the analysis state of the sequence information of the gene.
 管理サーバ(3)は、遺伝子の配列情報の解析状況に関する情報を、遺伝子解析装置(1)から遺伝子パネルに関する情報毎に受信してもよい。 The management server (3) may receive, from the gene analysis device (1), information on the analysis status of the sequence information of the gene for each information on the gene panel.
 管理サーバ(3)は、遺伝子の配列解析回数を、遺伝子パネルに関する情報毎に、遺伝子解析装置(1)から受信してもよい。 The management server (3) may receive the number of times of sequence analysis of the gene from the gene analysis device (1) for each information on the gene panel.
 管理サーバ(3)は、解析された遺伝子の数を、遺伝子パネルに関する情報毎に、遺伝子解析装置(1)から受信してもよい。 The management server (3) may receive the number of analyzed genes from the gene analysis device (1) for each information related to the gene panel.
 管理サーバ(3)は、遺伝子の配列解析において処理されたデータ量に関する情報を、遺伝子パネルに関する情報毎に、遺伝子解析装置(1)から受信してもよい。 The management server (3) may receive information on the amount of data processed in the sequence analysis of the gene from the gene analysis device (1) for each information on the gene panel.
 管理サーバ(3)は、ユーザが遺伝子解析装置(1)を用いて配列解析を行った場合の対価を、遺伝子の配列情報の解析状況に関する情報に基づいて計算してもよい。 The management server (3) may calculate the value when the user performs sequence analysis using the gene analysis device (1), based on the information on the analysis status of the gene sequence information.
 管理サーバ(3)は、遺伝子パネルに関する情報の更新要求を、遺伝子解析装置(1)から受信してもよい。 The management server (3) may receive an update request for information on the gene panel from the gene analysis device (1).
 上記の課題を解決するために、本発明の一態様に係る遺伝子解析システム(100)は、シーケンサー(2)により読み取られたリード配列情報および解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得する制御部(11)と、制御部(11)が取得した遺伝子パネルに関する情報に基づいた、リード配列情報の解析結果を出力する出力部(13)と、を備える遺伝子解析装置(1)と、遺伝子の配列解析を行うユーザを特定する情報と、使用された遺伝子パネルに関する情報と、遺伝子の配列の解析状況に関する情報とを含む情報を、遺伝子解析装置(1)からネットワーク(4)を介して受信する管理サーバ(3)と、を備える。 In order to solve the above problems, a gene analysis system (100) according to one aspect of the present invention comprises: information on a gene panel including lead sequence information read by a sequencer (2) and a plurality of genes to be analyzed A gene analysis device (1) comprising: a control unit (11) for acquiring data; and an output unit (13) for outputting an analysis result of lead sequence information based on the information on the gene panel acquired by the control unit (11) The information from the gene analyzer (1) to the network (4), including information specifying the user performing gene sequence analysis, information on the gene panel used, and information on the analysis status of gene sequences. And a management server (3) to receive the information.
 この態様によれば、遺伝子解析装置(1)は、リード配列情報の解析結果を、取得した遺伝子パネルに関する情報に基づいて出力する。一方、管理サーバ(3)は、遺伝子解析装置(1)から、遺伝子の配列解析を行うユーザを特定する情報と、使用された遺伝子パネルに関する情報と、遺伝子の配列の解析状況に関する情報とを含む情報を受信する。 According to this aspect, the gene analysis device (1) outputs the analysis result of the lead sequence information based on the acquired information on the gene panel. On the other hand, the management server (3) includes, from the gene analysis device (1), information specifying the user performing gene sequence analysis, information on the gene panel used, and information on the analysis status of the gene sequence Receive information
 この態様により、例えば、パネル検査を実施するユーザは、さまざまな遺伝子パネルを用いて種々の組合せの遺伝子を解析するにあたり、用いる遺伝子パネルに応じた出力が得られるため、利便性が向上する。さらに、管理サーバ(3)は、ユーザが遺伝子解析装置(1)を用いて行った解析の解析実績を確認・管理することができる。よって、例えば、遺伝子解析システム(100)の利用料などの対価を適切に決定し、ユーザに請求することができる。 According to this aspect, for example, when a user who performs panel inspection analyzes various combinations of genes using various gene panels, an output according to the gene panel to be used can be obtained, which improves convenience. Furthermore, the management server (3) can confirm and manage the analysis result of the analysis performed by the user using the gene analysis device (1). Therefore, for example, consideration such as the fee for using the gene analysis system (100) can be appropriately determined and charged to the user.
 ユーザが前記遺伝子解析装置を用いて配列解析を行った場合の対価を、遺伝子の配列情報の解析状況に関する情報に基づいて計算してもよい。 The value when the user performs sequence analysis using the gene analysis device may be calculated based on the information on the analysis status of the sequence information of the gene.
 本発明の各態様に係る遺伝子解析装置(1)は、コンピュータによって実現してもよく、この場合には、コンピュータを遺伝子解析装置(1)が備える各部(ソフトウェア要素)として動作させることにより遺伝子解析装置(1)をコンピュータにて実現させるプログラム、およびそれを記録したコンピュータ読み取り可能な記録媒体も、本発明の範疇に入る。 The gene analysis device (1) according to each aspect of the present invention may be realized by a computer, and in this case, the gene analysis is performed by operating the computer as each portion (software element) included in the gene analysis device (1). A program for realizing the device (1) by a computer, and a computer readable recording medium recording the same also fall within the scope of the present invention.
 上記の課題を解決するために、本発明の一態様に係るプログラムは、遺伝子の配列情報を解析するプログラムであって、コンピュータに、シーケンサーにより読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得する工程と、取得した遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果を出力する工程と、を実行させるためのプログラムである。 In order to solve the above-mentioned problems, a program according to an aspect of the present invention is a program for analyzing sequence information of a gene, and a computer is provided with read sequence information read by a sequencer and a plurality of analysis targets. It is a program for executing a step of acquiring information on a gene panel including a gene and a step of outputting an analysis result of lead sequence information based on the acquired information on the gene panel.
 この態様によれば、本発明の一態様に係る遺伝子解析方法と同様の効果を奏する。 According to this aspect, the same effect as the gene analysis method according to one aspect of the present invention is exerted.
 本発明の一態様に係る記録媒体は、本発明の一態様に係るプログラムを記録したコンピュータ読み取り可能な記録媒体である。 A recording medium according to an aspect of the present invention is a computer readable recording medium on which a program according to an aspect of the present invention is recorded.
 本発明の一態様に係る遺伝子解析方法は、シーケンサー(2)により読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得し、取得した遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果を出力する、遺伝子の配列情報を解析する遺伝子解析方法であって、取得した遺伝子パネルに関する情報が登録済のものでなかった場合に、エラーを表示させる。 A gene analysis method according to an aspect of the present invention acquires read sequence information read by a sequencer (2) and information on a gene panel including a plurality of genes to be analyzed, and the acquired information on the gene panel According to the gene analysis method for analyzing the sequence information of a gene, the analysis result of the lead sequence information is output, and an error is displayed when the acquired information on the gene panel is not registered.
 本発明の一態様に係る遺伝子解析方法は、シーケンサー(2)により読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得し、取得した遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果を出力する、遺伝子の配列情報を解析する遺伝子解析方法であって、取得した遺伝子パネルに関する情報が医療機関(210)から指定されたものでなかった場合に、エラーを表示させる。 A gene analysis method according to an aspect of the present invention acquires read sequence information read by a sequencer (2) and information on a gene panel including a plurality of genes to be analyzed, and the acquired information on the gene panel It is a gene analysis method for analyzing sequence information of a gene which outputs analysis result of lead sequence information based on the case where information on the acquired gene panel is not designated from a medical institution (210), Display an error.
 本発明によれば、さまざまな遺伝子パネルを用いて種々の組合せの解析対象遺伝子を測定するにあたり、ユーザの利便性を向上させることができる。 According to the present invention, it is possible to improve the convenience of the user in measuring various target genes to be analyzed using various gene panels.
図1は、本発明の一実施形態に係る遺伝子解析システムの適用例を示す図である。FIG. 1 is a view showing an application example of a gene analysis system according to an embodiment of the present invention. 図2は、遺伝子解析システムにおいて行われる主要な処理の例を示すシーケンス図である。FIG. 2 is a sequence diagram showing an example of main processing performed in the gene analysis system. 図3は、管理サーバに記憶されているデータのデータ構造の例を示す図である。FIG. 3 is a diagram showing an example of the data structure of data stored in the management server. 図4は、遺伝子解析装置の構成の例を示す図である。FIG. 4 is a diagram showing an example of the configuration of a gene analysis device. 図5は、遺伝子パネルに関する情報の入力を受け付ける処理の流れの一例を示すフローチャートである。FIG. 5 is a flow chart showing an example of the flow of processing for receiving input of information on a gene panel. 図6は、遺伝子パネルに関する情報の入力に用いられるGUIの例を示す図である。FIG. 6 is a diagram showing an example of a GUI used to input information on a gene panel. 図7は、遺伝子パネル関連情報データベースのデータ構造の例を示す図である。FIG. 7 is a diagram showing an example of the data structure of a gene panel related information database. 図8は、遺伝子パネルに関する情報をユーザが更新する場合に用いられるGUIの例を示す図である。FIG. 8 is a diagram showing an example of a GUI used when the user updates information on a gene panel. 図9は、試料DNAの塩基配列をシーケンサーによって解析するための前処理からシーケンシングまでの手順の一例を説明するフローチャートである。FIG. 9 is a flow chart for explaining an example of a procedure from pretreatment to sequencing for analyzing the base sequence of sample DNA by a sequencer. 図10は、試料の断片化の工程(a)、およびインデックス配列およびアダプター配列の付与の工程(b)の例について説明する図である。FIG. 10 is a view for explaining an example of the step (a) of fragmentation of a sample, and the step (b) of application of an index sequence and an adapter sequence. 図11は、ハイブリダイズの工程の一例について説明する図である。FIG. 11 is a view for explaining an example of the step of hybridization. 図12は、解析対象となるDNA断片を回収する工程の一例について説明する図である。FIG. 12 is a diagram for explaining an example of a process of recovering a DNA fragment to be analyzed. 図13は、DNA断片をフローセルに供する工程の一例について説明する図である。FIG. 13 is a figure explaining an example of the process of providing a DNA fragment to a flow cell. 図14は、解析対象となるDNA断片を増幅する工程の一例について説明する図である。FIG. 14 is a diagram for explaining an example of a process of amplifying a DNA fragment to be analyzed. 図15は、シーケンシング工程の一例について説明する図である。FIG. 15 is a diagram for explaining an example of the sequencing process. 図16は、遺伝子解析装置による解析の流れの一例を説明するフローチャートである。FIG. 16 is a flow chart for explaining an example of the flow of analysis by the gene analysis device. 図17は、リード配列情報のファイルフォーマットの一例を示す図である。FIG. 17 is a diagram showing an example of a file format of read sequence information. 図18の(a)は、データ調整部によるアライメントを説明する図であり、(b)は、データ調整部のアライメント結果のフォーマットの一例を示す図である。(A) of FIG. 18 is a figure explaining the alignment by a data adjustment part, (b) is a figure which shows an example of the format of the alignment result of a data adjustment part. 図19は、参照配列データベースの構造例を示す図である。FIG. 19 shows an example of the structure of a reference sequence database. 図20は、参照配列データベースに含まれる参照配列(野生型の配列を示すものでないもの)に組み込まれる既知の変異の例を示す図である。FIG. 20 shows an example of a known mutation incorporated into a reference sequence (not showing a wild-type sequence) contained in a reference sequence database. 図21は、アライメントの詳細な工程の一例を説明するフローチャートである。FIG. 21 is a flowchart for explaining an example of a detailed process of alignment. 図22の(a)は、スコア算出の一例を示す図であり、(b)は、スコア算出の他の例を示す図である。(A) of FIG. 22 is a figure which shows an example of score calculation, (b) is a figure which shows the other example of score calculation. 図23は、変異同定部が生成する結果ファイルのフォーマットの一例を示す図である。FIG. 23 is a diagram showing an example of the format of the result file generated by the mutation identification unit. 図24は、変異データベースの構造の一例を示す図である。FIG. 24 is a diagram showing an example of the structure of a mutation database. 図25は、変異データベース中の変異情報の構造の詳細例を示す図である。FIG. 25 is a diagram showing a detailed example of the structure of mutation information in the mutation database. 図26の(a)は、解析対象の遺伝子と位置情報との対応関係を示すテーブルであり、(b)は、遺伝子パネルに関する情報に対応しない変異を、結果ファイルから除外した様子を示す図である。(A) of FIG. 26 is a table showing the correspondence between a gene to be analyzed and position information, and (b) is a diagram showing a state in which a mutation not corresponding to the information on the gene panel is excluded from the result file is there. 図27は、遺伝子解析装置の構成の別の一例を示す図である。FIG. 27 is a diagram showing another example of the configuration of the gene analysis device. 図28は、薬剤検索部が変異に関する薬剤のリストを生成する処理の一例を示すフローチャートである。FIG. 28 is a flowchart showing an example of a process in which the drug search unit generates a list of drugs related to mutation. 図29は、薬剤データベースのデータ構造の例を示す図である。FIG. 29 shows an example of the data structure of a drug database. 図30は、薬剤データベースのデータ構造の例を示す図である。FIG. 30 shows an example of the data structure of a drug database. 図31は、薬剤検索部が変異に関する薬剤に関する情報を含むリストを生成する処理の一例を示すフローチャートである。FIG. 31 is a flowchart showing an example of a process in which the drug search unit generates a list including information on drugs related to mutation. 図32は、薬剤検索部が薬剤データベースを検索して得た情報に基づいて、適用外使用の可能性がある薬剤の有無を判定し、判定結果を含むリストを生成する処理の一例を示すフローチャートである。FIG. 32 is a flowchart showing an example of a process of determining the presence or absence of a drug that may be used outside the application based on the information obtained by searching the drug database by the drug search unit, and generating a list including the determination result. It is. 図33は、薬剤データベースのデータ構造の例を示す図である。FIG. 33 is a diagram showing an example of the data structure of a drug database. 図34は、薬剤検索部が薬剤の治験に関する情報を含むリストを生成する処理の一例を示すフローチャートである。FIG. 34 is a flowchart showing an example of a process in which the drug search unit generates a list including information on drug trials. 図35は、遺伝子解析装置の構成の他の一例を示す図である。FIG. 35 is a diagram showing another example of the configuration of the gene analysis device. 図36は、リファレンスデータベースのデータ構造の一例を示す図である。FIG. 36 shows an example of the data structure of the reference database. 図37は、作成されるリポートの一例を示す図である。FIG. 37 is a diagram showing an example of a created report. 図38は、遺伝子解析装置の構成の他の一例を示す図である。FIG. 38 is a diagram showing another example of the configuration of the gene analysis device. 図39は、遺伝子パネル関連情報データベースのデータ構造の例を示す図である。FIG. 39 is a diagram showing an example of the data structure of a gene panel related information database. 図40は、遺伝子パネルに関する情報の入力に用いられるGUIの別の例を示す図である。FIG. 40 is a diagram showing another example of a GUI used to input information on a gene panel. 図41は、遺伝子パネルに関する情報の入力に用いられるGUIの他の例を示す図である。FIG. 41 is a diagram showing another example of a GUI used to input information on a gene panel. 図42は、遺伝子パネルに関する情報の入力を受け付ける処理の流れの別の例を示すフローチャートである。FIG. 42 is a flowchart illustrating another example of the flow of processing for receiving input of information on a gene panel. 図43は、遺伝子解析装置の他の一例を示す図である。FIG. 43 is a diagram showing another example of the gene analysis device. 図44は、遺伝子配列を解析するための処理の流れの一例を示すフローチャートである。FIG. 44 is a flow chart showing an example of the flow of processing for analyzing gene sequences. 図45は、品質評価指標の一例を示す図である。FIG. 45 is a diagram showing an example of the quality evaluation index. 図46は、作成されるリポートの一例を示す図である。FIG. 46 is a diagram showing an example of a report to be created.
 〔実施形態1〕
 以下、本発明の一実施形態について、詳細に説明する。
Embodiment 1
Hereinafter, an embodiment of the present invention will be described in detail.
 (遺伝子解析方法の概要)
 本発明の一実施形態に係る遺伝子解析方法は、遺伝子パネルに関する情報を取得し、取得した遺伝子パネルに関する情報に基づいて、シーケンサーにより読み取られたリード配列の解析結果を出力する。これにより、さまざまな遺伝子パネルを用いて種々の組合せの解析対象遺伝子を解析するにあたって、遺伝子パネル毎に使用する解析プログラムを使い分けなくとも、遺伝子パネルに応じた適切な解析結果の出力を得ることができ、ユーザの利便性が向上する。
(Outline of gene analysis method)
A gene analysis method according to an embodiment of the present invention acquires information on a gene panel, and outputs an analysis result of a lead sequence read by a sequencer based on the acquired information on the gene panel. As a result, when analyzing genes to be analyzed in various combinations using various gene panels, it is possible to obtain an output of an analysis result appropriate for the gene panel without using different analysis programs for each gene panel. The convenience of the user is improved.
 (遺伝子解析システム100の適用例)
 まず、本発明の一実施形態に係る遺伝子解析システム100の概略について、図1を用いて説明する。図1は、本発明の一実施形態に係る遺伝子解析システム100の適用例を示す図である。遺伝子解析システム100は、遺伝子の配列情報を解析するシステムであって、少なくとも遺伝子解析装置1と、管理サーバ3とを備えている。
(Example of application of gene analysis system 100)
First, an outline of a gene analysis system 100 according to an embodiment of the present invention will be described with reference to FIG. FIG. 1 is a view showing an application example of a gene analysis system 100 according to an embodiment of the present invention. The gene analysis system 100 is a system that analyzes gene sequence information, and includes at least a gene analysis device 1 and a management server 3.
 図1に示す遺伝子解析システム100は、検査機関120において実行される解析全般を管理する解析システム管理機関130、および医療機関210からの解析依頼に応じて、提供された試料を解析して、解析結果を医療機関210に提供する検査機関120において適用されている。遺伝子解析装置1は検査機関120に設置され、管理サーバ3は解析システム管理機関130に設置されており、これらの遺伝子解析装置1および管理サーバ3により遺伝子解析システム100が構成されている。 The gene analysis system 100 shown in FIG. 1 analyzes and analyzes the provided sample in response to an analysis request from the analysis system management organization 130 that manages the entire analysis performed in the examination organization 120 and the medical institution 210. It is applied in the inspection organization 120 which provides the result to the medical institution 210. The gene analysis device 1 is installed at the inspection organization 120, and the management server 3 is installed at the analysis system management organization 130. The gene analysis device 100 and the management server 3 constitute a gene analysis system 100.
 検査機関120は、医療機関210から提供された試料を検査・解析し、解析結果に基づいたレポートを作成し、医療機関210に該レポートを提供する機関である。検査機関120には、シーケンサー2、および遺伝子解析装置1などが設置されているが、これに限定されるものではない。 The inspection organization 120 is an organization which inspects and analyzes the sample provided from the medical institution 210, creates a report based on the analysis result, and provides the medical institution 210 with the report. Although the sequencer 2 and the gene analyzer 1 and the like are installed in the inspection organization 120, the present invention is not limited to this.
 解析システム管理機関130は、遺伝子解析システム100を利用する各検査機関120において実行される解析全般を管理する機関である。例えば、解析システム管理機関130は、遺伝子解析装置1を検査機関120に設置し、さまざまな遺伝子パネルに対応する遺伝子解析サービスを提供する事業者である。解析システム管理機関130は、遺伝子解析装置1のデータベースに記憶されている情報を更新し、最新の情報に基づいて遺伝子解析が行われるよう遺伝子解析システム100の管理を行う。解析システム管理機関130は、遺伝子解析装置1における遺伝子解析の状況を取得し、遺伝子解析の実績に応じて検査機関120から報酬を得てもよい。 The analysis system management organization 130 is an organization that manages the entire analysis performed in each inspection organization 120 using the gene analysis system 100. For example, the analysis system management organization 130 is an enterprise that installs the gene analysis device 1 at the inspection organization 120 and provides gene analysis services corresponding to various gene panels. The analysis system management organization 130 updates the information stored in the database of the gene analyzer 1 and manages the gene analysis system 100 so that gene analysis is performed based on the latest information. The analysis system management organization 130 may acquire the status of the gene analysis in the gene analysis device 1 and may receive a reward from the inspection organization 120 according to the result of the gene analysis.
 医療機関210は、医師、看護師、薬剤師等が患者に対して診断、治療、調剤等の医療行為を行う機関であり、例えば、病院、診療所、薬局等が挙げられる。 The medical institution 210 is an institution where a doctor, a nurse, a pharmacist or the like performs medical operations such as diagnosis, treatment, dispensing for the patient, and examples thereof include a hospital, a clinic, a pharmacy and the like.
 (遺伝子解析システム100を適用例における処理)
 続いて、図1に示す遺伝子解析システム100の適用例における処理の流れについて、図2を用いてより具体的に説明する。図2は、遺伝子解析システム100において行われる主要な処理の例を示すシーケンス図である。なお、図2に示された処理は、各機関で行われる処理の一部分に過ぎない。
(Processing in the application example of the gene analysis system 100)
Subsequently, the flow of processing in the application example of the gene analysis system 100 shown in FIG. 1 will be more specifically described using FIG. FIG. 2 is a sequence diagram showing an example of main processing performed in the gene analysis system 100. The process shown in FIG. 2 is only a part of the process performed by each organization.
 <遺伝子解析システム利用の申請および利用開始>
 まず、遺伝子解析システム100の利用を希望する検査機関120は、遺伝子解析装置1を導入する。そして、遺伝子解析システム100の利用を解析システム管理機関130に申請する(ステップS101)。
<Application for use of gene analysis system and start of use>
First, the inspection organization 120 that desires to use the gene analysis system 100 introduces the gene analysis device 1. Then, the application for use of the gene analysis system 100 is applied to the analysis system management organization 130 (step S101).
 検査機関120および解析システム管理機関130は複数の契約種別の中から、遺伝子解析システム100の利用に関して、事前に所望の契約を締結することができる。例えば、解析システム管理機関130から検査機関120に提供されるサービス内容、解析システム管理機関130が検査機関120に対して請求するシステム利用料の決定方法、およびシステム利用料の支払い方法などが異なる複数の契約種別から選択されたものであってもよい。解析システム管理機関130の管理サーバ3は、検査機関120からの申請に応じて、検査機関120との間で締結された契約の内容を特定する(ステップS102)。 The inspection organization 120 and the analysis system management organization 130 can conclude a desired contract in advance regarding the use of the gene analysis system 100 among a plurality of contract types. For example, the service contents provided from the analysis system management organization 130 to the inspection organization 120, the method of determining the system usage fee charged to the inspection organization 120 by the analysis system management organization 130, and the method of paying the system usage fee differ. It may be selected from the contract types of The management server 3 of the analysis system management organization 130 specifies the contents of the contract concluded with the inspection organization 120 in response to the application from the inspection organization 120 (step S102).
 次に、解析システム管理機関130によって管理されている管理サーバ3は、契約を締結した検査機関120の遺伝子解析装置1に対して、検査機関IDを付与し、各種サービスの提供を開始する(ステップS103)。 Next, the management server 3 managed by the analysis system management organization 130 assigns an examination organization ID to the gene analysis device 1 of the examination organization 120 which has made a contract, and starts provision of various services (steps S103).
 遺伝子解析装置1は、各種サービスを、管理サーバ3から受信する。各種サービスには、遺伝子解析装置1から出力され得る遺伝子配列の解析結果、および該解析結果に基づくレポートなどを制御するためのプログラムや情報の提供が含まれる。これにより、遺伝子解析装置1は、入力された遺伝子パネルに関する情報に適合した、解析結果およびレポートなどを出力できる。 The gene analysis device 1 receives various services from the management server 3. The various services include analysis results of gene sequences that can be output from the gene analysis device 1, and provision of programs and information for controlling reports based on the analysis results. Thereby, the gene analysis device 1 can output an analysis result, a report, and the like that conform to the information on the input gene panel.
 <検査機関120への解析依頼>
 医療機関210では、医師等が必要に応じて、被検体の病変部位の組織および血液などの試料を採取する。採取した試料の解析を検査機関120に依頼する場合、例えば、医療機関210に設けられた通信端末5から解析依頼が送信される(ステップS105)。検査機関120に試料の解析を依頼する場合、医療機関210は、解析依頼の送信とともに、試料毎に付与された試料IDを検査機関120に提供する。試料毎に付与された試料IDは、各試料が採取された被検体の情報などと各試料とを対応付けるものである。
<Analysis request to inspection organization 120>
In the medical institution 210, a doctor or the like collects samples such as tissue and blood of a lesion site of a subject as needed. When requesting analysis of the collected sample to the inspection organization 120, for example, an analysis request is transmitted from the communication terminal 5 provided in the medical institution 210 (step S105). When requesting the examination organization 120 to analyze the sample, the medical institution 210 provides the examination organization 120 with the sample ID assigned to each sample together with the transmission of the analysis request. The sample ID given to each sample is to associate information on the subject from which each sample is collected with each sample.
 本明細書において「被検体」とは、ヒト被検体並びにヒトではない被検体、例えば、哺乳類、無脊椎動物、脊椎動物、菌類、酵母、細菌、ウイルスおよび植物などを指す。本明細書の実施例はヒト被検体に関しているが、本発明の概念はヒト以外の任意の動物または植物などの生物由来のゲノムに適用でき、医療、獣医学および動物科学などの分野において有用である。 As used herein, "subject" refers to human subjects as well as non-human subjects such as mammals, invertebrates, vertebrates, fungi, yeasts, bacteria, viruses and plants. Although the examples herein relate to human subjects, the concepts of the present invention are applicable to genomes from organisms other than humans, such as animals or plants, and are useful in the fields of medicine, veterinary medicine and animal science, etc. is there.
 以下では、医療機関210が、パネル検査を検査機関120に解析を依頼する場合を例に挙げて説明する。なお、パネル検査は臨床検査に限らず、研究用途の検査も含む。 Hereinafter, the case where the medical institution 210 requests the laboratory 120 to analyze the panel inspection will be described as an example. Panel inspection is not limited to clinical examinations, but includes examinations for research applications.
 医療機関210から遺伝子パネル検査が依頼される場合、所望の遺伝子パネルが指定されてもよい。それゆえ、図2のステップS105において医療機関210から送信される解析依頼には、遺伝子パネルに関する情報が含まれ得る。ここで、遺伝子パネルに関する情報は、遺伝子パネルを特定するために用いられ得る情報であればよく、例えば遺伝子パネル名、およびパネル検査における解析対象となる遺伝子の名などであってよい。 When a genetic panel test is requested from the medical institution 210, a desired gene panel may be designated. Therefore, the analysis request transmitted from the medical institution 210 in step S105 of FIG. 2 may include information on the gene panel. Here, the information on the gene panel may be any information that can be used to specify the gene panel, and may be, for example, the gene panel name and the name of the gene to be analyzed in the panel test.
 <検査機関120での解析>
 遺伝子解析装置1は、医療機関210から解析依頼を受信する(S106)。さらに、遺伝子解析装置1は、該解析依頼の送信元である医療機関210から試料を受け取る。
<Analysis at inspection organization 120>
The gene analysis device 1 receives an analysis request from the medical institution 210 (S106). Furthermore, the gene analysis device 1 receives a sample from the medical institution 210 that is the transmission source of the analysis request.
 なお、検査機関120が医療機関210から依頼を受ける解析において用いられ得る遺伝子パネルは複数あり、かつ、解析対象となる遺伝子群は遺伝子パネル毎に決まっている。検査機関120は、複数の遺伝子パネルを解析の目的に合わせて使い分けることも可能である。すなわち、医療機関210から提供された第1試料について、第1の解析対象遺伝子群を解析するためには第1遺伝子パネルが使用され、第2試料について、第2の解析対象遺伝子群を解析するためには第2遺伝子パネルが使用され得る。 Note that there are a plurality of gene panels that can be used in analysis in which the inspection organization 120 receives a request from the medical institution 210, and a gene group to be analyzed is determined for each gene panel. The inspection organization 120 can also use a plurality of gene panels according to the purpose of analysis. That is, the first gene panel is used to analyze the first analysis target gene group for the first sample provided from the medical institution 210, and the second analysis target gene group is analyzed for the second sample. For this purpose, a second gene panel can be used.
 遺伝子解析装置1は、ユーザから、試料を解析するために使用する遺伝子パネルに関する情報の入力を受け付ける(ステップS107)。 The gene analysis device 1 receives an input of information on a gene panel used to analyze a sample from the user (step S107).
 検査機関120では、受け取った試料の前処理が行われ、シーケンサー2を用いたシーケンシングが行われる(ステップS108)。 In the inspection organization 120, pretreatment of the received sample is performed, and sequencing using the sequencer 2 is performed (step S108).
 ここで、前処理とは、試料に含まれるDNAなどの遺伝子を断片化して、断片化された遺伝子を回収するまでの処理が含まれ得る。また、シーケンシングとは、前処理にて回収された解析対象となる1または複数のDNA断片の配列を読み取る処理を含んでいる。シーケンサー2によるシーケンシングによって読み取られた配列情報は、リード配列情報として遺伝子解析装置1に出力される。 Here, the pretreatment may include a process of fragmenting a gene such as DNA contained in a sample and recovering the fragmented gene. Sequencing also includes a process of reading the sequence of one or more DNA fragments to be analyzed collected in the pretreatment. Sequence information read by sequencing by the sequencer 2 is output to the gene analysis device 1 as read sequence information.
 続いて、遺伝子解析装置1は、シーケンサー2からリード配列情報を取得して、遺伝子配列の解析を行う(ステップS109)。 Subsequently, the gene analysis device 1 acquires the read sequence information from the sequencer 2 and analyzes the gene sequence (step S109).
 遺伝子解析装置1は、ステップS109における解析結果に基づいてレポートを作成し(ステップS110)、作成したレポートを通信端末5に送信する(ステップS111)。 The gene analysis device 1 creates a report based on the analysis result in step S109 (step S110), and transmits the created report to the communication terminal 5 (step S111).
 <医療機関210への解析料の請求>
 上述のように、検査機関120では、医療機関210からの解析依頼に応じて、試料が解析され、解析結果に基づいたレポートが作成される。医療機関210は、レポートを検査機関120から受信する(ステップS112)。検査機関120は、試料を解析し、解析結果に基づいたレポートを解析依頼元の医療機関210に提供する対価としての解析料を、該医療機関210に対して請求してもよい。
<Analysis fee request to medical institution 210>
As described above, in the inspection organization 120, in response to an analysis request from the medical institution 210, the sample is analyzed, and a report based on the analysis result is created. The medical institution 210 receives a report from the inspection institution 120 (step S112). The laboratory 120 may analyze the sample and charge the medical institution 210 for an analysis fee as a compensation for providing the medical institution 210 as the analysis request source with a report based on the analysis result.
 <システム利用料の請求>
 解析システム管理機関130は、上述のように、検査機関120との契約内容に応じた各種情報およびサービスを提供するとともに、システム利用料などの対価を各検査機関120に対して請求してもよい。
<Claim for system usage fee>
The analysis system management organization 130 may, as described above, provide various information and services according to the contents of a contract with the inspection organization 120, and may also request each inspection organization 120 for compensation such as a system usage fee. .
 遺伝子解析システム100を利用する検査機関120の遺伝子解析装置1は、管理サーバ3に、解析に用いた遺伝子パネルに関する情報、解析した遺伝子に関する情報、および解析実績などを通知する(ステップS113)。具体的には、遺伝子解析装置1は、検査機関ID、遺伝子パネルID、遺伝子IDおよび解析実績などを、管理サーバ3に送付する。 The gene analysis device 1 of the inspection organization 120 using the gene analysis system 100 notifies the management server 3 of the information on the gene panel used for the analysis, the information on the analyzed gene, the analysis result and the like (step S113). Specifically, the gene analysis device 1 sends the inspection organization ID, the gene panel ID, the gene ID, the analysis result, and the like to the management server 3.
 管理サーバ3は、取得した検査機関ID、遺伝子パネルID、遺伝子ID、および解析実績などを対応付けて記憶する(ステップS114)。 The management server 3 stores the acquired examination organization ID, the gene panel ID, the gene ID, the analysis result, and the like in association with each other (step S114).
 検査機関IDは、遺伝子の配列解析を行うユーザを特定する情報であり、遺伝子解析装置1を利用するユーザ毎に付与されている識別情報であるユーザIDであってもよい。 The examination institution ID is information for specifying a user who performs sequence analysis of a gene, and may be a user ID which is identification information assigned to each user who uses the gene analysis device 1.
 遺伝子パネルIDは、対象となる遺伝子の解析に用いる遺伝子パネルを特定するために付与される識別情報である。遺伝子パネルに付与された遺伝子パネルIDは、遺伝子パネル名および該遺伝子パネルを提供している会社名などと対応付けられる。 Gene panel ID is identification information provided to identify a gene panel used for analysis of a gene of interest. The gene panel ID assigned to the gene panel is associated with the gene panel name and the name of the company providing the gene panel.
 遺伝子IDは、解析対象の遺伝子を特定するために遺伝子毎に付与された識別情報である。 The gene ID is identification information provided for each gene in order to specify the gene to be analyzed.
 解析実績は、遺伝子の配列情報の解析状況に関する情報である。解析実績は、例えば、遺伝子解析装置1において所定の遺伝子パネルを用いた解析が実行された配列解析回数であってもよいし、解析された遺伝子数であってもよいし、同定された変異の数などの累計であってもよい。あるいは、解析において処理されたデータ量に関する情報であってもよい。 The analysis result is information on the analysis status of the gene sequence information. The analysis result may be, for example, the number of times of sequence analysis for which analysis using a predetermined gene panel was performed in the gene analysis apparatus 1, or the number of analyzed genes, or the identified mutation It may be a total such as a number. Alternatively, it may be information on the amount of data processed in the analysis.
 管理サーバ3は、所定の期間(例えば、日、週、月、年など任意の期間)における解析実績を検査機関120毎に集計し、集計結果および契約種別に応じたシステム利用料を決定する(ステップS115)。解析システム管理機関130は、決定したシステム利用料を検査機関120に対して請求し、システム利用料を解析システム管理機関130に支払うように要求してもよい。 The management server 3 tabulates the analysis results in a predetermined period (for example, any period such as day, week, month, year) for each inspection organization 120, and determines the system usage fee according to the tabulation result and the contract type ( Step S115). The analysis system management organization 130 may charge the determined system usage fee to the inspection organization 120 and request the analysis system management organization 130 to pay the system usage fee.
 (遺伝子解析システム100の構成)
 遺伝子解析システム100は、遺伝子の配列情報を解析するシステムであって、少なくとも遺伝子解析装置1と、管理サーバ3とを備える。遺伝子解析装置1はイントラネットおよびインターネットなどのネットワーク4を介して管理サーバ3と接続されている。
(Configuration of gene analysis system 100)
The gene analysis system 100 is a system that analyzes gene sequence information, and includes at least a gene analysis device 1 and a management server 3. The gene analysis device 1 is connected to the management server 3 via a network 4 such as an intranet and the Internet.
 (シーケンサー2)
 シーケンサー2は、試料に含まれる遺伝子の塩基配列を読み取るために利用される塩基配列解析装置である。
(Sequencer 2)
The sequencer 2 is a base sequence analyzer used to read the base sequence of a gene contained in a sample.
 本実施形態に係るシーケンサー2は、好ましくは、次世代シークエンシング技術を用いたシーケンシングを行う次世代シーケンサー、または第3世代のシーケンサーであることが好ましい。次世代シーケンサーは、近年開発の進められている一群の塩基配列解析装置であり、クローン的に増幅したDNAテンプレートまたは単独DNA分子をフローセル内で大量に並列処理を行うことによって、飛躍的に向上した解析能力を有している。 The sequencer 2 according to this embodiment is preferably a next generation sequencer that performs sequencing using a next generation sequencing technology, or a third generation sequencer. The next-generation sequencer is a group of base sequence analyzers that has been developed in recent years, and has dramatically improved by performing parallel processing of clonally amplified DNA templates or single DNA molecules in large quantities in a flow cell. It has analysis ability.
 また、本実施形態において使用可能なシークエンシング技術は、同一の領域を重複して読むこと(ディープシーケンシング)により複数のリードを取得するシーケンシング技術であり得る。 In addition, the sequencing technology that can be used in the present embodiment may be a sequencing technology that acquires multiple leads by reading the same region redundantly (deep sequencing).
 本実施形態において使用可能なシークエンシング技術の例としては、イオン半導体シークエンシング、ピロシークエンシング(pyrosequencing)、可逆色素ターミネータを使用するシークエンシング・バイ・シンセシス(sequencing-by-synthesis)、シークエンシング・バイ・リゲーション(sequencing-by-ligation)、およびオリゴヌクレオチドのプローブ結紮によるシークエンシングなどの、サンガー法以外のシーケンス原理に基づく、1ラン当たりに多数のリードを取得可能なシーケンシング技術が挙げられる。 Examples of sequencing techniques that can be used in this embodiment include ionic semiconductor sequencing, pyrosequencing, sequencing-by-synthesis using a reversible dye terminator, sequencing Sequencing technology that can obtain multiple reads per run based on sequencing principles other than the Sanger method, such as sequencing-by-ligation and sequencing by probe ligation of oligonucleotides .
 シーケンシングに用いるシーケンシングプライマーは特に限定されず、目的の領域を増幅させるのに適した配列に基づいて、適宜設定される。また、シーケンシングに用いられる試薬についても、用いるシーケンシング技術およびシーケンサー2に応じて好適な試薬を選択すればよい。前処理からシーケンシングまでの手順については、後に具体例を挙げて説明する。 The sequencing primer used for sequencing is not particularly limited, and is appropriately set based on a sequence suitable for amplifying a region of interest. Further, as a reagent used for sequencing, a suitable reagent may be selected according to the sequencing technology and sequencer 2 used. The procedure from pre-processing to sequencing will be described later with specific examples.
 (管理サーバ3)
 次に、管理サーバ3に格納されているデータについて、図3を用いて説明する。図3は、管理サーバ3に記憶されているデータのデータ構造の例を示す図である。解析システム管理機関130は、図3に示す各データに基づいて、各検査機関に請求するシステム利用料を決定する。管理サーバ3は、遺伝子の配列解析を行うユーザを特定する情報(例えば、検査機関ID)と、使用された遺伝子パネルに関する情報と、遺伝子の配列の解析状況に関する情報(例えば、解析実績)とを含む情報を、遺伝子解析装置1からネットワーク4を介して受信する。
(Management server 3)
Next, data stored in the management server 3 will be described with reference to FIG. FIG. 3 is a view showing an example of the data structure of data stored in the management server 3. The analysis system management organization 130 determines the system usage fee charged to each inspection organization based on each data shown in FIG. 3. The management server 3 includes information (for example, a laboratory ID) for specifying a user who performs gene sequence analysis, information on a gene panel used, and information on analysis status of gene sequences (for example, analysis results). Information to be included is received from the gene analyzer 1 via the network 4.
 図3に示すデータ3Aでは、遺伝子解析システム100を利用する検査機関の名称と、検査機関毎に付与された検査機関IDとが関連付けられている。図3に示すデータ3Bでは、解析システム管理機関130が検査機関120との間で締結する契約の種別と、各契約を締結した検査機関に対して提供されるサービス(例えば、使用可能な遺伝子パネル)と、システム利用料とが関連付けられている。 In the data 3A shown in FIG. 3, the name of the testing organization using the gene analysis system 100 and the testing organization ID assigned to each testing organization are associated. In the data 3B shown in FIG. 3, the type of contract that the analysis system management organization 130 concludes with the inspection organization 120 and the service provided to the inspection organization that has made each contract (for example, available gene panel ) And the system usage fee are associated.
 例えば、検査機関「P機関」が解析システム管理機関130との間で「プラン1」の契約を締結している場合、解析システム管理機関130は検査機関Pに対して、動作回数に応じた利用料を請求する。なお、「動作回数」とは、例えば、遺伝子解析装置1が行ったパネル検査の回数である。 For example, when the inspection organization "P organization" concludes a contract of "plan 1" with the analysis system management organization 130, the analysis system management organization 130 uses the inspection organization P according to the number of operations. Charge a fee. The “number of operations” is, for example, the number of panel tests performed by the gene analyzer 1.
 図3に示すデータ3C~3Eはそれぞれ、遺伝子解析システム100を利用する検査機関が2017年8月1日~2017年8月31日までの期間に行った動作回数、解析した遺伝子、および同定した変異の総数、に関する解析実績である。これらの解析実績は、遺伝子解析装置1から管理サーバ3に送信され、管理サーバ3において記憶される。解析システム管理機関130は、これらの解析実績のデータに基づいて、各検査機関に請求するシステム利用料を決定する。実績の集計期間は、上記に限らず、日、週、月、年など任意の期間で集計すればよい。 The data 3C to 3E shown in FIG. 3 were respectively identified by the number of operations performed by a laboratory using the gene analysis system 100 during the period from August 1, 2017 to August 31, 2017, the analyzed genes, and It is an analysis result about the total number of mutations. These analysis results are transmitted from the gene analyzer 1 to the management server 3 and stored in the management server 3. The analysis system management organization 130 determines the system usage fee charged to each inspection organization based on the data of these analysis results. The actual aggregation period is not limited to the above, and may be aggregated in any period such as day, week, month, year.
 なお、解析システム管理機関130がシステム利用料を決定する場合、検査に用いられた遺伝子パネルを提供(例えば、製造または販売)する会社によって提供したものであるかに応じて、システムの利用料を変えてもよい。この場合、管理サーバ3には、図3に示すデータ3Fを記憶しておけばよい。図3に示すデータ3Fでは、「A社」、「B社」などの遺伝子パネルを提供する会社名と、遺伝子パネルIDと、およびシステム利用料に関する取り決め(例えば、システム利用料の要否など)とが関連付けられている。 When the analysis system management organization 130 determines the system usage fee, the system usage fee is determined depending on whether it is provided by a company that provides (for example, manufacturing or selling) the gene panel used for the test. You may change it. In this case, data 3F shown in FIG. 3 may be stored in the management server 3. In data 3F shown in FIG. 3, the company name providing gene panels such as "company A" and "company B", gene panel ID, and agreement on system usage fee (for example, necessity of system usage fee, etc.) And are associated.
 「P機関」が、解析システム管理機関130との間で「プラン1」の契約を締結しており、その解析実績が図3に示すようなものであった場合を例に挙げて説明する。P機関は、A社によって提供された遺伝子パネル(遺伝子パネルID「AAA」)を用いた検査を5回行い、B社によって提供された遺伝子パネル(遺伝子パネルID「BBB」)を用いた検査を10回行っている。図3に示すデータによれば、A社によって提供された遺伝子パネルを用いた5回分についてはシステム利用料が不要である。それゆえ、解析システム管理機関130はP機関に対し、A社によって提供された遺伝子パネルを用いた検査の回数は除外して、システム利用料を決定する。 The case where the “P organization” concludes a contract of “plan 1” with the analysis system management organization 130 and the analysis result is as shown in FIG. 3 will be described as an example. The P organization conducts five tests using the gene panel (gene panel ID "AAA") provided by company A, and tests using the gene panel (gene panel ID "BBB") provided by company B. It has been done 10 times. According to the data shown in FIG. 3, no system fee is required for 5 batches using the gene panel provided by Company A. Therefore, the analysis system management organization 130 determines the system usage fee to the P organization excluding the number of examinations using the gene panel provided by the company A.
 (遺伝子解析装置1の構成)
 図4は遺伝子解析装置1の構成の一例である。遺伝子解析装置1は、シーケンサー2により読み取られたリード配列情報および解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得する制御部11と、制御部11が取得した遺伝子パネルに関する情報に基づいた、リード配列情報の解析結果を出力する出力部13と、を備える装置である。遺伝子解析装置1は、コンピュータを用いて構成することができる。例えば、制御部11は、CPU等のプロセッサであり、記憶部12は、ハードディスクドライブである。
(Configuration of Gene Analysis Device 1)
FIG. 4 is an example of the configuration of the gene analysis device 1. The gene analysis device 1 is based on the control unit 11 for acquiring the read sequence information read by the sequencer 2 and the information on the gene panel including a plurality of genes to be analyzed, and the information on the gene panel acquired by the control unit 11 And an output unit 13 for outputting an analysis result of the lead arrangement information. The gene analysis device 1 can be configured using a computer. For example, the control unit 11 is a processor such as a CPU, and the storage unit 12 is a hard disk drive.
 また、記憶部12には、配列解析のためのプログラム、単一の参照配列を生成するためのプログラム等も記憶されている。出力部13は、ディスプレイ、プリンタ、スピーカ等を含む。入力部17は、キーボード、マウス、タッチセンサ等を含む。また、タッチセンサとディスプレイとが一体化されたタッチパネルのような、入力部および出力部の双方の機能を有する装置を用いてもよい。通信部14は、制御部11が外部の装置と通信するためのインターフェースである。 The storage unit 12 also stores a program for sequence analysis, a program for generating a single reference sequence, and the like. The output unit 13 includes a display, a printer, a speaker, and the like. The input unit 17 includes a keyboard, a mouse, a touch sensor, and the like. Alternatively, a device having both an input unit and an output unit function, such as a touch panel in which a touch sensor and a display are integrated, may be used. The communication unit 14 is an interface for the control unit 11 to communicate with an external device.
 遺伝子解析装置1は、遺伝子解析装置1が備える各部を統括して制御する制御部11、解析実行部110が使用する各種データを記憶する第1記憶部12、出力部13、通信部14、表示部16、および入力部17を備えている。制御部11は、解析実行部110および管理部116を備えている。さらに、解析実行部110は、配列データ読取部111、情報選択部112、データ調整部113、変異同定部114、およびレポート作成部115を備えている。第1記憶部12には、遺伝子パネル関連情報データベース121、参照配列データベース122、変異データベース123、および解析実績ログ151が記憶されている。 The gene analysis device 1 controls the units included in the gene analysis device 1 to control all units, the first storage unit 12 that stores various data used by the analysis execution unit 110, the output unit 13, the communication unit 14, the display A unit 16 and an input unit 17 are provided. The control unit 11 includes an analysis execution unit 110 and a management unit 116. Furthermore, the analysis execution unit 110 includes a sequence data reading unit 111, an information selection unit 112, a data adjustment unit 113, a mutation identification unit 114, and a report creation unit 115. In the first storage unit 12, a gene panel related information database 121, a reference sequence database 122, a mutation database 123, and an analysis result log 151 are stored.
 遺伝子解析装置1は、解析毎に異なる遺伝子パネルが使用された場合であっても、使用された遺伝子パネルに対応した解析結果を含むレポートを作成する。遺伝子解析システム100を利用するユーザは、遺伝子パネルの種別によらず、共通の解析プログラムでパネル検査の結果を解析し、レポートを作成することが可能となる。よって、パネル検査を実施する場合に、遺伝子パネル毎に使用する解析プログラムを使い分けたり、解析プログラムに対して使用する遺伝子パネル毎に特殊な設定を行ったりしなければならないという煩わしさが解消され、ユーザの利便性が向上する。 Even when a different gene panel is used for each analysis, the gene analysis device 1 creates a report including analysis results corresponding to the used gene panel. A user who uses the gene analysis system 100 can analyze the result of panel inspection with a common analysis program regardless of the type of gene panel, and create a report. Therefore, when performing panel inspection, the trouble that the analysis program used for every gene panel is properly used or special settings for each gene panel used for the analysis program are eliminated is eliminated. User convenience is improved.
 遺伝子解析装置1のユーザが入力部17から遺伝子パネルに関する情報を入力した場合、情報選択部112は、遺伝子パネル関連情報データベース121を参照し、入力された遺伝子パネルに関する情報に応じて、解析プログラムが解析対象の遺伝子の解析を実行するように、解析プログラムのアルゴリズムを制御する。すなわち、遺伝子解析装置1は、入力された遺伝子パネルに関する情報に応じて、解析アルゴリズムを変更する。 When the user of the gene analysis apparatus 1 inputs information on the gene panel from the input unit 17, the information selection unit 112 refers to the gene panel related information database 121, and the analysis program receives the information on the input gene panel. An algorithm of an analysis program is controlled to execute analysis of a gene to be analyzed. That is, the gene analysis device 1 changes the analysis algorithm according to the input information on the gene panel.
 ここで、遺伝子パネルに関する情報は、シーケンサー2による測定に用いた遺伝子パネルを特定するものであればよく、例えば、遺伝子パネル名、遺伝子パネルの解析対象となっている遺伝子名、および遺伝子パネルIDなどである。 Here, the information on the gene panel may be any information that specifies the gene panel used for measurement by the sequencer 2. For example, gene panel name, gene name targeted for analysis of gene panel, gene panel ID, etc. It is.
 情報選択部112は、入力部17から入力された遺伝子パネルに関する情報に基づいて、該遺伝子パネルに関する情報が示す遺伝子パネルの解析対象である遺伝子に対応した解析を行うための解析アルゴリズムを変更する。本実施形態における具体的な解析アルゴリズムの変更点としては、(1)参照配列の変更、および(2)変異を同定するために参照する変異データベース123の領域の変更、が挙げられる。 The information selection unit 112 changes the analysis algorithm for performing analysis corresponding to the gene to be analyzed of the gene panel indicated by the information on the gene panel based on the information on the gene panel input from the input unit 17. The changes of the specific analysis algorithm in the present embodiment include (1) change of reference sequence, and (2) change of region of mutation database 123 which is referred to identify mutations.
 情報選択部112は、データ調整部113、変異同定部114、およびレポート作成部115の少なくとも何れか1つに対し、遺伝子パネルに関する情報に基づいた指示を出力する。この構成を採用することより、遺伝子解析装置1は、リード配列情報の解析結果を、入力された遺伝子パネルに関する情報に基づいて出力することができる。 The information selection unit 112 outputs an instruction based on the information on the gene panel to at least one of the data adjustment unit 113, the mutation identification unit 114, and the report creation unit 115. By adopting this configuration, the gene analysis device 1 can output the analysis result of the lead sequence information based on the input information on the gene panel.
 すなわち、情報選択部112は、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報を取得し、取得した遺伝子パネルに関する情報に基づいて、リード配列情報の解析結果が出力部13から出力されるように制御する機能ブロックである。 That is, the information selection unit 112 acquires information on a gene panel including a plurality of genes to be analyzed, and based on the acquired information on the gene panel, the analysis result of the lead sequence information is output from the output unit 13 Is a functional block to control the
 パネル検査を実施するユーザによってさまざまな試料に含まれる遺伝子が解析される場合、試料毎の解析対象遺伝子群に応じてさまざまな遺伝子パネルが用いられる。 When genes contained in various samples are analyzed by the user performing panel inspection, various gene panels are used according to a group of genes to be analyzed for each sample.
 すなわち、遺伝子解析装置1は、第1試料から第1の解析対象遺伝子群を解析するための第1遺伝子パネルを用いて読み取られた第1リード配列情報、および第2試料から第2の解析対象遺伝子群を解析するための第2遺伝子パネルを用いて読み取られた第2リード配列情報を取得し得る。 That is, the gene analysis device 1 reads the first read sequence information read from the first sample using the first gene panel for analyzing the first analysis target gene group, and the second analysis target from the second sample A second gene panel for analyzing gene groups can be used to obtain second read sequence information read.
 遺伝子解析装置1は、種々の組合せの解析対象遺伝子がさまざまな遺伝子パネルを用いて解析された場合であっても、情報選択部112を備えることにより、リード配列情報を解析した解析結果を適切に出力することができる。 Even when the analysis target genes of various combinations are analyzed using various gene panels, the gene analysis apparatus 1 includes the information selection unit 112 to appropriately analyze the analysis result of the lead sequence information. It can be output.
 すなわち、ユーザに対して、解析対象遺伝子毎にリード配列情報の解析に用いる解析プログラムを設定させたり、解析を行わせたりすることなく、遺伝子パネルに関する情報を選択させるだけで、各リード配列情報の解析結果を適切に出力することが可能である。 That is, the user can select the information on the gene panel without setting the analysis program used for the analysis of the lead sequence information for each analysis target gene or performing the analysis, and It is possible to output an analysis result appropriately.
 例えば、情報選択部112が、データ調整部113に対して遺伝子パネルに関する情報に基づいた指示を出力する場合には、データ調整部113によって該遺伝子パネルに関する情報を反映したアライメント処理などが行われる。 For example, when the information selection unit 112 outputs an instruction based on the information on the gene panel to the data adjustment unit 113, the data adjustment unit 113 performs an alignment process or the like reflecting the information on the gene panel.
 情報選択部112は、遺伝子パネルに関する情報に応じて、データ調整部113がリード配列情報のマッピングに用いる参照配列(野生型のゲノム配列および変異配列が組込まれた参照配列)を、遺伝子パネルに関する情報に対応する遺伝子に関する参照配列のみに限定するよう指示する。 The information selection unit 112 uses the reference sequence (the wild type genomic sequence and the reference sequence into which the mutant sequence is integrated) used by the data adjustment unit 113 to map the lead sequence information according to the information on the gene panel as information on the gene panel. It is instructed to limit only to the reference sequence for the gene corresponding to
 この場合、データ調整部113による処理の結果には既に遺伝子パネルに関する情報が反映されているため、情報選択部112は、データ調整部113による処理の次に処理を行う変異同定部114に対して、遺伝子パネルに関する情報に基づいた指示を出力しなくてもよい。 In this case, since the information on the gene panel is already reflected in the result of the processing by the data adjustment unit 113, the information selection unit 112 instructs the mutation identification unit 114 to perform processing after the processing by the data adjustment unit 113. It is not necessary to output an instruction based on information on the gene panel.
 例えば、情報選択部112が、変異同定部114に対し、遺伝子パネルに関する情報に基づいた指示を出力する場合には、変異同定部114によって該遺伝子パネルに関する情報を反映した処理が行われる。 For example, when the information selection unit 112 outputs an instruction based on the information on the gene panel to the mutation identification unit 114, the mutation identification unit 114 performs a process reflecting the information on the gene panel.
 例えば、情報選択部112は、遺伝子パネルに関する情報に応じて、変異同定部114が参照する変異データベース123の領域を、遺伝子パネルに関する情報に対応する遺伝子に関する変異のみに限定するよう指示する。これにより、変異同定部114による処理の結果に遺伝子パネルに関する情報が反映されることになる。 For example, in accordance with the information on the gene panel, the information selecting unit 112 instructs to limit the region of the mutation database 123 to which the mutation identifying unit 114 refers to only the mutation on the gene corresponding to the information on the gene panel. Thereby, the information on the gene panel is reflected in the result of the processing by the mutation identifying unit 114.
 (遺伝子パネル関する情報の入力)
 ここでは、図2のステップS107に示す、遺伝子パネル関する情報の入力を受け付ける処理について、図5を用いて説明する。図5は、遺伝子パネル関する情報の入力を受け付ける処理の流れの一例を示すフローチャートである。
(Input of information on gene panel)
Here, the process of receiving the input of the information on the gene panel shown in step S107 of FIG. 2 will be described with reference to FIG. FIG. 5 is a flow chart showing an example of the flow of processing for receiving input of information on a gene panel.
 ここでは、制御部11が遺伝子パネルに関する情報を入力するためのGUIを表示部16に表示させて、ユーザに遺伝子パネルに関する情報を入力させる構成を例に挙げて説明する。 Here, a configuration will be described as an example in which the control unit 11 causes the display unit 16 to display a GUI for inputting information related to the gene panel and allows the user to input information related to the gene panel.
 この場合、入力部17は、ユーザに対して提示したGUIに対する入力操作が可能なデバイス(例えば、マウスおよびキーボードなど)であり得る。表示部16にタッチパネルが重畳されている場合には、表示部16が入力部17としての機能を有する。つまり、表示部16としてタッチパネルを用いた場合には、表示部16が入力部17としての機能も兼ねる。 In this case, the input unit 17 may be a device (for example, a mouse and a keyboard) capable of performing an input operation on the GUI presented to the user. When the touch panel is superimposed on the display unit 16, the display unit 16 has a function as the input unit 17. That is, when a touch panel is used as the display unit 16, the display unit 16 also functions as the input unit 17.
 まず、遺伝子解析装置1の制御部11は、表示部16に遺伝子パネルに関する情報をユーザに選択させるためのGUIを表示させる。GUIに対するユーザの入力操作に基づいて、遺伝子パネルに関する情報の取得を行う(ステップS201)。 First, the control unit 11 of the gene analysis device 1 causes the display unit 16 to display a GUI for causing the user to select information on a gene panel. Information on the gene panel is acquired based on the user's input operation on the GUI (step S201).
 情報選択部112は、GUIとして表示させた情報のうち、ユーザによって選択された情報に基づいて遺伝子パネル関連情報データベース121を検索し、選択された情報に対応する遺伝子パネルに関する情報を読み出す。 The information selection unit 112 searches the gene panel related information database 121 based on the information selected by the user among the information displayed as a GUI, and reads out information on a gene panel corresponding to the selected information.
 また、遺伝子解析装置1は、医療機関210から受け付けた解析依頼に含まれる遺伝子パネルに関する情報を読み出す。 In addition, the gene analysis device 1 reads out information on the gene panel included in the analysis request received from the medical institution 210.
 選択された情報に対応する遺伝子パネルが、遺伝子パネル関連情報データベース121に登録されており(ステップS202にてYES)、かつその遺伝子パネルが医療機関210から受け付けた解析依頼に含まれる遺伝子パネルと一致している場合(ステップS203にてYES)には、情報選択部112は該入力を受け付ける。そして、情報選択部112は、表示部16に対し入力された遺伝子パネルが使用可能である旨のメッセージを表示する(ステップS204)。 The gene panel corresponding to the selected information is registered in the gene panel related information database 121 (YES in step S 202), and the gene panel is one of the gene panels included in the analysis request received from the medical institution 210. If the user has made a decision (YES in step S203), the information selection unit 112 accepts the input. Then, the information selection unit 112 displays a message indicating that the gene panel input to the display unit 16 is usable (step S204).
 一方、選択された情報に対応する遺伝子パネルが、遺伝子パネル関連情報データベース121に登録されていない場合、すなわち、未登録の遺伝子パネルが選択された場合(ステップS202にてNO)、情報選択部112は、情報選択部112は表示部16に、入力された遺伝子パネルが使用不可である旨のメッセージを表示し(ステップS205)、遺伝子解析装置1による解析を禁止する。 On the other hand, when the gene panel corresponding to the selected information is not registered in gene panel related information database 121, that is, when the unregistered gene panel is selected (NO in step S202), information selector 112 The information selection unit 112 causes the display unit 16 to display a message indicating that the input gene panel can not be used (step S205), and prohibits analysis by the gene analysis device 1.
 この場合、遺伝子パネルが使用不可である旨のメッセージに代えてエラーを知らせるメッセージを表示させてもよい。このようなメッセージとしては、例えば、「選択された遺伝子パネルは登録されていません。」というメッセージであってもよいし、さらに「遺伝子パネルに関する情報を入力し直してください」などの再入力を促すメッセージを加えたものであってもよい。 In this case, a message indicating an error may be displayed instead of the message that the gene panel is not usable. Such a message may be, for example, the message "The selected gene panel has not been registered." Or "Please re-enter information on the gene panel". It may be one that adds a prompting message.
 また、選択された情報に対応する遺伝子パネルが、医療機関210から受け付けた解析依頼に含まれる遺伝子パネルと一致していない場合(ステップS203にてNO)には、情報選択部112は表示部16に、入力された遺伝子パネルが使用不可である旨のメッセージを表示し(ステップS205)、遺伝子解析装置1による解析を禁止する。 Further, when the gene panel corresponding to the selected information does not match the gene panel included in the analysis request received from the medical institution 210 (NO in step S203), the information selection unit 112 displays the display unit 16 A message indicating that the input gene panel is not available is displayed (step S205), and analysis by the gene analysis device 1 is prohibited.
 この場合にも、遺伝子パネルが使用不可である旨のメッセージに代えてエラーを知らせるメッセージを表示させてもよい。このようなメッセージとしては、例えば、「選択された遺伝子パネルがオーダと異なります。」というメッセージであってもよいし、さらに「遺伝子パネルに関する情報を入力し直してください」などの再入力を促すメッセージを加えたものであってもよい。 Also in this case, instead of the message that the gene panel is not usable, a message may be displayed to notify an error. Such a message may be, for example, a message such as "The selected gene panel is different from the order.", Or "Re-enter information on the gene panel", etc. It may be a message.
 このような処理により、不適切な遺伝子パネルを使用してシーケンスを行ったり、また、不要な解析動作を実行することが防止され、遺伝子パネルの無駄な使用や遺伝子解析システム100の無駄な可動をなくすことができる。 Such processing prevents sequencing using an inappropriate gene panel and execution of unnecessary analysis operations, and wasteful use of the gene panel and useless movement of the gene analysis system 100. It can be eliminated.
 (遺伝子パネルに関する情報の入力に用いられるGUIの例)
 続いて、図6を用いて、遺伝子パネルに関する情報をユーザに入力させる入力画面のいくつかの例について説明する。図6は、遺伝子パネルに関する情報の入力に用いられるGUIの例を示す図である。
(Example of GUI used to input information on gene panel)
Subsequently, with reference to FIG. 6, several examples of input screens for causing the user to input information on a gene panel will be described. FIG. 6 is a diagram showing an example of a GUI used to input information on a gene panel.
 図6に示すように、遺伝子パネルに関する情報として、「xxxxx」、「yyyyy」などの遺伝子パネル名のリストをGUIに表示し、リストに示した遺伝子パネルの中からユーザに所望の遺伝子パネルを選択させてもよい。 As shown in FIG. 6, a list of gene panel names such as "xxxxx" and "yyyyy" is displayed on the GUI as information on the gene panel, and a desired gene panel for the user is selected from the gene panels shown in the list. You may
 GUIに表示される遺伝子パネル名のリストは、遺伝子パネル関連情報データベース121に登録されている、遺伝子パネルIDが付与された遺伝子パネルの遺伝子パネル名を基に表示される。 The list of gene panel names displayed on the GUI is displayed based on the gene panel name of the gene panel to which the gene panel ID is assigned, which is registered in the gene panel related information database 121.
 図6に示すGUIでは、「遺伝子パネル2(遺伝子パネル名:「yyyyy」)」がユーザによって選択された様子が示されている。情報選択部112は、選択された遺伝子パネル名「yyyyy」に関連付けられた遺伝子パネルIDをキーとして用い、遺伝子パネル関連情報データベース121を検索して、入力された遺伝子パネル名に対応する遺伝子パネルに関する情報を取得する。 The GUI shown in FIG. 6 shows that “gene panel 2 (gene panel name:“ yyyyy ”)” is selected by the user. The information selection unit 112 searches the gene panel related information database 121 using the gene panel ID associated with the selected gene panel name “yyyyy” as a key, and relates to the gene panel corresponding to the input gene panel name Get information.
 (遺伝子パネル関連情報データベース121)
 次に、入力部17を介して遺伝子パネルに関する情報が入力された場合に、情報選択部112が参照する遺伝子パネル関連情報データベース121に記憶されているデータについて、図7を用いて説明する。図7は、遺伝子パネル関連情報データベース121のデータ構造の例を示す図である。
(Gene panel related information database 121)
Next, data stored in the gene panel related information database 121 which is referred to by the information selection unit 112 when the information on the gene panel is input through the input unit 17 will be described using FIG. 7. FIG. 7 is a view showing an example of the data structure of the gene panel related information database 121. As shown in FIG.
 遺伝子パネル関連情報データベース121には、図7に示すデータ121Aのように、解析対象となり得る遺伝子の名称および遺伝子毎に付与された遺伝子IDが、遺伝子パネル毎に記憶されている。 In the gene panel related information database 121, as in the data 121A shown in FIG. 7, the names of genes that can be analyzed and the gene ID assigned to each gene are stored for each gene panel.
 また、遺伝子パネル関連情報データベース121には、図7に示すデータ121Bのように、選択可能な遺伝子パネルの名称、各遺伝子パネルに付与された遺伝子パネルID、および各遺伝子パネルが解析対象としている遺伝子の遺伝子ID(関連遺伝子ID)が関連付けられて記憶されている。なお、各遺伝子パネルについて、公的機関(例えば、日本の厚生省等)によってその使用が承認されているか否かに関する情報も対応付けられていてもよい。 Also, in the gene panel related information database 121, as in the data 121B shown in FIG. 7, names of selectable gene panels, gene panel IDs assigned to each gene panel, and genes targeted by each gene panel are analyzed. Gene ID (related gene ID) is associated and stored. In addition, about each gene panel, the information regarding whether the use is approved by the public organization (for example, the Ministry of Health, etc. of Japan) may also be matched.
 図6に示すように、GUIに提示した遺伝子パネルの中からユーザに所望の遺伝子パネルを選択させた場合、情報選択部112は、遺伝子パネル関連情報データベース121を参照して、選択された遺伝子パネル名に関連付けられた遺伝子パネルIDおよび関連遺伝子IDを抽出する。 As shown in FIG. 6, when the user is caused to select a desired gene panel from the gene panels presented on the GUI, the information selection unit 112 refers to the gene panel related information database 121 to select the selected gene panel. Extract gene panel ID and related gene ID associated with the name.
 図40に示すように、GUIに提示した遺伝子名の中から解析対象の遺伝子を選択させた場合、情報選択部112は、遺伝子パネル関連情報データベース121を参照して、選択された遺伝子名に関連付けられた遺伝子ID、およびこれらの遺伝子IDを関連遺伝子IDに含む遺伝子パネルの遺伝子パネルIDを抽出する。 As shown in FIG. 40, when a gene to be analyzed is selected from the gene names presented on the GUI, the information selection unit 112 refers to the gene panel related information database 121 and associates it with the selected gene name. The gene ID of the gene panel including the identified gene ID and the gene ID of the related gene ID is extracted.
 なお、遺伝子パネル関連情報データベース121には、図7に示すデータ121Cのように、疾病に関する遺伝子パネルの名称および各遺伝子パネルの解析対象となる遺伝子名(あるいは遺伝子ID)が関連付けられて記憶されていてもよい。 In the gene panel related information database 121, as in the data 121C shown in FIG. 7, the names of gene panels related to diseases and the gene names (or gene IDs) to be analyzed in each gene panel are stored in association with each other. May be
 GUIに提示した疾患毎の遺伝子パネル名のリストの中から所望の疾病に関する遺伝子パネルを選択させた場合(すなわち、図41に示すような場合)、情報選択部112は、遺伝子パネル関連情報データベース121を参照して、選択された疾病に関する遺伝子パネル名に関連付けられた遺伝子名から、それらの遺伝子ID、およびこれらの遺伝子IDを関連遺伝子IDに含む遺伝子パネルの遺伝子パネルIDを抽出する。 When the gene panel relating to the desired disease is selected from the list of gene panel names for each disease presented on the GUI (that is, as shown in FIG. 41), the information selection unit 112 selects the gene panel related information database 121. The gene panel ID of the gene panel including those gene IDs and their gene IDs in the related gene ID is extracted from the gene name associated with the gene panel name for the selected disease, with reference to FIG.
 <遺伝子パネル関連情報データベース121の更新>
 ここでは、遺伝子パネル関連情報データベース121に記憶されている情報の更新について、図8を用いて説明する。図8は、遺伝子パネル関連情報データベース121をユーザが更新する場合に用いられるGUIの例を示す図である。
<Update of gene panel related information database 121>
Here, the update of the information stored in the gene panel related information database 121 will be described with reference to FIG. FIG. 8 is a diagram showing an example of a GUI used when the user updates the gene panel related information database 121. As shown in FIG.
 遺伝子パネル関連情報データベース121に記憶されている情報の更新は、解析システム管理機関130から検査機関120に提供される更新パッチによって行われ得る。例えば、遺伝子パネルの解析対象となる遺伝子が変更されたり、新しい遺伝子パネルの追加などが行われたりした場合、遺伝子パネル関連情報データベース121に記憶される情報が最新のものに更新される。 The update of the information stored in the gene panel related information database 121 may be performed by an update patch provided from the analysis system management organization 130 to the inspection organization 120. For example, when a gene to be analyzed in the gene panel is changed, or a new gene panel is added, the information stored in the gene panel related information database 121 is updated to the latest one.
 なお、解析システム管理機関130からの更新パッチの提供は、システム利用料を納付済の検査機関120を対象にして行う構成であってもよい。例えば、解析システム管理機関130は、提供可能な更新パッチが存在すること、およびシステム利用料が支払われることが更新パッチの提供の条件である旨を検査機関120に通知してもよい。このように通知することによって、システム利用料の支払いを、検査機関120に対して適切に促すことができる。 The provision of the update patch from the analysis system management organization 130 may be performed on the inspection organization 120 for which the system usage fee has been paid. For example, the analysis system management organization 130 may notify the inspection organization 120 that there is an available update patch and that it is a condition of providing the update patch that the system usage fee is paid. By notifying in this manner, payment of the system usage fee can be appropriately urged to the inspection agency 120.
 複数の遺伝子を一括して更新する場合、図8の(a)に示すように、「登録ファイル名」を入力させる欄を表示させ、その欄に、「遺伝子パネル対象遺伝子.csv」など、遺伝子名が記載されたファイル名を入力させてもよい。図8の(a)に示す例では、この「遺伝子パネル対象遺伝子.csv」には、RET、CHEK2、PTEN、MEK1という複数の遺伝子名が含まれている。 When updating a plurality of genes at one time, as shown in (a) of FIG. 8, a field for inputting "registered file name" is displayed, and in that field, genes such as "gene panel target gene .csv", etc. You may enter a file name in which the name is written. In the example shown in (a) of FIG. 8, the “gene panel target gene. Csv” includes a plurality of gene names such as RET, CHEK2, PTEN and MEK1.
 ファイル名が入力された後に「登録」ボタンが押下されると、該ファイルに含まれている遺伝子名に対応する遺伝子に関する情報の更新要求が、検査機関IDと対応付けられ、通信部14を介して管理サーバ3に送信される。この更新要求の生成および検査機関IDとの対応付けは、例えば、図4の制御部11が行う構成であってもよい。 When the “register” button is pressed after the file name is input, an update request for information on the gene corresponding to the gene name contained in the file is associated with the examination organization ID, and the communication unit 14 And sent to the management server 3. The generation of the update request and the association with the inspection organization ID may be performed by, for example, the control unit 11 in FIG. 4.
 解析システム管理機関130は、管理サーバ3が受信した更新要求に含まれる遺伝子名に対して付与した遺伝子ID、および該遺伝子を解析対象とする遺伝子パネルに対して付与した遺伝子パネルIDを含む情報を遺伝子解析装置1がダウンロードすることを許可する。 The analysis system management organization 130 includes information including the gene ID given to the gene name included in the update request received by the management server 3 and the gene panel ID given to the gene panel for analysis of the gene. The gene analyzer 1 permits downloading.
 あるいは、ユーザが遺伝子名を個別に入力して更新する場合、図8の(b)に示すように、「遺伝子名」を入力させる欄を表示させ、その欄に、「FBXW7」など、遺伝子名を入力させてもよい。 Alternatively, when the user inputs and updates the gene name individually, as shown in (b) of FIG. 8, a field for inputting “gene name” is displayed, and the gene name such as “FBXW7” is displayed in the field. May be input.
 遺伝子名が入力された後に「登録」ボタンが押下されると、該遺伝子名に対応する遺伝子に関する情報の更新要求が、検査機関IDと対応付けられ、通信部14を介して管理サーバ3に送信される。解析システム管理機関130は、管理サーバ3が受信した更新要求に含まれる遺伝子名に対して付与した遺伝子ID、および該遺伝子を解析対象とする遺伝子パネルに対して付与した遺伝子パネルIDを含む情報を遺伝子解析装置1がダウンロードすることを許可する。 When the “register” button is pressed after the gene name is input, an update request for information on the gene corresponding to the gene name is associated with the examination organization ID, and is transmitted to the management server 3 via the communication unit 14 Be done. The analysis system management organization 130 includes information including the gene ID given to the gene name included in the update request received by the management server 3 and the gene panel ID given to the gene panel for analysis of the gene. The gene analyzer 1 permits downloading.
 なお、図8の(a)の「登録ファイル名」を入力させる欄、および図8の(b)の「遺伝子名」を入力させる欄には、入力候補をサジェスチョンとして表示させる構成を備えていてもよい。 In the field for entering "registered file name" in (a) of Fig. 8 and the field for entering "gene name" in (b) of Fig. 8, there is provided a configuration for displaying input candidates as a suggestion. It is also good.
 例えば、表示させる入力候補の情報は、予め管理サーバ3から遺伝子解析装置1に提供され、第1記憶部12に記憶されている。そして、入力させる欄のGUIに対するクリック操作を検出した場合に、更新可能な遺伝子名を入力候補としてすべて提示し、その中からユーザに選択させたり、ユーザが入力した文字列と一致する更新可能な遺伝子名を入力候補として提示したりすればよい。あるいは、例えば、ユーザが図8の(b)の「遺伝子名」を入力させる欄に「E」と入力した時点で、「EGFR」および「ESR」などの更新可能な遺伝子名のリストを表示し、そのリストの中からユーザに選択させるようにしてもよい。このように入力候補を提示することにより、ユーザによる入力誤りを防止することができる。 For example, information of input candidates to be displayed is provided in advance from the management server 3 to the gene analysis device 1 and stored in the first storage unit 12. Then, when a click operation on the GUI of the field to be input is detected, all updatable gene names are presented as input candidates, allowing the user to select from among them, or updating possible matching the character string input by the user The gene name may be presented as an input candidate. Alternatively, for example, when the user inputs “E” in the field for entering “gene name” in (b) of FIG. 8, a list of updatable gene names such as “EGFR” and “ESR” is displayed. Alternatively, the user may select one from the list. By presenting input candidates in this manner, input errors by the user can be prevented.
 遺伝子パネル関連情報データベース121に、各遺伝子名と、該遺伝子の遺伝子IDと、該遺伝子がコードするタンパク質名とが関連付けられて記憶されていてもよい。 In the gene panel related information database 121, each gene name, the gene ID of the gene, and the protein name encoded by the gene may be stored in association with each other.
 この場合、入力された文字列が遺伝子名ではなく、該遺伝子がコードするタンパク質などであった場合にも、情報選択部112は、遺伝子パネル関連情報データベース121を参照して、入力されたタンパク質名に関連付けられた遺伝子名および遺伝子IDを取得することができる。 In this case, even when the input character string is not a gene name but a protein encoded by the gene, etc., the information selection unit 112 refers to the gene panel related information database 121 and the input protein name. The gene name and gene ID associated with can be obtained.
 なお、「遺伝子名」を入力させる欄にタンパク質名が入力され、登録ボタンが押下された場合に、該タンパク質名に関連付けられた遺伝子名を表示させて、ユーザにこの遺伝子名で間違いないことを確認させるGUIを表示させてもよい。 In addition, when a protein name is input in the field for inputting “gene name” and the registration button is pressed, the gene name associated with the protein name is displayed, and the user is not wrong with this gene name. A GUI for confirmation may be displayed.
 (管理部116)
 管理部116は、解析実行部110が動作した動作回数、解析した遺伝子数、および同定した権威の総数などを含む解析実績を、遺伝子パネルID、遺伝子IDと関連付けて、随時、解析実績ログ151に記憶させる。管理部116は、任意の頻度(例えば、日毎、週毎、月毎)に、解析実績ログ151から解析実績などを含むデータを読み出して、該データを検査機関IDと対応付けて通信部14を介して管理サーバに送信する。
(Management section 116)
The management unit 116 associates the analysis record including the number of times the analysis execution unit 110 has been operated, the number of analyzed genes, the total number of identified authorities, etc. with the gene panel ID and the gene ID, and analyzes the analysis record log 151 as needed. Remember. The management unit 116 reads data including analysis results from the analysis result log 151 at an arbitrary frequency (for example, every day, every week, every month), associates the data with the inspection organization ID, and communicates the communication unit 14 Send to the management server via
 (通信部14)
 通信部14は、遺伝子解析装置1がネットワーク4を介して、管理サーバ3と通信するためのものである。通信部14から管理サーバ3に送信されるデータには、検査機関ID、遺伝子パネルID、遺伝子ID、解析実績、更新要求などが含まれ得る。また、管理サーバ3から受信するデータには、遺伝子パネルに関する情報、更新可能な遺伝子名などが含まれ得る。
(Communication unit 14)
The communication unit 14 is for the gene analysis device 1 to communicate with the management server 3 via the network 4. The data transmitted from the communication unit 14 to the management server 3 may include a laboratory ID, a gene panel ID, a gene ID, an analysis record, an update request, and the like. The data received from the management server 3 may include information on gene panels, gene names that can be updated, and the like.
 (シーケンサー2によるリード配列の読み取り)
 ここでは、図10~図15を適宜参照しながら、図2のS108に示すシーケンシングの手順について図9に示す流れに沿って説明する。図9は、試料DNAの塩基配列をシーケンサー2によって解析するための前処理からシーケンシングまでの手順の一例を説明するフローチャートである。
(Reading of read sequence by sequencer 2)
Here, the procedure of sequencing shown in S108 of FIG. 2 will be described along the flow shown in FIG. 9 with reference to FIG. 10 to FIG. 15 as appropriate. FIG. 9 is a flow chart for explaining an example of a procedure from pretreatment to sequencing for analyzing the base sequence of sample DNA by the sequencer 2.
 本実施形態において使用することができるシーケンサー2の種類は特に限定されず、複数の解析対象を一度のランで解析することができるシーケンサーを好適に用いることができる。以下では、一例として、イルミナ社(サンディエゴ、CA)のシーケンサー(例えば、MySeq、HiSeq、NextSeqなど)、または、イルミナ社のシーケンサーと同様の方式を採用する装置を用いる場合について説明する。 The type of sequencer 2 that can be used in the present embodiment is not particularly limited, and a sequencer that can analyze a plurality of analysis targets in a single run can be suitably used. In the following, as an example, a case will be described where a device (for example, MySeq, HiSeq, NextSeq, etc.) of Illumina (San Diego, Calif.), Or a device adopting the same system as Illumina's sequencer is used.
 イルミナ社のシーケンサーは、Bridge PCR法とSequencing-by-synthesisという手法との組合せにより、フローセル上で膨大な数の目的DNAを増幅させ、合成しながらシーケンシングを行うことができる。 Illumina's sequencer can perform sequencing while synthesizing and synthesizing a large number of target DNAs on a flow cell by a combination of Bridge PCR method and a technique called Sequencing-by-synthesis.
 (a.前処理)
 まず、図10の(a)に示すように、試料(DNA)を、シーケンサー2で配列を読み取るための長さに断片化する(図9のステップS301)。試料DNAの断片化は、例えば、超音波処理や、核酸を断片化する試薬による処理などの公知の方法によって行うことができる。得られるDNA断片(核酸断片)は、例えば、数十から数百bpの長さであり得る。なお、以下では、解析対象となる遺伝子がDNAである場合を例に挙げて説明するが、解析対象となる遺伝子はRNAであってもよい。
(A. Pre-treatment)
First, as shown in (a) of FIG. 10, the sample (DNA) is fragmented into a length for reading the sequence by the sequencer 2 (step S301 of FIG. 9). Fragmentation of sample DNA can be performed by known methods such as, for example, ultrasonication, and treatment with a reagent that fragments nucleic acid. The resulting DNA fragment (nucleic acid fragment) may be, for example, tens to hundreds of bp in length. In the following, the case where the gene to be analyzed is DNA is described as an example, but the gene to be analyzed may be RNA.
 続いて、図10の(b)に示すように、ステップS301で得られたDNA断片の両端(3´末端および5´末端)に、使用するシーケンサー2の種類やシーケンシングプロトコルに対応するアダプター配列を付与する(図9のステップS302)。但し、本工程は、シーケンサー2が、イルミナ社のシーケンサー、または、イルミナ社のシーケンサーと同様の方式を採用する装置である場合には必須の工程であるが、他の種類のシーケンサー2を用いる場合には、省略できる場合もある。 Subsequently, as shown in (b) of FIG. 10, adapter sequences corresponding to the type of sequencer 2 and the sequencing protocol to be used at both ends (3 'end and 5' end) of the DNA fragment obtained in step S301. (Step S302 in FIG. 9). However, this step is an essential step when the sequencer 2 is a device that adopts the same method as Illumina's sequencer or Illumina's sequencer, but when using other types of sequencer 2 May be omitted.
 アダプター配列は、後の工程においてシーケンシングを実行するために使用する配列であり、一実施形態において、Bridge PCR法において、フローセルに固定化したオリゴDNAにハイブリダイズするための配列であり得る。 The adapter sequence is a sequence used to perform sequencing in a later step, and in one embodiment may be a sequence for hybridizing to oligo DNA immobilized on a flow cell in Bridge PCR method.
 一態様において、図10の(b)の上段に示すように、DNA断片の両端に直接アダプター配列(例えば、図10中のアダプター1配列およびアダプター2配列)を付加してもよい。DNA断片へのアダプター配列の付加は、当該分野において公知の手法を用いることができる。例えば、DNA配列を平滑化し、アダプター配列をライゲーションしてもよい。 In one embodiment, as shown in the upper part of (b) of FIG. 10, adapter sequences (eg, adapter 1 and adapter 2 sequences in FIG. 10) may be added directly to both ends of the DNA fragment. Addition of adapter sequences to DNA fragments can be carried out using techniques known in the art. For example, DNA sequences may be blunted and adapter sequences may be ligated.
 また、他の一態様において、図10の(b)の下段に示すように、DNA断片の両端とアダプター配列との間に、インデックス配列を挿入してもよい。 In another embodiment, as shown in the lower part of (b) of FIG. 10, an index sequence may be inserted between both ends of the DNA fragment and the adapter sequence.
 インデックス配列は、各試料のデータを区別するための、試料毎、遺伝子パネル毎、および遺伝子パネルを提供している会社毎に固有の配列である。インデックス配列として用いられる塩基配列は、これに限定されるものではないが、例えば、アデニンが10~14連続する配列、アデニンが5~7連続した後にグアニンが5~7連続するなどの配列パターン、および所与の長さを有している。 The index sequence is a sequence unique to each sample, each gene panel, and each company providing a gene panel to distinguish data of each sample. Although the base sequence used as the index sequence is not limited to this, for example, a sequence in which 10 to 14 consecutive adenine, 5 to 7 consecutive adenine and 5 to 7 consecutive guanine, etc. And have a given length.
 インデックス配列は、その配列パターンおよび長さに基づいて、当該インデックス配列が付加されたDNA断片の配列について、どの試料のリード配列情報か、用いられた遺伝子パネルは何か、用いられた遺伝子パネルを提供している会社はどの会社か、などに関する情報を識別するために用いることができる。インデックス配列を利用して、パネルに関する情報を識別する構成については、後に詳述する(実施形態4参照)。 The index sequence is based on the sequence pattern and length, and for which sequence of the DNA fragment the DNA sequence to which the index sequence is added, what sample lead sequence information, what gene panel was used, the gene panel used It can be used to identify information on which company providing the company, etc. A configuration for identifying information on a panel using an index array will be described in detail later (see Embodiment 4).
 例えば、遺伝子パネルAを用いた解析におけるインデックス配列を、アデニンが14連続する配列パターンとし、遺伝子パネルBを用いた解析におけるインデックス配列を、アデニンが7連続した後にグアニンが7連続する配列パターンとしてもよい。あるいは、遺伝子パネルAを用いた解析におけるインデックス配列を、アデニンが14連続する配列(すなわち、インデックス配列の長さは14)とし、遺伝子パネルCを用いた解析におけるインデックス配列を、アデニンが10連続する配列(すなわち、インデックス配列の長さは10)としてもよい。 For example, the index sequence in analysis using gene panel A is a sequence pattern in which adenine is 14 consecutive, and the index sequence in analysis using gene panel B is a sequence pattern in which guanine is 7 consecutive after 7 adenine is continuous Good. Alternatively, the index sequence in analysis using gene panel A is a sequence in which adenine is 14 consecutive (that is, the length of the index sequence is 14), and the index sequence in analysis using gene panel C is 10 consecutive adenines It may be an array (ie, the length of the index array is 10).
 DNA断片へのインデックス配列およびアダプター配列の付加は、当該分野において公知の手法を用いることができる。例えば、DNA断片を平滑化し、インデックス配列をライゲーションした後に、さらに、アダプター配列をライゲーションさせてもよい。 Addition of index sequences and adapter sequences to DNA fragments can be carried out using techniques known in the art. For example, after blunting a DNA fragment and ligating an index sequence, an adapter sequence may be further ligated.
 次に、図11に示すように、アダプター配列を付与したDNA断片に対し、ビオチン化RNAベイトライブラリをハイブリダイズさせる(図9のステップS303)。ビオチン化RNAベイトライブラリは、解析対象となる遺伝子とハイブリダイズするビオチン化RNA(以下、RNAベイトと称する。)によって構成されている。RNAベイトの長さは任意であるが、例えば、特異性を高めるために120bp程度のロングオリゴRNAベイトを使用してもよい。 Next, as shown in FIG. 11, a biotinylated RNA bait library is hybridized to the DNA fragment to which the adapter sequence is attached (Step S303 in FIG. 9). The biotinylated RNA bait library is composed of biotinylated RNA (hereinafter referred to as RNA bait) that hybridizes to a gene to be analyzed. Although the length of the RNA bait is arbitrary, for example, a long oligo RNA bait of about 120 bp may be used to enhance the specificity.
 なお、本実施形態におけるシーケンサー2を用いたパネル検査では、多数の遺伝子(例えば、100以上)が解析対象の遺伝子となる。パネル検査で用いられる試薬には、当該多数の遺伝子の各々に対応するRNAベイトのセットが含まれる。パネルが異なれば、検査対象の遺伝子の数および種類が異なるため、パネル検査で用いられる試薬に含まれるRNAベイトのセットも異なる。 In the panel test using the sequencer 2 in the present embodiment, a large number of genes (for example, 100 or more) are genes to be analyzed. The reagents used in the panel test include a set of RNA bait corresponding to each of the large number of genes. Since different panels have different numbers and types of genes to be tested, the set of RNA bait contained in the reagent used in the panel test is also different.
 そして、図12に示すように、解析対象となるDNA断片を回収する(図9のステップS304)。詳細には、図12の上段に示すように、ビオチン化RNAベイトライブラリをハイブリダイズさせたDNA断片に対し、ストレプトアビジンと磁性ビーズとが結合したストレプトアビジン磁性ビーズを混合する。これにより、図12の中段に示すように、ストレプトアビジン磁性ビーズのストレプトアビジン部分と、RNAベイトのビオチン部分とが結合する。 Then, as shown in FIG. 12, the DNA fragment to be analyzed is recovered (step S304 in FIG. 9). Specifically, as shown in the upper part of FIG. 12, Streptavidin magnetic beads in which streptavidin and magnetic beads are bound are mixed with the DNA fragment hybridized with the biotinylated RNA bait library. As a result, as shown in the middle of FIG. 12, the streptavidin portion of the streptavidin magnetic beads and the biotin portion of the RNA bait are bound.
 そして、図12の下段に示すように、ストレプトアビジン磁性ビーズを、磁石で集磁するとともに、RNAベイトとハイブリダイズしていない断片(即ち、解析対象とならないDNA断片)を洗浄により除去する。これにより、RNAベイトとハイブリダイズしたDNA断片、すなわち、解析対象となるDNA断片を選択・濃縮することができる。シーケンサー2は、このように複数のRNAベイトを用いて選択されたDNA断片の核酸配列を読み取ることによって複数のリード配列を取得する。 Then, as shown in the lower part of FIG. 12, the streptavidin magnetic beads are collected with a magnet, and fragments not hybridized with the RNA bait (ie, DNA fragments not to be analyzed) are removed by washing. Thus, the DNA fragment hybridized with the RNA bait, that is, the DNA fragment to be analyzed can be selected and concentrated. The sequencer 2 obtains a plurality of lead sequences by reading the nucleic acid sequence of the DNA fragment thus selected using a plurality of RNA baits.
 さらに、図13の左欄から中央欄に示すように、濃縮されたDNA断片からストレプトアビジン磁性ビーズおよびRNAベイトを外し、PCR法によって増幅することにより、前処理を完了させる。 Furthermore, as shown in the left column to the center column of FIG. 13, the streptavidin magnetic beads and RNA bait are removed from the concentrated DNA fragment, and the pretreatment is completed by amplification by the PCR method.
 (b.シーケンシング)
 まず、図13の右欄に示すように、増幅されたDNA断片の配列をフローセルにアプライする(図9のステップS305)。続いて、図14に示すように、フローセル上において、Bridge PCR法により、解析対象となるDNA断片を増幅する(図9のステップS306)。
(B. Sequencing)
First, as shown in the right column of FIG. 13, the sequence of the amplified DNA fragment is applied to the flow cell (step S305 of FIG. 9). Subsequently, as shown in FIG. 14, the DNA fragment to be analyzed is amplified on the flow cell by Bridge PCR (step S306 in FIG. 9).
 すなわち、解析対象となるDNA断片(例えば、図14中のTemplate DNA)は、上述した前処理によって、両末端に2種類の異なるアダプター配列(例えば、図14中のアダプター1配列およびアダプター2配列)が付加された状態であり(図14の「1」)、このDNA断片を1本鎖にし、5’末端側のアダプター1配列をフローセル上に固定させる(図14の「2」)。フローセル上には予め5’末端側のアダプター2配列が固定されており、DNA断片の3’末端側のアダプター2配列が、フローセル上の5’末端側のアダプター2配列と結合することにより、橋渡しをしたような状態となり、ブリッジが形成される(図14の「3」)。この状態でDNAポリメラーゼによってDNA伸長反応を行い(図14の「4」)、変性させると、2本の1本鎖DNA断片が得られる(図14の「5」)。このようなブリッジの形成、DNA伸長反応および変性をこの順に繰り返すことにより、多数の1本鎖DNA断片を局所的に増幅固定させて、クラスターを形成することができる(図14の「6」~「10」)。 That is, the DNA fragment to be analyzed (for example, Template DNA in FIG. 14) has two different adapter sequences (for example, adapter 1 sequence and adapter 2 sequence in FIG. 14) at both ends by the above-described pretreatment. Is added (“1” in FIG. 14), this DNA fragment is rendered single stranded, and the adapter 1 sequence on the 5 ′ end side is immobilized on the flow cell (“2” in FIG. 14). The adapter 2 sequence at the 5 'end is fixed in advance on the flow cell, and the adapter 2 sequence at the 3' end of the DNA fragment is bridged by binding to the adapter 2 sequence at the 5 'end on the flow cell. The bridge is formed (“3” in FIG. 14). In this state, the DNA elongation reaction is carried out by DNA polymerase ("4" in FIG. 14), and when it is denatured, two single-stranded DNA fragments are obtained ("5" in FIG. 14). By repeating formation of such a bridge, DNA extension reaction and denaturation in this order, a large number of single-stranded DNA fragments can be locally amplified and fixed to form clusters (FIG. 14 “6” to "10").
 そして、図15に示すように、クラスターを形成する1本鎖DNAを鋳型として、Sequencing-by-synthesisにより、配列を読み取る(図9のステップS307)。 Then, as shown in FIG. 15, the sequence is read by sequencing-by-synthesis using single-stranded DNA forming a cluster as a template (step S307 in FIG. 9).
 まず、フローセル上に固定された1本鎖DNA(図15の上段左欄)に対し、DNAポリメラーゼ、および、蛍光標識され、3’末端側がブロックされたdNTPを添加し(図15の上段中央欄)、さらに、シーケンスプライマーを添加する(図15の上段右欄)。シーケンスプライマーは、例えば、アダプター配列の一部分にハイブリダイズするように設計されていればよい。換言すれば、シーケンスプライマーは、試料DNA由来のDNA断片を増幅するように設計されていればよく、インデックス配列を付加した場合には、さらにインデックス配列を増幅するように設計されていればよい。 First, to the single-stranded DNA immobilized on the flow cell (upper left column in FIG. 15), DNA polymerase and fluorescence-labeled dNTP blocked at the 3 'end are added (upper middle column in FIG. 15) ), And further add a sequence primer (upper right column in FIG. 15). The sequence primer may be designed, for example, to hybridize to a portion of the adapter sequence. In other words, the sequence primer may be designed to amplify the DNA fragment derived from the sample DNA, and may be designed to further amplify the index sequence when the index sequence is added.
 シーケンスプライマーを添加後、DNAポリメラーゼによって3’末端ブロック蛍光dNTPの1塩基伸長反応を行う。3’末端側がブロックされたdNTPを用いるため、1塩基分伸長したところで、ポリメラーゼ反応は停止する。そして、DNAポリメラーゼを除去し(図15の中段右欄)、1塩基伸長した1本鎖DNA(図15の下段右欄)に対し、レーザー光により塩基に結合している蛍光物質を励起させて、そのときに起こる発光を写真として記録する(図15の下段左欄)。写真は、蛍光顕微鏡を用いて、4種類の塩基を決定させるために、波長フィルタを変更しながら、A、C、G、Tそれぞれに対応する蛍光色毎に撮影する。すべての写真を取り込んだ後、写真データから塩基を決定する。そして、蛍光物質および3’末端側をブロックしている保護基を除去して、次のポリメラーゼ反応に進む。この流れを1サイクルとして、2サイクル目、3サイクル目と繰り返していくことにより、全長をシーケンシングすることができる。 After addition of the sequence primer, DNA polymerase performs single base extension reaction of 3 'end-blocked fluorescent dNTP. In order to use dNTP blocked at the 3 'end side, the polymerase reaction is stopped when it is extended by one base. Then, the DNA polymerase is removed (the middle right column in FIG. 15) and the fluorescent substance bound to the base is excited by laser light to the single-stranded extended single-stranded DNA (lower right column in FIG. 15). The light emission occurring at that time is recorded as a picture (lower left column in FIG. 15). Photographs are taken for each of the fluorescent colors corresponding to A, C, G, and T, respectively, while changing the wavelength filter in order to determine four types of bases using a fluorescence microscope. After capturing all photos, determine the bases from the photo data. Then, the fluorescent substance and the protecting group blocking the 3 'end are removed to proceed to the next polymerase reaction. The entire length can be sequenced by repeating this flow as one cycle and the second cycle and the third cycle.
 以上の手法によれば、解析できる鎖長は150塩基×2までに達し、ピコタイタープレートよりもはるかに小さい単位での解析が可能であるため、高密度化することにより、1回の解析において40~200Gbという膨大な配列情報を入手することができる。 According to the above method, the chain length that can be analyzed is up to 150 bases × 2, and analysis is possible in units much smaller than the picotiter plate, so by densifying, in one analysis A huge amount of sequence information of 40 to 200 Gb can be obtained.
 (c.遺伝子パネル)
 シーケンサー2によるリード配列の読み取りに用いられる遺伝子パネルは、上述したように、複数の解析対象を一度のランで解析するための解析キットを意味し、一実施形態において、特定の疾病に関する複数の遺伝子配列を解析するための解析キットであり得る。
(C. Gene panel)
The gene panel used for reading a lead sequence by the sequencer 2 means an analysis kit for analyzing a plurality of analysis objects in a single run, as described above, and in one embodiment, a plurality of genes related to a specific disease It can be an analysis kit for analyzing sequences.
 本明細書中にて使用される場合、用語「キット」は、特定の材料を内包する容器(例えば、ボトル、プレート、チューブ、ディッシュなど)を備えた包装が意図される。好ましくは各材料を使用するための指示書を備える。本明細書中にてキットの局面において使用される場合、「備えた(備えている)」は、キットを構成する個々の容器のいずれかの中に内包されている状態が意図される。また、キットは、複数の異なる組成物を1つに梱包した包装であり得、ここで、組成物の形態は上述したような形態であり得、溶液形態の場合は容器中に内包されていてもよい。キットは、物質Aおよび物質Bを同一の容器に混合して備えていても別々の容器に備えていてもよい。「指示書」には、キット中の各構成を、治療および/または診断に適用する手順が示されている。なお、「指示書」は、紙またはその他の媒体に書かれていても印刷されていてもよく、あるいは磁気テープ、コンピュータ読み取り可能ディスクまたはテープ、CD-ROMなどのような電子媒体に付されてもよい。キットはまた、希釈剤、溶媒、洗浄液またはその他の試薬を内包した容器を備え得る。さらに、キットは、治療および/または診断に適用するために必要な器具をあわせて備えていてもよい。 As used herein, the term "kit" is intended for packaging comprising a container (eg, a bottle, a plate, a tube, a dish, etc.) containing the particular material. Preferably, instructions for using each material are provided. As used herein in the context of a kit, "provided" is intended to be contained within any of the individual containers that make up the kit. Also, the kit may be a package in which a plurality of different compositions are packaged together, wherein the form of the composition may be as described above, and in the case of a solution form it may be enclosed in a container It is also good. The kit may be prepared by mixing substance A and substance B in the same container or in separate containers. The "instructions" indicate procedures for applying each component in the kit to treatment and / or diagnosis. The “instruction manual” may be written or printed on paper or other medium, or attached to an electronic medium such as magnetic tape, computer readable disc or tape, CD-ROM, etc. It is also good. The kit can also include a container containing a diluent, solvent, wash solution or other reagent. Furthermore, the kit may be provided with the necessary equipment for therapeutic and / or diagnostic applications.
 一実施形態において、遺伝子パネルは、上述した、核酸を断片化する試薬、ライゲーション用試薬、洗浄液、PCR試薬(dNTP、DNAポリメラーゼなど)などの試薬、および磁性ビーズのうち一つ以上を備えていてもよい。また、遺伝子パネルは、断片化したDNAにアダプター配列を付加するためのオリゴヌクレオチド、断片化したDNAにインデックス配列を付加するためのオリゴヌクレオチド、RNAベイトライブラリなどのうち一つ以上を備えていてもよい。 In one embodiment, the gene panel comprises one or more of the above-described reagents for fragmenting nucleic acids, reagents for ligation, reagents for washing, reagents such as PCR reagents (dNTP, DNA polymerase etc.), and magnetic beads. It is also good. Also, the gene panel may be provided with one or more of an oligonucleotide for adding an adapter sequence to fragmented DNA, an oligonucleotide for adding an index sequence to fragmented DNA, an RNA bait library, etc. Good.
 特に、各遺伝子パネルが備えるインデックス配列は、当該遺伝子パネル固有の、当該遺伝子パネルを識別するための配列であり得る。また、各遺伝子パネルが備えるRNAベイトライブラリは、当該遺伝子パネルの各検査遺伝子に対応するRNAベイトを含む、当該遺伝子パネル固有のライブラリであり得る。 In particular, the index sequence included in each gene panel may be a sequence unique to the gene panel for identifying the gene panel. Also, the RNA bait library provided in each gene panel may be a library unique to the gene panel, including RNA bait corresponding to each test gene of the gene panel.
 (配列データ読取部111、データ調整部113、変異同定部114)
 続いて、解析実行部110の配列データ読取部111、データ調整部113、および変異同定部114の処理について、図17~図26を適宜参照しながら、図16に示す処理の流れに沿って説明する。
(Sequence data reading unit 111, data adjustment unit 113, mutation identification unit 114)
Subsequently, the processing of sequence data reading unit 111, data adjustment unit 113, and mutation identification unit 114 of analysis execution unit 110 will be described along the flow of processing shown in FIG. 16 with reference to FIGS. 17 to 26 as appropriate. Do.
 図16は、遺伝子解析装置1による解析の流れの一例を説明するフローチャートである。なお、図16に示す処理は、図2に示すステップS109に対応している。 FIG. 16 is a flow chart for explaining an example of the flow of analysis by the gene analysis device 1. The process shown in FIG. 16 corresponds to step S109 shown in FIG.
 <配列データ読取部111>
 まず、図16のステップS11において、配列データ読取部111は、シーケンサー2から提供されたリード配列情報を読み込む。
<Sequence data reading unit 111>
First, in step S11 of FIG. 16, the array data reading unit 111 reads the read array information provided from the sequencer 2.
 リード配列情報は、シーケンサー2で読み取られた塩基配列を示すデータである。シーケンサー2は、特定の遺伝子パネルを用いて得られた多数の核酸断片をシーケンシングして、それらの配列情報を読み取り、リード配列情報として遺伝子解析装置1に提供する。 The read sequence information is data indicating the base sequence read by the sequencer 2. The sequencer 2 sequences a large number of nucleic acid fragments obtained using a specific gene panel, reads their sequence information, and provides the information to the gene analyzer 1 as lead sequence information.
 一態様において、リード配列情報には、読み取られた配列と共に、配列中の各塩基のクオリティスコアが含まれていてもよい。また、被検体の病変部位から採取されたFFPE試料をシーケンサー2に供して得られたリード配列情報と、同被検体の血液試料をシーケンサー2に供して得られたリード配列情報との両方が、遺伝子解析装置1に入力される。 In one aspect, the read sequence information may include the quality score of each base in the sequence, as well as the read sequence. Further, both of the lead sequence information obtained by applying the FFPE sample collected from the lesion site of the subject to the sequencer 2 and the lead sequence information obtained by applying the blood sample of the subject to the sequencer 2 are It is input to the gene analyzer 1.
 図17は、リード配列情報のファイルフォーマットの一例を示す図である。図17に示す例では、リード配列情報には、配列名、配列、および、クオリティスコアが含まれている。配列名は、シーケンサー2が出力するリード配列情報に付与された配列IDなどであってもよい。配列は、シーケンサー2で読み取られた塩基配列を示す。クオリティスコアは、シーケンサー2による塩基割当が正しく行われない確率を示す。任意の塩基のシーケンスクオリティスコア(Q)は、次の式により表される。
  Q=-10log10
FIG. 17 is a diagram showing an example of a file format of read sequence information. In the example shown in FIG. 17, the read sequence information includes the sequence name, the sequence, and the quality score. The sequence name may be a sequence ID assigned to the read sequence information output from the sequencer 2 or the like. The sequence shows the base sequence read by sequencer 2. The quality score indicates the probability that the base 2 assignment by the sequencer 2 is not correctly performed. The sequence quality score (Q) of an arbitrary base is represented by the following formula.
Q = -10 log 10 E
 この式において、Eは、塩基割当が正しく行われない確率の推定値を表す。Q値が高いほど、エラーの確率が低いことを意味する。Q値が低いほど、そのリードは使用できない部分が大きくなる。また、偽陽性の変異割当も増加し、結果の精度が低下する恐れがある。なお、「偽陽性」は、リード配列が判定対象となる真の変異を有していないにもかかわらず、変異を有すると判断されることを意味する。なお、「陽性」は、リード配列が判定対象となる真の変異を有していることを意味し、「陰性」は、リード配列が対象となる変異を有していないことを意味する。 In this equation, E represents an estimated value of the probability that base assignment is not correctly performed. The higher the Q value, the lower the probability of error. The lower the Q value, the larger the unusable part of the lead. Also, false positive mutation assignments may also increase, which may reduce the accuracy of the results. "False positive" means that although the lead sequence has no true mutation to be judged, it is judged to have a mutation. "Positive" means that the lead sequence has a true mutation to be determined, and "negative" means that the lead sequence does not have a targeted mutation.
 <データ調整部113>
 続いて、図16のステップS12において、データ調整部113は、配列データ読取部111が読み込んだリード配列情報に基づいて、リード配列情報に含まれる各核酸断片のリード配列のアライメントを実行する。
<Data adjustment unit 113>
Subsequently, in step S12 of FIG. 16, the data adjustment unit 113 executes alignment of the lead sequence of each of the nucleic acid fragments contained in the read sequence information based on the read sequence information read by the sequence data reading unit 111.
 図18の(a)は、データ調整部113によるアライメントを説明する図である。データ調整部113は、参照配列データベース122に格納された参照配列を参照し、各核酸断片のリード配列を、リード配列情報の比較対象とすべき参照配列に対してマッピングすることにより、アライメントを実行する。一態様において、参照配列データベース122には、各解析対象の遺伝子に対応する参照配列が複数種類格納されている。 (A) of FIG. 18 is a diagram for explaining alignment by the data adjustment unit 113. The data adjustment unit 113 executes alignment by referring to the reference sequence stored in the reference sequence database 122 and mapping the lead sequence of each nucleic acid fragment to the reference sequence to be compared with the read sequence information. Do. In one embodiment, the reference sequence database 122 stores a plurality of types of reference sequences corresponding to the genes to be analyzed.
 また、データ調整部113は、被検体の病変部位から採取されたFFPE試料をシーケンサー2に供して得られたリード配列情報と、同被検体の血液試料をシーケンサー2に供して得られたリード配列情報との両方について、アライメントを実行する。 In addition, the data adjustment unit 113 also provides the read sequence information obtained by applying the FFPE sample collected from the lesion site of the subject to the sequencer 2 and the read sequence obtained by applying the blood sample of the subject to the sequencer 2 Perform an alignment, both with the information.
 図18の(b)は、データ調整部113のアライメント結果のフォーマットの一例を示す図である。アライメント結果のフォーマットは、リード配列、参照配列およびマッピング位置をそれぞれ特定し得るものであれば特に限定されないが、図18の(b)のように、参照配列情報、リード配列名、ポジション情報、マップ品質および配列を含むものであってもよい。 (B) of FIG. 18 is a diagram illustrating an example of the format of the alignment result of the data adjustment unit 113. The format of the alignment result is not particularly limited as long as it can identify the read sequence, reference sequence and mapping position, but as shown in FIG. 18 (b), reference sequence information, read sequence name, position information, map It may include quality and alignment.
 参照配列情報は、参照配列データベース122における参照配列名(参照配列ID)、参照配列の配列長などを示す情報である。参照配列情報は、参照配列を識別できることが好ましく、例えば、参照配列名、参照配列IDを含んでいる。リード配列名は、アライメント対象となった各リード配列の名称(リード配列ID)を示す情報である。 The reference sequence information is information indicating the reference sequence name (reference sequence ID) in the reference sequence database 122, the sequence length of the reference sequence, and the like. The reference sequence information is preferably capable of identifying the reference sequence, and includes, for example, a reference sequence name and a reference sequence ID. The read sequence name is information indicating the name (read sequence ID) of each read sequence that has become the alignment target.
 ポジション情報は、リード配列の最左塩基がマッピングされた参照配列上の位置(Leftmost mapping position)を示す情報である。マップ品質は、当該リード配列に対応するマッピング品質を示す情報である。配列は、各リード配列に対応する塩基配列(例: …GTAAGGCACGTCATA…)を示す情報である。 The position information is information indicating a position (Leftmost mapping position) on the reference sequence to which the leftmost base of the read sequence is mapped. The map quality is information indicating the mapping quality corresponding to the lead arrangement. The sequence is information indicating a nucleotide sequence (eg, ... GTAAGGCACGTCATA ...) corresponding to each read sequence.
 図19は、参照配列データベース122の構造例を示す図である。図19に示すように、参照配列データベース122には、野生型の配列を示す参照配列(例えば、染色体#1~23のゲノム配列)と、野生型の配列に対して既知の変位が組み込まれた参照配列とが記憶されている。 FIG. 19 shows an example of the structure of the reference sequence database 122. As shown in FIG. As shown in FIG. 19, the reference sequence database 122 incorporates a reference sequence (for example, the genomic sequence of chromosomes # 1 to 23) representing a wild-type sequence and a known displacement relative to the wild-type sequence. A reference sequence is stored.
 さらに、参照配列データベース122中の各参照配列には、遺伝子パネルに関する情報を示すメタデータが付与されている。各参照配列に付与する遺伝子パネルに関する情報は、例えば、各参照配列が対応する解析対象の遺伝子を直接的または間接的に示すものであり得る。 Furthermore, each reference sequence in the reference sequence database 122 is provided with metadata indicating information on a gene panel. The information on the gene panel provided to each reference sequence may be, for example, one directly or indirectly indicating the gene to be analyzed to which each reference sequence corresponds.
 一実施形態において、情報選択部112は、データ調整部113が参照配列データベース122から参照配列を取得する際に、入力された遺伝子パネルに関する情報と、各参照配列のメタデータとを参照して、当該遺伝子パネルに関する情報に対応する参照配列を選択するよう制御してもよい。例えば、一態様において、情報選択部112は、入力された遺伝子パネルに関する情報によって特定される解析対象の遺伝子に対応する参照配列を選択するようデータ調整部113を制御してもよい。これにより、データ調整部113は、使用された遺伝子パネルに関連する参照配列のみに対するマッピングを行えばよいため、解析の効率を向上させることができる。 In one embodiment, when the data adjustment unit 113 acquires the reference sequence from the reference sequence database 122, the information selection unit 112 refers to the input information on the gene panel and the metadata of each reference sequence. Control may be performed to select a reference sequence corresponding to the information on the gene panel. For example, in one aspect, the information selection unit 112 may control the data adjustment unit 113 to select a reference sequence corresponding to a gene to be analyzed identified by the input information on the gene panel. As a result, the data adjustment unit 113 may perform mapping only to the reference sequences related to the used gene panel, so that the analysis efficiency can be improved.
 また、他の実施形態において、情報選択部112は、上記制御を行わなくともよい。その場合、情報選択部112は、後述するように、変異同定部114またはレポート作成部115を制御すればよい。 Further, in another embodiment, the information selection unit 112 may not perform the above control. In that case, the information selection unit 112 may control the mutation identification unit 114 or the report creation unit 115 as described later.
 図20は、参照配列データベース122に含まれる参照配列(野生型の配列を示すものでないもの)に組み込まれる既知の変異の例を示す図である。 FIG. 20 shows an example of a known mutation incorporated into the reference sequence (not showing the wild-type sequence) contained in the reference sequence database 122.
 既知の変異は、外部のデータベース(例えば、COSMIC、ClinVarなど)に登録された変異であり、図20に示すように、染色体位置、遺伝子名および変異が特定されているものである。 Known mutations are mutations registered in an external database (for example, COSMIC, ClinVar, etc.), and as shown in FIG. 20, chromosomal positions, gene names and mutations are identified.
 図20の例では、アミノ酸の変異が特定されているが、核酸の変異が特定されていてもよい。変異の種類は、特に限定されず、置換、挿入、欠失など様々な変異であってもよく、他の染色体の一部の配列または逆相補配列が結合している変異であってもよい。 In the example of FIG. 20, mutations of amino acids are identified, but mutations of nucleic acids may be identified. The type of mutation is not particularly limited, and may be various mutations such as substitution, insertion, deletion and the like, or may be a mutation to which a partial sequence of another chromosome or a reverse complementary sequence is bound.
 図21は、図16のステップS12におけるアライメントの詳細な工程の一例を説明するフローチャートである。一態様において、図16のステップS12におけるアライメントは、図21に示すステップS401~S405によって実行される。 FIG. 21 is a flow chart for explaining an example of a detailed process of alignment in step S12 of FIG. In one aspect, the alignment in step S12 of FIG. 16 is performed by steps S401 to S405 shown in FIG.
 図21のステップS401において、データ調整部113は、配列データ読取部111が取得したリード配列情報に含まれる各核酸断片のリード配列のうち、アライメントを行っていないものを選択して、参照配列データベース122から取得した参照配列と比較する。そして、ステップS402において、データ調整部113は、リード配列との一致度が所定の基準を満たす参照配列上の位置を特定する。ここで、一致度とは、取得したリード配列情報と参照配列とがどの程度一致しているかを示す値であり、例えば、一致する塩基の数や割合などが一例として挙げられる。 In step S401 in FIG. 21, the data adjustment unit 113 selects one of the read sequences of each of the nucleic acid fragments contained in the read sequence information acquired by the sequence data reading unit 111 that has not been aligned, and uses the reference sequence database. Compare with the reference sequence obtained from 122. Then, in step S402, the data adjustment unit 113 identifies the position on the reference array where the degree of coincidence with the read array satisfies a predetermined reference. Here, the degree of coincidence is a value indicating how much the acquired read sequence information and the reference sequence are in agreement, and, for example, the number and ratio of coincident bases can be mentioned as an example.
 一態様において、データ調整部113は、リード配列と参照配列の一致度を示すスコアを算出する。一致度を示すスコアは、例えば2つの配列間の同一性のパーセンテージ(percentage identity)とすることができる。 In one aspect, the data adjustment unit 113 calculates a score indicating the degree of matching between the read sequence and the reference sequence. The score indicating the degree of identity can be, for example, the percentage identity between the two sequences.
 データ調整部113は、例えば、リード配列の塩基と参照配列の塩基とが同一となる位置の数を特定し、一致した位置の数を求め、一致した位置の数を参照配列と比較されたリード配列の塩基数(比較ウィンドウの塩基数)で除算することによってパーセンテージを算出する。 For example, the data adjustment unit 113 identifies the number of positions where the base of the read sequence and the base of the reference sequence are identical, obtains the number of matched positions, and reads the number of matched positions compared with the reference sequence. The percentage is calculated by dividing by the number of bases in the sequence (number of bases in comparison window).
 図22の(a)は、スコア算出の一例を示す図である。一態様において、図22の(a)に示す位置において、リード配列R1と参照配列との一致度のスコアは、リード配列13塩基中13塩基が一致しているため100%となり、リード配列R2と参照配列との一致度のスコアは、リード配列13塩基中12塩基が一致しているため92.3%となる。 (A) of FIG. 22 is a figure which shows an example of score calculation. In one embodiment, at the position shown in (a) of FIG. 22, the score of the degree of coincidence between the lead sequence R1 and the reference sequence is 100% because 13 bases out of the 13 bases of the lead sequence are identical, and The score of the degree of coincidence with the reference sequence is 92.3% because 12 bases out of the 13 bases of the lead sequence are coincident.
 また、データ調整部113は、リード配列と参照配列の一致度を示すスコアの計算において、リード配列が参照配列に対して所定の変異(例えば、挿入・欠失(InDel : Insertion/Deletion))を含む場合には、通常の計算よりも低いスコアが付くように計算してもよい。 In addition, in the calculation of the score indicating the degree of coincidence between the read sequence and the reference sequence, the data adjustment unit 113 determines that the lead sequence has a predetermined mutation (for example, insertion / deletion (InDel: Insertion / Deletion)) with respect to the reference sequence. If it is included, it may be calculated to have a lower score than the normal calculation.
 一態様において、データ調整部113は、リード配列が参照配列に対して挿入および欠失の少なくとも一方を含む配列について、例えば、上述したような通常計算で算出されたスコアに、挿入・欠失に対応する塩基数に応じた重み係数を乗算することで、スコアを補正してもよい。重み係数Wは、例えば、W={1-(1/100)×(挿入・欠失に対応する塩基数)}で計算してもよい。 In one embodiment, the data adjustment unit 113 inserts or deletes, for example, a score calculated by the usual calculation as described above, for a sequence in which the lead sequence includes at least one of an insertion and a deletion relative to the reference sequence. The score may be corrected by multiplying by a weighting factor according to the corresponding number of bases. The weighting factor W may be calculated, for example, by W = {1− (1/100) × (number of bases corresponding to insertion / deletion)}.
 図22の(b)は、スコア算出の他の例を示す図である。一態様において、図22の(b)に示す位置において、リード配列R3と参照配列との一致度のスコアは、通常計算では、リード配列17塩基(欠失を示す*も一塩基として計算)中15塩基が一致しているため88%となり、補正後のスコアは88%×0.98=86%となる。 (B) of FIG. 22 is a figure which shows the other example of score calculation. In one embodiment, at the position shown in FIG. 22 (b), the score of the match between the lead sequence R3 and the reference sequence is usually within 17 bases of the lead sequence (* indicates deletion as well as one base). Since the 15 bases match, it is 88%, and the corrected score is 88% × 0.98 = 86%.
 また、リード配列R4と参照配列との一致度のスコアは、通常計算では、リード配列21塩基中17塩基が一致しているため81%となり、補正後のスコアは81%×0.96=77.8%となる。 Further, the score of the degree of coincidence between the lead sequence R4 and the reference sequence is 81% in the normal calculation because 17 bases out of the 21 bases of the lead sequence coincide, and the score after correction is 81% × 0.96 = 77 .8%.
 データ調整部113は、各参照配列に対するリード配列のマッピング位置を変えながら一致度のスコアを算出することにより、リード配列との一致度が所定の基準を満たす参照配列上の位置を特定する。その際、動的計画法、FASTA法、BLAST法などの当該分野において公知のアルゴリズムを使用してもよい。 The data adjustment unit 113 specifies the position on the reference sequence that satisfies the predetermined criteria by calculating the score of the matching degree while changing the mapping position of the reading sequence to each reference sequence. At that time, algorithms known in the art such as dynamic programming, FASTA, BLAST may be used.
 図21に戻り、次に、データ調整部113は、リード配列との一致度が所定の基準を満たす参照配列上の位置が単一の位置であった場合には(ステップS403にてNO)、当該位置にリード配列をアライメントし、リード配列との一致度が所定の基準を満たす参照配列上の位置が複数の位置であった場合には(ステップS403にてYES)、データ調整部113は、最も一致度が高い位置に、リード配列をアライメントする(ステップS404)。 Referring back to FIG. 21, next, when the position on the reference array where the degree of coincidence with the read array satisfies the predetermined reference is a single position (NO in step S403), the data adjustment unit 113 If the read sequence is aligned at the corresponding position, and the position on the reference sequence at which the degree of coincidence with the read sequence satisfies the predetermined reference is a plurality of positions (YES in step S403), the data adjustment unit 113 The lead array is aligned at the position with the highest degree of coincidence (step S404).
 そして、データ調整部113は、配列データ読取部111が取得したリード配列情報に含まれる全リード配列をアライメントしていない場合には(ステップS405にてNO)、ステップS401に戻り、リード配列情報に含まれる全リード配列をアライメントした場合には(ステップS405にてYES)、ステップS12の処理を完了する。 Then, when the data adjustment unit 113 does not align all the read sequences included in the read sequence information acquired by the sequence data reading unit 111 (NO in step S405), the process returns to step S401, and If all the included read sequences are aligned (YES in step S405), the process of step S12 is completed.
 <データ調整部113のその他の機能>
 なお、データ調整部113は、リード配列情報と、取得した遺伝子パネルに関する情報に関連付けられた遺伝子パネルが解析対象とする遺伝子の配列情報とを比較した比較結果を、リード配列情報の解析結果として出力してもよい。
<Other Functions of Data Adjustment Unit 113>
The data adjustment unit 113 outputs, as an analysis result of the lead sequence information, a comparison result of comparison between the lead sequence information and the sequence information of the gene to be analyzed by the gene panel associated with the acquired information about the gene panel. You may
 遺伝子パネルが解析対象とする遺伝子の配列情報には、解析対象となる遺伝子(例えば、エクソン)の配列、および、解析対象となる遺伝子の配列に付加されたインデックス配列が含まれ得る。 The sequence information of the gene to be analyzed by the gene panel may include the sequence of the gene (eg, exon) to be analyzed and the index sequence added to the sequence of the gene to be analyzed.
 例えば、以下の(1)、および(2)に示す場合には、データ調整部113は、リード配列情報の解析結果として、表示部16にエラーを表示させてもよい。 For example, in the following cases (1) and (2), the data adjustment unit 113 may cause the display unit 16 to display an error as an analysis result of the lead arrangement information.
 (1)リード配列のマッピングを行う場合に、配列データ読取部111が読み取ったリード配列情報に含まれるインデックス配列が、情報選択部112が取得した遺伝子パネルに関する情報に対応するインデックス配列(例えば、図39参照)と異なっている。 (1) When mapping the read sequence, the index sequence included in the read sequence information read by the sequence data reading unit 111 corresponds to the information corresponding to the information on the gene panel acquired by the information selection unit 112 (for example, FIG. (See 39).
 (2)リード配列情報が、情報選択部112が取得した遺伝子パネルに関する情報に対応する遺伝子パネルが解析対象としない遺伝子の配列を所定数以上含んでいる。あるいは、リード配列情報が、情報選択部が取得した遺伝子パネルが示す遺伝子パネルが解析対象とする遺伝子の配列を所定数未満しか含んでいない。 (2) The gene array corresponding to the information on the gene panel acquired by the information selection unit 112 includes a predetermined number or more of sequences of genes that are not to be analyzed. Alternatively, the lead sequence information contains less than a predetermined number of sequences of genes to be analyzed by the gene panel indicated by the gene panel acquired by the information selection unit.
 これらは、ユーザによる遺伝子パネルに関する情報の入力誤りによって生じる可能性が高い。そこで、データ調整部113は、「解析ができません」、および「遺伝子パネルに関する情報に誤りがあります」などのエラーを表示部16に表示してもよい。 These are likely to be caused by the user's erroneous input of information on the gene panel. Therefore, the data adjustment unit 113 may display on the display unit 16 errors such as “the analysis can not be performed” and “the information on the gene panel is incorrect”.
 あるいは、データ調整部113は、「再度、遺伝子パネルに関する情報を入力してください」などのメッセージを表示部16にさらに表示し、遺伝子パネル名および解析対象の遺伝子名などの入力をやり直すよう、ユーザに促してもよい。 Alternatively, the data adjustment unit 113 further displays a message such as “Please enter information on the gene panel again” on the display unit 16, and the user may input the gene panel name and the gene name to be analyzed again. You may
 なお、遺伝子パネルに関する情報に対応する遺伝子パネルが解析対象としない遺伝子の配列を含むリード配列情報の数が所定数以上である場合にのみエラーを表示部16に表示する構成であってもよい。あるいはリード配列情報のうち、遺伝子パネルに関する情報に対応する遺伝子パネルが解析対象としない遺伝子に対してマッピングされたリード配列情報の数が所定数以上である場合にのみ、エラーを表示させる構成であってもよい。 The error may be displayed on the display unit 16 only when the number of pieces of lead sequence information including sequences of genes not to be analyzed is equal to or more than a predetermined number. Alternatively, an error is displayed only when the number of pieces of lead sequence information mapped to genes not to be analyzed by the gene panel corresponding to the information on the gene panel among the lead sequence information is a predetermined number or more. May be
 なお、エラーを出力する出力先として表示部16を用いる例について説明したが、エラーを出力する態様はこれに限定されない。例えば、スピーカからエラー内容を音声によって出力してもよい。あるいは、ランプなどを点灯させたり点滅させたりすることにより、ユーザにエラーを知らせる構成であってもよい。 In addition, although the example which uses the display part 16 as an output destination which outputs an error was demonstrated, the aspect which outputs an error is not limited to this. For example, the error content may be output by voice from a speaker. Alternatively, the user may be notified of an error by lighting or blinking a lamp or the like.
 <変異同定部114>
 続いて、図16に戻り、ステップS13において、変異同定部114は、被検体の病変部位から採取された試料を供して得られたリード配列がアライメントされた参照配列の配列(アライメント配列)と、同被検体の血液試料を供して得られたリード配列がアライメントされた参照配列の配列とを比較する。
<Mutagenesis Identification Unit 114>
Subsequently, referring back to FIG. 16, in step S13, the mutation identification unit 114 supplies the sample obtained from the lesion site of the subject and the sequence of the reference sequence to which the lead sequence obtained is aligned (alignment sequence); A blood sample of the same subject is provided, and the lead sequence obtained is compared with the sequence of the aligned reference sequence.
 そして、図16のステップS14において、両アライメント配列間の相違を、変異として抽出する。例えば、同じ解析対象の遺伝子の同じ位置に対する血液検体由来のアライメント配列がATCGAであり、腫瘍組織由来のアライメント配列がATCCAであれば、変異同定部114は、GとCとの相違を変異として抽出する。 Then, in step S14 of FIG. 16, the difference between both alignment sequences is extracted as a mutation. For example, if the alignment sequence derived from the blood sample for the same position of the same gene to be analyzed is ATCGA and the alignment sequence derived from the tumor tissue is ATCCA, the mutation identification unit 114 extracts the difference between G and C as a mutation. Do.
 一態様において、変異同定部114は、抽出した変異に基づいて結果ファイルを生成する。図23は、変異同定部114が生成する結果ファイルのフォーマットの一例を示す図である。当該フォーマットは、例えば、Variant Call Format(VCF)に基づくものであり得る。 In one aspect, the mutation identification unit 114 generates a result file based on the extracted mutations. FIG. 23 is a diagram showing an example of the format of the result file generated by the mutation identifying unit 114. As shown in FIG. The format may be based on, for example, Variant Call Format (VCF).
 図23に示すように、結果ファイルには、抽出された変異毎に、位置情報、参照塩基および変異塩基が記述されている。位置情報は、参照ゲノム上の位置を示し、例えば、染色体番号と、該染色体上の位置とを含む。参照塩基は、上記位置情報が示す位置における参照塩基(A,T,C,Gなど)を示す。変異塩基は、参照塩基の変異後の塩基を示す。参照塩基は、血液検体由来のアライメント配列上の塩基であり、変異塩基は、腫瘍組織由来のアライメント配列上の塩基である。 As shown in FIG. 23, in the result file, position information, reference bases and mutant bases are described for each extracted mutation. The positional information indicates the position on the reference genome, and includes, for example, the chromosome number and the position on the chromosome. The reference base indicates a reference base (A, T, C, G, etc.) at the position indicated by the position information. The mutated base indicates the base after mutation of the reference base. The reference base is a base on the alignment sequence derived from the blood sample, and the variant base is a base on the alignment sequence derived from the tumor tissue.
 なお、図23において、参照塩基がC、変異塩基がGである変異は、置換変異の例であり、参照塩基がC、変異塩基がCTAGである変異は、挿入(Insertion)変異の例であり、参照塩基がTCG、変異塩基がTである変異は、欠失(Deletion)変異の例である。また、変異塩基がG]17:198982]、]13:123456]T、C[2:321682[、または、[17:198983[Aである変異は、他の染色体の一部の配列または逆相補配列が結合している変異の例である。 In FIG. 23, a mutation in which the reference base is C and the mutant base is G is an example of substitution mutation, and a mutation in which the reference base is C and the mutant base is CTAG is an example of insertion mutation. A mutation in which the reference base is TCG and the mutant base is T is an example of a deletion mutation. In addition, mutations whose mutant bases are G! 17: 198982], 13: 123456] T, C [2: 321682 [or, [17: 198983 [A] are sequences of other parts of chromosomes or reverse complements It is an example of a mutation bound to a sequence.
 図16に戻り、続いて、ステップS15において、変異同定部114は、変異データベース123を検索する。そして、ステップS16において、変異同定部114は、変異データベース123の変異情報を参照して、結果ファイルに含まれる変異にアノテーションを付与することで、変異を同定する。 Returning to FIG. 16, subsequently, in step S15, the mutation identification unit 114 searches the mutation database 123. Then, in step S16, the mutation identifying unit 114 refers to the mutation information in the mutation database 123, and annotates the mutation included in the result file to identify the mutation.
 図24は、変異データベース123の構造の一例を示す図である。変異データベース123は、例えば、COSMICやClinVarなどの外部データベースを基に構築される。また、一態様において、データベース中の各変異情報には、遺伝子パネルに関する情報に関するメタデータが付与されている。図24に示す例では、データベース中の各変異情報には、解析対象の遺伝子の遺伝子IDがメタデータとして付与されている。 FIG. 24 shows an example of the structure of mutation database 123. As shown in FIG. The mutation database 123 is constructed, for example, based on an external database such as COSMIC or ClinVar. Also, in one aspect, each mutation information in the database is provided with metadata about information on a gene panel. In the example shown in FIG. 24, the gene ID of the gene to be analyzed is attached as metadata to each piece of mutation information in the database.
 図25は、変異データベース123中の変異情報の構造の詳細例を示す図である。図25に示すように、一態様において、変異データベース123に含まれる変異情報には、変異ID、変異の位置情報(例えば、「CHROM」、および「POS」)、「REF」、「ALT」、「Annotation」が含まれていてもよい。変異IDは、変異を識別するための識別子である。変異の位置情報のうち、「CHROM」は染色体番号を示し、「POS」は染色体番号上の位置を示す。「REF」は、野生型(Wild type)における塩基を示し、「ALT」は、変異後の塩基を示す。 FIG. 25 is a diagram showing a detailed example of the structure of mutation information in the mutation database 123. As shown in FIG. 25, in one embodiment, mutation information included in mutation database 123 includes mutation ID, positional information of mutation (eg, “CHROM” and “POS”), “REF”, “ALT”, "Annotation" may be included. Mutation ID is an identifier for identifying a mutation. Among positional information of mutations, "CHROM" indicates a chromosome number, and "POS" indicates a position on the chromosome number. "REF" indicates a base in wild type (Wild type), and "ALT" indicates a base after mutation.
 「Annotation」は、変異に関する情報を示す。「Annotation」は、例えば、「EGFR C2573G」、「EGFR L858R」といったアミノ酸の変異を示す情報であってもよい。例えば、「EGFR C2573G」は、タンパク質「EGFR」の2573残基目のシステインがグリシンに置換した変異であることを示す。 "Annotation" indicates information on mutation. “Annotation” may be information indicating a mutation of an amino acid such as “EGFR C2573G” or “EGFR L858R”, for example. For example, "EGFR C2573G" indicates that the cysteine at residue 2573 of the protein "EGFR" is a mutation substituted with glycine.
 上記の例のように、変異情報の「Annotation」は、塩基情報に基づく変異を、アミノ酸情報に基づく変異に変換するための情報であってもよい。この場合、変異同定部114は、参照した「Annotation」の情報に基づいて、塩基情報に基づく変異を、アミノ酸情報に基づく変異に変換可能である。 As in the above example, "Annotation" of mutation information may be information for converting a mutation based on base information into a mutation based on amino acid information. In this case, the mutation identification unit 114 can convert a mutation based on base information into a mutation based on amino acid information based on the referenced “Annotation” information.
 変異同定部114は、結果ファイルに含まれる変異を特定する情報(例えば、変異の位置情報と変異に対応する塩基情報)をキーとして、変異データベース123を検索する。例えば、変異同定部114は、「CHROM」、「POS」、「REF」および「ALT」の情報のいずれかをキーとして変異データベース123を検索してもよい。変異同定部114は、血液検体由来のアライメント配列と、病変部位由来のアライメント配列とを比較することで抽出した変異が変異データベース123に登録されていた場合に、当該変異を試料中に存在する変異として同定し、結果ファイルに含まれる当該変異にアノテーション(例えば、「EGFR L858R」、「BRAF V600E」など)を付与する。 The mutation identification unit 114 searches the mutation database 123 using information (for example, positional information on the mutation and base information corresponding to the mutation) specifying the mutation included in the result file as a key. For example, the mutation identification unit 114 may search the mutation database 123 using any of the information of “CHROM”, “POS”, “REF” and “ALT” as a key. When a mutation extracted by comparing an alignment sequence derived from a blood sample with an alignment sequence derived from a lesion site is registered in the mutation database 123, the mutation identification unit 114 detects the mutation existing in the sample. And assign annotations (eg, “EGFR L858R”, “BRAF V600E”, etc.) to the mutations included in the result file.
 なお、一実施形態において、情報選択部112は、変異同定部114が、結果ファイルに基づいて変異データベース123を検索する前に、変異同定部114に入力された遺伝子パネルに関する情報に対応しない変異を、結果ファイルからマスク(除外)させてもよい。 In one embodiment, the information selection unit 112 causes the mutation identification unit 114 to search for mutations that do not correspond to the information on the gene panel input to the mutation identification unit 114 before searching the mutation database 123 based on the result file. You may mask (exclude) from the result file.
 例えば、一態様において、情報選択部112から遺伝子パネルに関する情報が通知された変異同定部114は、図26の(a)のような、解析対象の遺伝子と位置情報(例えば、「CHROM」と「POS」)との対応関係を示すテーブルを参照し、通知された遺伝子パネルに関する情報が特定する解析対象の遺伝子に対応する変異の位置を特定し、図26の(b)のように、それ以外の位置の変異を、結果ファイルからマスク(除外)させてもよい。これにより、変異同定部114は、結果ファイル中の、使用された遺伝子パネルに関連する変異のみにアノテーションを付与すればよいため、変異の同定の効率を向上させることができる。 For example, in one embodiment, the mutation identification unit 114 notified of the information on the gene panel from the information selection unit 112 is a gene to be analyzed and position information (for example, “CHROM” and “ The position of the mutation corresponding to the gene to be analyzed identified by the information on the notified gene panel is identified with reference to the table showing the correspondence with “POS”), and as shown in FIG. The mutation at the position of may be masked (excluded) from the result file. As a result, the mutation identification unit 114 only needs to annotate the mutations associated with the used gene panel in the result file, so that the efficiency of mutation identification can be improved.
 また、一実施形態において、情報選択部112は、変異同定部114が、アノテーションを付与するために、変異データベース123中の変異情報を参照する際に、入力された遺伝子パネルに関する情報と、各変異情報のメタデータとを参照して、変異同定部114が、当該遺伝子パネルに関する情報に対応する変異情報を選択して参照するように制御してもよい。 Moreover, in one embodiment, when the information identifying unit 114 refers to the mutation information in the mutation database 123 in order to add the annotation, the information identifying unit 114 receives information on the input gene panel and each mutation. The mutation identification unit 114 may control to select and refer to mutation information corresponding to information on the gene panel with reference to information metadata.
 例えば、一態様において、情報選択部112は、入力された遺伝子パネルに関する情報によって特定される解析対象の遺伝子に対応する変異情報を参照するよう変異同定部114を制御してもよい。これにより、変異同定部114は、変異データベース123中の、使用された遺伝子パネルに関連する変異情報のみを参照すればよいため、アノテーションの効率を向上させることができる。 For example, in one aspect, the information selection unit 112 may control the mutation identification unit 114 to refer to mutation information corresponding to the gene to be analyzed identified by the information on the input gene panel. As a result, the mutation identification unit 114 only needs to refer to the mutation information related to the used gene panel in the mutation database 123, so that the efficiency of the annotation can be improved.
 なお、同定されたすべての変異の中から、入力された遺伝子パネルに関する情報に対応する変異を、該遺伝子パネルに関する情報に基づいて選択し、リード配列情報の解析結果として、選択された変異に関連する情報を出力してもよい。 Among all the identified mutations, a mutation corresponding to the information on the input gene panel is selected based on the information on the gene panel, and as a result of analysis of the lead sequence information, a mutation associated with the selected mutation is selected. Information may be output.
 この場合、例えば、変異データベースに記憶されている各変異情報のメタデータには、解析対象の遺伝子の遺伝子IDに加えて、該遺伝子の変異毎に、遺伝子パネルが解析対象とする変異であるか否かに関する情報が含まれていればよい。 In this case, for example, in the metadata of each mutation information stored in the mutation database, in addition to the gene ID of the gene to be analyzed, is it a mutation to be analyzed by the gene panel for each mutation of the gene? It should just contain the information regarding whether or not.
 この構成によれば、変異同定部114は、情報選択部112からの遺伝子パネルに関する情報と、各変異情報のメタデータとを参照して、同定したすべての変異の中から、当該遺伝子パネルに関する情報に対応する変異情報のみを選択するように制御してもよい。例えば、異なる遺伝子パネルが、同じ遺伝子IDの遺伝子を解析対象とするものの、解析対象となる変異が互いに異なる場合があり得る。 According to this configuration, the mutation identification unit 114 refers to the information on the gene panel from the information selection unit 112 and the metadata of each mutation information, and among all the mutations identified, the information on the gene panel It may be controlled to select only mutation information corresponding to For example, although different gene panels analyze genes of the same gene ID, there may be cases where mutations to be analyzed are different from one another.
 このような場合であっても、上記の構成とすることにより、変異同定部114は、ユーザによって入力された遺伝子パネルに関する情報に対応する変異情報のみをレポート作成部115に出力することができる。なお、リード配列情報の解析結果として、変異情報を出力部13から出力したり、表示部16に表示させたりする構成であってもよい。 Even in such a case, with the above configuration, the mutation identification unit 114 can output only the mutation information corresponding to the information on the gene panel input by the user to the report generation unit 115. The mutation information may be output from the output unit 13 or displayed on the display unit 16 as the analysis result of the lead sequence information.
 (レポート作成部115)
 パネル検査によってエクソン領域全体を解析した場合、被検体の遺伝子において多くの変異が検出される。ここで、変異の中にはその変異の臨床的意義や治療に有効な薬剤が確立しておらず、医師が実際の治療に活用できる情報以外のものも含まれる。医師が遺伝子検査の結果を被検体の実際の治療に適用しようとする場合には、検出された多くの変異の中から実際の治療に活用可能となる変異を選択的に知りたいという要望がある。
(Report creation unit 115)
When the entire exon region is analyzed by panel inspection, many mutations are detected in the gene of the subject. Here, among the mutations, clinical significance of the mutation and an effective drug for treatment have not been established, and include information other than information that the doctor can use for actual treatment. When a doctor intends to apply the result of a genetic test to the actual treatment of a subject, there is a demand to selectively know which mutations can be used for the actual treatment among many mutations detected. .
 レポート作成部115は、変異同定部114が出力した情報、および情報選択部112から提供される遺伝子パネルに関する情報に基づいてレポートを作成する(図2のステップS110に対応)。作成されるレポートに掲載される情報は、遺伝子パネルに関する情報、および同定された変異に関する情報を含んでいる。 The report creation unit 115 creates a report based on the information output from the mutation identification unit 114 and the information on the gene panel provided from the information selection unit 112 (corresponding to step S110 in FIG. 2). The information contained in the generated report includes information on the gene panel and information on the identified mutations.
 レポート作成部115は、情報選択部112が情報選択部112からの遺伝子パネルに関する情報に基づいて、レポートに掲載する対象を取捨選択し、選択されなかった情報はレポートから削除する。あるいは、情報選択部112が、入力部17を介して入力された遺伝子パネルに関する情報に対応する遺伝子に関連する情報を、レポートに掲載する対象として選択し、選択されなかった情報はレポートから削除されるよう、レポート作成部115を制御する構成であってもよい。 The report creation unit 115 causes the information selection unit 112 to select the target to be included in the report based on the information on the gene panel from the information selection unit 112, and deletes the information not selected from the report. Alternatively, the information selection unit 112 selects the information related to the gene corresponding to the information on the gene panel input through the input unit 17 as a target to be included in the report, and the information not selected is deleted from the report. May be configured to control the report generation unit 115.
 (出力部13)
 レポート作成部115によって作成されたレポートは、リード配列情報の解析結果として、出力部13から、医療機関210に設置された端末装置5にデータ送信されてもよい(図2のステップS111に対応)。あるいは、遺伝子解析装置1と接続されているプリンタ(図示せず)に送信され、該プリンタによって印刷された後に、紙媒体として、検査機関120から医療機関210へ送付されてもよい。
(Output unit 13)
The report created by the report creation unit 115 may be data transmitted from the output unit 13 to the terminal device 5 installed in the medical institution 210 as an analysis result of the lead arrangement information (corresponding to step S111 in FIG. 2) . Alternatively, it may be sent to a printer (not shown) connected to the gene analysis device 1 and printed by the printer, and then sent from the examination institution 120 to the medical institution 210 as a paper medium.
 〔実施形態2〕
 本発明の他の実施形態について、以下に説明する。なお、説明の便宜上、上記実施形態にて説明した部材と同じ機能を有する部材については、同じ符号を付記し、その説明を繰り返さない。
Second Embodiment
Other embodiments of the present invention are described below. In addition, about the member which has the same function as the member demonstrated in the said embodiment for convenience of explanation, the same code | symbol is appended, and the description is not repeated.
 (遺伝子解析装置1aの構成)
 ここでは、変異同定部114によって同定された変異に関連する薬剤に関する情報(薬剤情報)を含むレポートを作成することが可能な遺伝子解析装置1aについて、図27を用いて説明する。
(Configuration of Gene Analysis Device 1a)
Here, a gene analysis device 1a capable of creating a report including information (drug information) on a drug related to a mutation identified by the mutation identification unit 114 will be described using FIG.
 図27は遺伝子解析装置1aの構成の別の一例を示す図である。遺伝子解析装置1aの解析実行部110aは薬剤検索部117をさらに備え、第1記憶部12aは薬剤データベース124をさらに備えている点で、図4に示す遺伝子解析装置1と異なっている。 FIG. 27 is a diagram showing another example of the configuration of the gene analysis device 1a. The analysis execution unit 110a of the gene analysis apparatus 1a further includes a drug search unit 117, and the first storage unit 12a is different from the gene analysis apparatus 1 illustrated in FIG. 4 in that the first storage unit 12a further includes a drug database 124.
 (薬剤検索部117)
 薬剤検索部117が薬剤に関する情報を含むリストを生成する処理の流れについて、図28を用いて説明する。図28は、薬剤検索部117が変異に関する薬剤のリストを生成する処理の一例を示すフローチャートである。
(Pharmaceutical search unit 117)
A flow of processing in which the drug search unit 117 generates a list including information on drugs will be described with reference to FIG. FIG. 28 is a flowchart showing an example of a process in which the drug search unit 117 generates a drug list related to mutation.
 薬剤検索部117は、変異同定部114によって同定された変異に付与された変異IDをキーとして、薬剤データベース124を検索する(ステップS15a)。検索結果に基づいて、薬剤検索部117は、変異に関する薬剤に関する情報を含むリストを生成する(ステップS16a)。生成されたリストは、レポート作成部115が作成するレポートに組み込まれる。 The drug search unit 117 searches the drug database 124 using the mutation ID assigned to the mutation identified by the mutation identification unit 114 as a key (step S15a). Based on the search results, the drug search unit 117 generates a list including information on drugs related to mutation (step S16a). The generated list is incorporated into the report generated by the report generation unit 115.
 (薬剤データベース124)
 薬剤検索部117が薬剤データベース124を検索して薬剤リストを生成する場合に、薬剤データベース124に記憶されているデータ124Aについて、図29を用いて説明する。図29は、薬剤データベース124のデータ構造の例を示す図である。
(Medication database 124)
When the drug search unit 117 searches the drug database 124 and generates a drug list, data 124A stored in the drug database 124 will be described with reference to FIG. FIG. 29 shows an example of the data structure of the medicine database 124. As shown in FIG.
 薬剤データベース124には、図29に示すように、変異毎に付与された変異ID、関連薬剤名、および薬剤毎に付与された薬剤IDが互いに関連付けられて記憶されている。なお、図29の変異ID「♯3」に対して、「薬剤A」および「薬剤B」が関連付けられているように、各変異IDについて複数の関連薬剤が関連付けられてもよい。 In the drug database 124, as shown in FIG. 29, a mutation ID given for each mutation, a related drug name, and a drug ID given for each drug are stored in association with each other. It should be noted that a plurality of related drugs may be associated with each mutation ID so that “drug A” and “drug B” are associated with the mutation ID “# 3” in FIG.
 また、薬剤データベース124の各変異IDには、遺伝子パネルに関する情報に関するメタデータである「遺伝子パネル関連情報に関するメタデータ」が付与されていてもよい。薬剤検索部117は、情報選択部112からの指示に応じて、この「遺伝子パネル関連情報に関するメタデータ」を参照する。 Further, each mutation ID of the drug database 124 may be provided with “metadata related to gene panel related information” which is metadata related to information related to a gene panel. In response to the instruction from the information selection unit 112, the drug search unit 117 refers to the "metadata related to gene panel related information".
 そして、薬剤検索部117は、薬剤データベース124を検索する範囲を、該メタデータに示された範囲に変更する。これにより、薬剤検索部117は、各薬剤に付与されている「遺伝子パネル関連情報に関するメタデータ」と入力された遺伝子パネルに関する情報に応じて、薬剤データベース中で参照すべき薬剤を絞り込むことができ、遺伝子パネルに関する情報に応じた薬剤に関する情報を含むリストを生成することができる。 Then, the drug search unit 117 changes the range in which the drug database 124 is searched to the range indicated in the metadata. As a result, the drug search unit 117 can narrow down the drugs to be referred to in the drug database according to the information on the gene panel input as "metadata on gene panel related information" given to each drug. A list can be generated that contains information about the drug depending on the information about the gene panel.
 <変形例1>
 薬剤検索部117は、図30に示すデータ構造を有する薬剤データベース124を検索して、変異に関連する薬剤に関する他の情報を含むリストを生成してもよい。具体的には、実施形態2において生成する変異に関連する薬剤のリストに加え、薬剤の承認情報を付加する。このことに関し、図31を用いて説明する。図31は、薬剤検索部117が変異に関する薬剤に関する情報を含むリストを生成する処理の一例を示すフローチャートである。
<Modification 1>
The drug search unit 117 may search the drug database 124 having the data structure shown in FIG. 30 and generate a list including other information on the drug related to the mutation. Specifically, in addition to the list of drugs associated with mutations generated in Embodiment 2, drug approval information is added. This will be described with reference to FIG. FIG. 31 is a flowchart showing an example of a process in which the drug search unit 117 generates a list including information on drugs related to mutation.
 薬剤検索部117は、図30に示すデータを記憶している薬剤データベース124から、関連薬剤が当局(FDA、PMDAなど)で承認されているか否かを検索する。具体的には、薬剤検索部117は、例えば、「変異ID」等の変異に関する情報をキーとして、変異に対応する関連薬剤が当局で承認されているかを示す「承認状況」、どの国の当局で承認されているかを示す「承認国」を検索する(ステップS15b)。 The drug search unit 117 searches the drug database 124 storing the data shown in FIG. 30 to see if the relevant drug has been approved by the authority (FDA, PMDA, etc.). Specifically, the drug search unit 117 uses, for example, information on a mutation such as a “mutation ID” as a key, and indicates “approval status” indicating whether the related drug corresponding to the mutation is approved by the authority, Search for "approved country" indicating whether or not it is approved in (step S15b).
 薬剤検索部117は、検索結果に基づき、変異、該変異に対応する関連薬剤、および該関連薬剤の承認に関する情報などを含むリストを生成する(ステップS16b)。 The drug search unit 117 generates a list including the mutation, the related drug corresponding to the mutation, information on approval of the related drug, and the like based on the search result (step S16b).
 <変形例2>
 薬剤検索部117は、図30に示すデータ構造を有する薬剤データベース124を検索して、変異に関連する薬剤に関するさらに他の情報を含むリストを生成してもよい。具体的には、実施形態2において生成する変異に関連する薬剤のリストに加え、被検体の疾患に対応する薬剤の情報を付加する。このことに関し、図32を用いて説明する。図32は、薬剤検索部117が薬剤データベース124を検索して得た情報に基づいて、Off-label use(適用外使用)の可能性がある薬剤の有無を判定し、判定結果を含むリストを生成する処理の一例を示すフローチャートである。
<Modification 2>
The drug search unit 117 may search the drug database 124 having the data structure shown in FIG. 30 and generate a list including further information on drugs related to the mutation. Specifically, in addition to the list of agents associated with mutations generated in Embodiment 2, information of agents corresponding to the disease of the subject is added. This will be described with reference to FIG. FIG. 32 determines the presence or absence of a drug having a possibility of Off-label use based on the information obtained by the drug search unit 117 searching the drug database 124, and a list including the determination result is displayed. It is a flow chart which shows an example of processing to generate.
 薬剤検索部117は、図30に示すデータ124Bを記憶している薬剤データベース124から、関連薬剤が当局(FDA、PMDAなど)で承認されているか否かを検索する(ステップS15b)。検索された薬剤が未承認である場合(ステップS21にてNO)、薬剤検索部117は、該薬剤を未承認薬として変異に関連付け(ステップS23)、変異に関連する薬剤のレポートを生成する(ステップS16a)。 The drug search unit 117 searches the drug database 124 storing the data 124B shown in FIG. 30 to see if the relevant drug is approved by the authority (FDA, PMDA, etc.) (step S15 b). If the searched drug is unapproved (NO in step S21), the drug search unit 117 associates the drug as a non-approved drug with the mutation (step S23), and generates a report of the drug related to the mutation (step S23). Step S16a).
 検索された薬剤が承認済みである場合(ステップS21にてYES)、薬剤検索部117は、試料が採取された被検体の疾患と、薬剤データベース124から検索された関連薬剤に対応する疾患(例えば、図30に示す「対象疾患」)と、が一致するか否かを判定する(ステップS22)。 If the retrieved drug is approved (YES in step S21), the drug retrieval unit 117 determines the disease of the subject from which the sample was collected and the disease corresponding to the related drug retrieved from the drug database 124 (for example, It is determined whether or not “the target disease” shown in FIG. 30 matches (step S22).
 被検体の疾患と「対象疾患」とが一致する場合(ステップS22にてYES)、検索結果の薬剤を承認薬として変異に関連付けを行い(ステップS24)、変異、該変異に対応する関連薬剤、および該関連薬剤の承認に関する情報などを含むリストを生成する(ステップS16a)。 When the disease of the subject and the "target disease" coincide (YES in step S22), the drug of the search result is associated with the mutation as an approved drug (step S24), the mutation, the related drug corresponding to the mutation, And a list including information related to the approval of the related drug (step S16a).
 一方、被検体の疾患と「対象疾患」とが異なる場合(ステップS22にてNO)、検索された関連薬剤はOff-label use(適用外使用)の可能性がある薬剤であると判定し、その判定結果を変異に関連付けて(ステップS25)、変異、該変異に対応する関連薬剤、および該関連薬剤の承認に関する情報などを含むリストを生成する(ステップS16a)。 On the other hand, when the disease of the subject and the "target disease" are different (NO in step S22), it is determined that the related drug retrieved is a drug having the possibility of off-label use (use outside application), The determination result is associated with the mutation (Step S25), and a list including the mutation, the related drug corresponding to the mutation, and information on approval of the related drug is generated (Step S16a).
 なお、被検体の疾患に関する情報は、例えば、遺伝子解析を実行する際に操作者などによって入力部17から入力され得る。また、例えば、リード配列情報のヘッダ領域に、被検体の疾患に対応する識別情報である疾患IDが含まれていてもよい。 The information on the disease of the subject may be input from the input unit 17 by the operator or the like, for example, when performing the gene analysis. In addition, for example, the header area of the lead arrangement information may include a disease ID which is identification information corresponding to a disease of a subject.
 <変形例3>
 薬剤検索部117は、図33に示すデータ構造を有する薬剤データベース124を検索して、変異に関連する薬剤の治験に関する情報を含むリストを生成してもよい。具体的には、実施形態2において生成する変異に関連する薬剤のリストに加え、薬剤の治験情報を付加する。このことに関し、図34を用いて説明する。図34は、薬剤検索部117が薬剤の治験に関する情報を含むリストを生成する処理の一例を示すフローチャートである。
<Modification 3>
The drug search unit 117 may search the drug database 124 having the data structure shown in FIG. 33 and generate a list including information on trials of drugs related to mutation. Specifically, in addition to the list of drugs related to mutations generated in Embodiment 2, drug trial information is added. This will be described with reference to FIG. FIG. 34 is a flowchart showing an example of a process in which the drug search unit 117 generates a list including information on clinical trials of drugs.
 薬剤検索部117は、図33に示すデータ124Cを記憶している薬剤データベース124から、関連薬剤の治験の進捗具合などの情報を検索する。具体的には、薬剤検索部117は、変異IDなどをキーとして、変異の治験に関する情報、例えば、図33に示す「治験/臨床試験状況」、治験を実施している「実施国」、および「実施機関」などを検索する(図34のステップS15c)。薬剤検索部117は、検索結果に基づき、変異、該変異に対応する関連薬剤、および該関連薬剤の治験に関する情報などを含むリストを生成する(図34のステップS16c)。 The drug search unit 117 searches the drug database 124 storing the data 124C shown in FIG. 33 for information such as the progress of the clinical trial of the related drug. Specifically, the drug search unit 117 uses the mutation ID or the like as a key, and information on the trial of the mutation, for example, the “trial / clinical test status” shown in FIG. 33, the “implementation country” performing the trial, Search for "implementing agency" and the like (step S15c in FIG. 34). The drug search unit 117 generates a list including the mutation, the related drug corresponding to the mutation, information on the trial of the related drug, and the like based on the search result (step S16c in FIG. 34).
 なお、図29に示すデータ124A、図30に示すデータ124B、および図33に示すデータ124Cは、一つに統合させて薬剤データベース124に記憶されていてもよいし、薬剤データベース124を含む複数のデータベースに分散させて記憶されていてもよい。 Note that the data 124A shown in FIG. 29, the data 124B shown in FIG. 30, and the data 124C shown in FIG. 33 may be integrated into one and stored in the medicine database 124, and a plurality of medicine databases 124 are included. It may be distributed and stored in a database.
 〔実施形態3〕
 本発明の他の実施形態について、以下に説明する。なお、説明の便宜上、上記実施形態にて説明した部材と同じ機能を有する部材については、同じ符号を付記し、その説明を繰り返さない。
Third Embodiment
Other embodiments of the present invention are described below. In addition, about the member which has the same function as the member demonstrated in the said embodiment for convenience of explanation, the same code | symbol is appended, and the description is not repeated.
 (遺伝子解析装置1bの構成)
 ここでは、変異同定部114によって同定された変異に関連するさまざまなリファレンス情報(参照情報)を含むレポートを作成することが可能な遺伝子解析装置1bについて図35を用いて説明する。
(Configuration of Gene Analysis Device 1b)
Here, a gene analysis device 1b capable of creating a report including various reference information (reference information) related to the mutation identified by the mutation identification unit 114 will be described with reference to FIG.
 図35は遺伝子解析装置1bの構成の他の一例を示す図である。遺伝子解析装置1bの解析実行部110bはリファレンス検索部118をさらに備え、第1記憶部12bはリファレンスデータベース125をさらに備えている点で、図4に示す遺伝子解析装置1と異なっている。 FIG. 35 is a diagram showing another example of the configuration of the gene analysis device 1b. The analysis execution unit 110b of the gene analysis apparatus 1b further includes a reference search unit 118, and the first storage unit 12b is different from the gene analysis apparatus 1 illustrated in FIG. 4 in that the first storage unit 12b further includes a reference database 125.
 (リファレンス検索部118)
 リファレンス検索部118は、変異同定部114によって同定された変異に付与された変異IDをキーとして、リファレンスデータベース125を検索する。検索結果に基づいて、リファレンス検索部118は、変異に関するリファレンス情報を抽出する。抽出されたリファレンス情報は、レポート作成部115が作成するレポートに組み込まれる。
(Reference search unit 118)
The reference search unit 118 searches the reference database 125 using the mutation ID assigned to the mutation identified by the mutation identification unit 114 as a key. Based on the search result, the reference search unit 118 extracts reference information on the mutation. The extracted reference information is incorporated into the report created by the report creation unit 115.
 (リファレンスデータベース125)
 リファレンス検索部118が検索するリファレンスデータベース125に記憶されているデータについて、図36を用いて説明する。図36は、リファレンスデータベース125のデータ構造の例を示す図である。
(Reference database 125)
Data stored in the reference database 125 searched by the reference search unit 118 will be described with reference to FIG. FIG. 36 is a diagram showing an example of the data structure of the reference database 125. As shown in FIG.
 リファレンスデータベース125には、図36に示すように、変異ID、該変異の生物学的背景に関する情報、分子機能情報、臨床情報、および該変異に関する著書ならびに科学論文などの文献情報などが互いに関連付けられて記憶されている。 In the reference database 125, as shown in FIG. 36, a mutation ID, information on the biological background of the mutation, molecular function information, clinical information, and literature information such as a book and a scientific article on the mutation are mutually associated. Are stored.
 また、リファレンスデータベース125の各変異IDには、遺伝子パネルに関する情報に関するメタデータである「遺伝子パネル関連情報に関するメタデータ」が付与されていてもよい(図示せず)。この場合、リファレンス検索部118は、情報選択部112からの指示に応じて、この「遺伝子パネル関連情報に関するメタデータ」を参照し、リファレンスデータベース125を検索する範囲を、該メタデータに示された範囲に変更する。これにより、リファレンス検索部118は、各変異に関連付けられた「遺伝子パネル関連情報に関するメタデータ」と入力された遺伝子パネルに関する情報とに応じて、薬剤データベース中で参照すべきリファレンス情報を絞り込むことができ、遺伝子パネルに関する情報に応じたリファレンス情報を抽出することができる。 Further, each mutation ID of the reference database 125 may be provided with “metadata related to gene panel related information” which is metadata related to information related to a gene panel (not shown). In this case, the reference search unit 118 refers to the “metadata related to gene panel related information” according to the instruction from the information selection unit 112, and the range for searching the reference database 125 is indicated by the metadata. Change to a range. Thereby, the reference search unit 118 narrows down the reference information to be referred to in the drug database according to the "metadata related to gene panel related information" associated with each mutation and the information related to the input gene panel. It is possible to extract reference information according to the information on the gene panel.
 (遺伝子解析装置1a、1bのレポート作成部115)
 レポート作成部115は、薬剤検索部117が出力した情報に基づいてレポートを作成してもよいし、リファレンス検索部118が出力した情報に基づいてレポートを作成してもよい。さらに、レポート作成部115は、薬剤検索部117およびリファレンス検索部118の双方が出力した情報に基づいてレポートを作成してもよい。
(Report creation unit 115 of the gene analysis device 1a, 1b)
The report creation unit 115 may create a report based on the information output by the drug search unit 117 or may create a report based on the information output by the reference search unit 118. Furthermore, the report creation unit 115 may create a report based on the information output from both the drug search unit 117 and the reference search unit 118.
 レポート作成部115によって作成されるレポートには、同定された変異に関する情報、該変異に関連する薬剤の情報、該変異に関するリファレンス(例えば、各変異についての分子生物学的な知見および文献に関する情報などを含む)、もしくは、これらの情報を任意に組み合わせた情報が掲載され得る。 The report created by the report creation unit 115 includes information on the identified mutation, information on the drug related to the mutation, a reference on the mutation (for example, information on molecular biological knowledge and documents on each mutation, etc. Or any combination of these information may be posted.
 情報選択部112は、例えば、入力された遺伝子パネルに関する情報に対応する対象遺伝子に関連する情報を、レポートに掲載する対象として選択し、選択された情報を掲載したレポートをレポート作成部115が作成するよう制御する。 The information selection unit 112 selects, for example, information related to the target gene corresponding to the input information on the gene panel as a target to be included in the report, and the report generation unit 115 creates a report on which the selected information is posted. Control to
 図37は、レポート作成部115によって作成されたレポートの一例を示す図である。この例に示すレポートの左上の部分には、被検体IDを示す「患者ID」、「患者の性別」、「患者の病名」、医療機関210において該被検体を担当する医師の名前である「担当医師名」、および医療機関名を示す「機関名」が記載されている。さらに、遺伝子パネルに関する情報として、「Aパネル」という遺伝子パネル名も含まれている。このレポートでは、「検出された遺伝子変異および関連薬剤」という欄に、変異同定部114によって同定された変異に関する情報と、薬剤検索部117が薬剤データベース124を検索して、検索結果に基づいて生成したリストが含まれている。 FIG. 37 is a diagram showing an example of a report created by the report creation unit 115. As shown in FIG. In the upper left part of the report shown in this example, “patient ID” indicating “subject ID”, “patient's gender”, “patient's disease name”, and the name of the doctor in charge of the subject at the medical institution 210 “ The name of the doctor in charge and the name of the institution showing the name of the medical institution are described. Furthermore, the gene panel name "A panel" is also included as information on the gene panel. In this report, information on the mutation identified by the mutation identification unit 114 and the drug search unit 117 search the drug database 124 in the column of “Detected gene mutation and related drug”, and are generated based on the search result. List is included.
 また、「臨床試験一覧」の欄には、薬剤検索部117が薬剤データベース124を検索して、検索結果に基づいて生成した薬剤の治験に関する情報のリストが含まれている。 Further, the column of “clinical test list” includes a list of information on clinical trials of drugs generated by the drug search unit 117 by searching the drug database 124 and based on the search results.
 〔実施形態4〕
 本発明の他の実施形態について、以下に説明する。なお、説明の便宜上、上記実施形態にて説明した部材と同じ機能を有する部材については、同じ符号を付記し、その説明を繰り返さない。
Embodiment 4
Other embodiments of the present invention are described below. In addition, about the member which has the same function as the member demonstrated in the said embodiment for convenience of explanation, the same code | symbol is appended, and the description is not repeated.
 (遺伝子解析装置1cの構成)
 ここでは、ユーザに遺伝子パネルに関する情報を入力させる機能に加えて、リード配列情報に含まれるインデックス配列に基づいて、情報選択部112cが遺伝子パネルに関する情報を取得する機能も備える遺伝子解析装置1cについて説明する。以下では、特に図38に示す遺伝子パネル関連情報データベース121c、データ調整部113c、および情報選択部112cについて、図39を参照しながら説明する。
(Configuration of gene analyzer 1c)
Here, in addition to the function of allowing the user to input information on the gene panel, the gene analysis device 1c having the function of acquiring information on the gene panel by the information selection unit 112c based on the index sequence included in the lead sequence information will be described. Do. Hereinafter, the gene panel related information database 121c, the data adjustment unit 113c, and the information selection unit 112c shown in FIG. 38 will be described with reference to FIG.
 図38は遺伝子解析装置1cの構成の他の一例を示す機能ブロック図である。なお、配列データ読取部111が読み取るリード配列情報には、例えば、試料毎、または遺伝子パネルの種別毎にリード配列情報を識別するためのインデックス配列が挿入されていてもよい。 FIG. 38 is a functional block diagram showing another example of the configuration of the gene analysis device 1c. In the read sequence information read by the sequence data reading unit 111, for example, an index sequence for identifying the read sequence information may be inserted for each sample or each type of gene panel.
 また、インデックス配列は、遺伝子パネルが解析対象とする遺伝子のうち、特定の遺伝子の配列にのみ挿入されてもよい。インデックス配列が挿入されていないリード配列情報であれば、図6に示すように、ユーザに遺伝子パネルに関する情報を入力させればよい。 Also, the index sequence may be inserted only into the sequence of a specific gene among the genes to be analyzed by the gene panel. If it is the read sequence information in which the index sequence is not inserted, it is sufficient to allow the user to input information on the gene panel as shown in FIG.
 <遺伝子パネル関連情報データベース121c>
 まず、情報選択部112cが参照する遺伝子パネル関連情報データベース121cに記憶されているデータ121Dについて、図39を用いて説明する。図39は、遺伝子パネル関連情報データベース121cのデータ構造の例を示す図である。遺伝子パネル関連情報データベース121cには、選択可能な遺伝子パネルの名称、各遺伝子パネルに付与された遺伝子パネルID、および遺伝子パネル毎に、挿入されるインデックス配列情報が関連付けられて記憶されている。
<Gene panel related information database 121c>
First, data 121D stored in the gene panel related information database 121c, to which the information selection unit 112c refers, will be described using FIG. FIG. 39 is a diagram showing an example of the data structure of the gene panel related information database 121 c. In the gene panel related information database 121 c, names of selectable gene panels, gene panel IDs assigned to the respective gene panels, and index sequence information to be inserted are stored in association with each other.
 図39に示す例では、遺伝子パネルIDが「AAA」である遺伝子パネル「Aパネル」を用いて解析されたリード配列情報には、インデックス配列「pppppppppp」が含まれており、遺伝子パネルIDが「BBB」である遺伝子パネル「Bパネル」を用いて解析されるリード配列情報には、インデックス配列「qqqqqqqqqq」が含まれていることを示すデータを示している。なお、「p」および「q」は塩基を示している。 In the example shown in FIG. 39, the lead sequence information analyzed using the gene panel "A panel" having the gene panel ID "AAA" includes the index sequence "ppppppppppp", and the gene panel ID is " The reading sequence information analyzed using the gene panel "B panel" which is BBB "indicates data indicating that the index sequence" qqqqqqqqqqqq "is included. In addition, "p" and "q" have shown the base.
 <データ調整部113c>
 データ調整部113cは、配列データ読取り部111が読み取ったリード配列情報を解析し、その配列中に、遺伝子パネル関連情報データベース121cに記憶されているインデックス配列「pppppppppp」、「qqqqqqqqqq」などが含まれているか否かを判定する。インデックス配列が含まれていない場合、データ調整部113cは、情報選択部112cにその旨を通知する。一方、インデックス配列が含まれている場合、データ調整部113cは、検出されたインデックス配列(例えば、「pppppppppp」)を情報選択部112cへ出力する。
<Data adjustment unit 113c>
The data adjustment unit 113c analyzes the read sequence information read by the sequence data reading unit 111, and the sequence includes the index sequences “ppppppppppp”, “qqqqqqqqqqq”, etc. stored in the gene panel related information database 121c. It is determined whether the If the index array is not included, the data adjustment unit 113c notifies the information selection unit 112c to that effect. On the other hand, when the index arrangement is included, the data adjustment unit 113 c outputs the detected index arrangement (for example, “ppppppppppp”) to the information selection unit 112 c.
 <情報選択部112c>
 情報選択部112cは、データ調整部113cから、インデックス配列が含まれていないことを通知された場合、「遺伝子パネルに関する情報を入力してください」などのメッセージとともに、図6に示すGUIを表示部16に表示させる。一方、インデックス配列をデータ調整部113cから受信した場合、そのインデックス配列をキーとして遺伝子パネル関連情報データベース121cを検索し、該インデックス配列に対応する遺伝子パネル名、および遺伝子パネルIDなどの遺伝子パネル関連情報を特定する。例えば、データ調整部113cから受信したインデックス配列が「qqqqqqqqqq」であった場合、情報選択部112cは、遺伝子パネル関連情報データベース121cを検索し、遺伝子パネルとして「Bパネル」が使用されたことを特定し、該遺伝子パネルの遺伝子パネル関連情報を取得する。取得された遺伝子パネル関連情報は、上述したように、データ調整部113c、変異同定部114、レポート作成部115などへの制御に適用される。
<Information Selection Unit 112c>
The information selection unit 112c, when notified by the data adjustment unit 113c that the index array is not included, displays the GUI shown in FIG. 6 together with a message such as "Please enter information about gene panel". Display on 16 On the other hand, when the index sequence is received from the data adjustment unit 113c, the gene panel related information database 121c is searched using the index sequence as a key, and gene panel related information such as gene panel name and gene panel ID corresponding to the index sequence. Identify For example, when the index sequence received from the data adjustment unit 113c is "qqqqqqqqqqq", the information selection unit 112c searches the gene panel related information database 121c, and specifies that "B panel" is used as a gene panel. And obtain gene panel related information of the gene panel. The acquired gene panel related information is applied to control of the data adjustment unit 113c, the mutation identification unit 114, the report creation unit 115, and the like as described above.
 このようにインデックス配列がリード配列情報に挿入されている場合には、ユーザに遺伝子パネル関連情報の入力をさせることなく、遺伝子パネル関連情報を特定することが可能である。よって、ユーザに対して更なる利便性を提供することができる。 As described above, when the index sequence is inserted into the read sequence information, it is possible to specify the gene panel related information without having the user input the gene panel related information. Thus, further convenience can be provided to the user.
 本発明は上述した各実施形態に限定されるものではなく、請求項に示した範囲で種々の変更が可能であり、異なる実施形態にそれぞれ開示された技術的手段を適宜組み合わせて得られる実施形態についても本発明の技術的範囲に含まれる。 The present invention is not limited to the above-described embodiments, and various modifications can be made within the scope of the claims, and embodiments obtained by appropriately combining the technical means disclosed in the different embodiments. Is also included in the technical scope of the present invention.
 たとえば、図1には、1つの医療機関210および1つの検査機関120を示しているが、これに限定されるものではない。すなわち、医療機関210は、複数の検査機関120に対して解析を依頼してもよく、検査機関120は、複数の医療機関210からの解析依頼を受け付けてもよい。すなわち、医療機関210および検査機関120のそれぞれが、複数であってもよい。 For example, although FIG. 1 shows one medical institution 210 and one laboratory 120, it is not limited thereto. That is, the medical institution 210 may request the analysis to a plurality of inspection institutions 120, and the inspection institution 120 may receive an analysis request from a plurality of medical institutions 210. That is, each of the medical institution 210 and the examination institution 120 may be plural.
 図1および図2において、検査機関120のシーケンサー2および遺伝子解析装置1を1つずつ示しているが、これに限定されない。すなわち、検査機関120には複数のシーケンサー2および複数の遺伝子解析装置1が備えられていてもよい。 Although FIG. 1 and FIG. 2 show the sequencer 2 and the gene analysis device 1 of the inspection organization 120 one by one, it is not limited thereto. That is, the inspection organization 120 may be provided with a plurality of sequencers 2 and a plurality of gene analysis devices 1.
 また、医療機関210と検査機関120との双方の機能を有する機関(例えば、臨床施設と検査施設とを兼備した研究所、および大学病院など)においても、遺伝子解析システム100を好適に適用することが可能である。これは遺伝子解析システム100に限られず、遺伝子解析装置1によって実行される遺伝子解析方法、遺伝子解析方法をコンピュータにて実現させた遺伝子解析装置1を制御するためのプログラム、およびそれを記録したコンピュータ読み取り可能な記録媒体も、医療機関210と検査機関120との双方の機能を有する機関においても好適に適用され得る。 In addition, the genetic analysis system 100 should preferably be applied also to an institution having functions of both the medical institution 210 and the examination institution 120 (for example, a research institute which combines a clinical institution and an examination institution, and a university hospital). Is possible. The present invention is not limited to the gene analysis system 100, and a gene analysis method executed by the gene analysis device 1, a program for controlling the gene analysis device 1 having a computer realized the gene analysis method, and a computer reading the same A possible recording medium may also be suitably applied to an organization having the functions of both the medical institution 210 and the inspection institution 120.
 なお、遺伝子パネルを用いた解析は、一塩基多型(SNP、Single Nucleotide Polymorphism)、およびコピー数多型(CNV、Copy Number Polymorphism)などの多型の解析に用いられてもよい。また、遺伝子パネルは、解析対象遺伝子全体の変異などの量に関する情報(Tumor Mutation Burdenなどとも呼ばれる)の出力や、メチル化頻度の算出に用いられてもよい。 Analysis using a gene panel may be used for analysis of polymorphisms such as single nucleotide polymorphism (SNP, Single Nucleotide Polymorphism) and copy number polymorphism (CNV, Copy Number Polymorphism). In addition, the gene panel may be used for the output of information (also referred to as Tumor Mutation Burden etc.) regarding the amount of mutation or the like of the entire analysis target gene, and for calculation of the methylation frequency.
 また、ユーザに遺伝子パネルに関する情報を入力させるための手段として、入力用のGUIを表示する例を示したが、これに限定されない。例えば、入力部17がバーコードリーダであって、ユーザにバーコードを読み取らせる構成であってもよい。各遺伝子パネルの各試薬の容器のラベル、および遺伝子パネルの一揃いの試薬を収容している箱の表面などにバーコードが示されている場合、バーコードリーダを用いて該バーコードを、読み取ることにより、遺伝子パネルに関する情報が入力される。 In addition, although an example in which a GUI for input is displayed as a means for allowing the user to input information on a gene panel has been shown, the present invention is not limited to this. For example, the input unit 17 may be a barcode reader, and the user may read the barcode. If a barcode is indicated on the label of the container of each reagent of each gene panel and on the surface of a box containing a set of reagents of the gene panel, the barcode is read using a barcode reader. Thus, information on the gene panel is input.
 なお、制御部11が、遺伝子パネルに関する情報を入力するためのGUIを表示部16に表示させる場合、ユーザに、解析対象の遺伝子を選択させてもよい。この場合、図40に示すように、GUIに候補となる遺伝子のリストを表示させ、ユーザに遺伝子パネルが解析対象とする遺伝子を選択させてもよい。 When the control unit 11 causes the display unit 16 to display a GUI for inputting information related to the gene panel, the user may select a gene to be analyzed. In this case, as shown in FIG. 40, a list of candidate genes may be displayed on the GUI, and the user may select a gene to be analyzed by the gene panel.
 GUIに表示される遺伝子名は、遺伝子パネル関連情報データベース121に登録されている、遺伝子IDが付与された遺伝子の遺伝子名を基に表示される。なお、選択枝として表示されるリスト中の遺伝子名は、遺伝子パネル関連情報データベース121に登録されている遺伝子パネルに関する情報を基に表示される。 The gene name displayed on the GUI is displayed based on the gene name of the gene assigned with the gene ID registered in the gene panel related information database 121. In addition, the gene name in the list displayed as a selection branch is displayed based on the information regarding the gene panel registered in the gene panel related information database 121.
 図40には、解析対象となる遺伝子名(例えば、「AKT1」および「APC」など)が複数含まれるリストが示され、各遺伝子名の左側にチェックボックスが設けられた例が示されている。図40に示す例では、「AKT1」および「APC」などの遺伝子名が選択され、「EML4」および「JAK3」などの遺伝子名は選択されていない。情報選択部112は、選択された遺伝子名から、これらの遺伝子名に関連付けられた遺伝子パネルIDを特定し、遺伝子パネル関連情報データベース121を検索して、入力された遺伝子パネル名に対応する遺伝子パネルに関する情報を取得する。 FIG. 40 shows a list including a plurality of gene names (for example, “AKT1” and “APC” etc.) to be analyzed, and an example in which a check box is provided on the left side of each gene name is shown . In the example shown in FIG. 40, gene names such as “AKT1” and “APC” are selected, and gene names such as “EML4” and “JAK3” are not selected. The information selection unit 112 specifies gene panel IDs associated with the selected gene names from the selected gene names, searches the gene panel related information database 121, and selects a gene panel corresponding to the input gene panel name. Get information about
 あるいは、図41に示すように、「肺がんパネル」、「大腸がんパネル」などの疾患毎に遺伝子パネル名のリストをGUIに表示し、リストに示した遺伝子パネルの中からユーザに所望の疾患に関する遺伝子パネルを選択させてもよい。「肺がん」、「大腸がん」などの疾患名のリストをGUIに表示し、リストに示した疾患名の中からユーザに所望の疾患を選択させてもよい。 Alternatively, as shown in FIG. 41, a list of gene panel names is displayed on the GUI for each disease such as “lung cancer panel” or “colorectal cancer panel”, and a desired disease for the user from among the gene panels shown in the list. You may select the gene panel regarding. A list of disease names such as “lung cancer” and “colorectal cancer” may be displayed on the GUI, and the user may select a desired disease from among the disease names shown in the list.
 この場合、情報選択部112は、選択された疾患名から、該疾患名に関連付けられた遺伝子パネルIDを特定し、遺伝子パネル関連情報データベース121を検索して、選択された疾患名に対応する遺伝子パネルに関する情報を取得すればよい。 In this case, the information selection unit 112 specifies the gene panel ID associated with the disease name from the selected disease name, searches the gene panel related information database 121, and selects the gene corresponding to the selected disease name. Get information about the panel.
 選択された疾患に関連する遺伝子パネルを選択させる選択枝としてGUIに表示される遺伝子名は、遺伝子パネル関連情報データベース121に登録されている情報を基に表示される。 The gene name displayed on the GUI as a selection branch for selecting a gene panel associated with the selected disease is displayed based on the information registered in the gene panel related information database 121.
 なお、疾病に関する遺伝子パネルの遺伝子パネル名は、試薬キット名であってもよい。遺伝子パネルには、解析対象の遺伝子の配列をシーケンサー2によって読み取るために行う、ターゲットシーケンシングに用いる各種バッファー、酵素、およびプライマーなど、一揃いの試薬が含まれている。これら一揃いの試薬に対して、試薬キット名あるいは遺伝子パネル名が付与されている。 In addition, the gene panel name of the gene panel regarding disease may be a reagent kit name. The gene panel includes a set of reagents such as various buffers, enzymes, and primers used for target sequencing, which are performed to read the sequence of the gene to be analyzed by the sequencer 2. The reagent kit name or gene panel name is given to the entire set of reagents.
 ここでは、図2のステップS107に示す、遺伝子パネル関する情報の入力を受け付ける処理の流れの別の例について、図42を用いて説明する。なお、説明の便宜上、図5にて説明した処理と同じ処理については、同じ符号を付記し、その説明を繰り返さない。 Here, another example of the flow of the process for receiving the input of the information on the gene panel shown in step S107 of FIG. 2 will be described using FIG. Note that, for convenience of explanation, the same processing as the processing described in FIG. 5 is denoted with the same reference numeral, and the description will not be repeated.
 図5に示した処理の流れは、例えば、医療機関210からの解析依頼を受けた検査機関120において、医療機関210から指定された遺伝子パネルを用いたパネル検査を行う場合を想定している。しかし、これに限定されず、試料提供元から指定された遺伝子パネル以外の遺伝子パネルを用いて解析する場合もあり得る。例えば、最適な遺伝子パネルを探索したり、より有効な遺伝子パネルの利用方法を模索したりする研究機関では、医療機関210から試料を取得して、指定された遺伝子パネルを用いた解析に加え、さまざまな遺伝子パネルを用いたパネル検査も行うことがあり得る。 The flow of the process shown in FIG. 5 assumes, for example, a case where a panel inspection using a gene panel designated from the medical institution 210 is performed in the inspection institution 120 which has received an analysis request from the medical institution 210. However, the present invention is not limited to this, and analysis may be performed using a gene panel other than the gene panel designated by the sample provider. For example, in research institutes searching for an optimal gene panel or searching for a more efficient gene panel utilization method, samples are obtained from medical institution 210 and, in addition to analysis using a designated gene panel, Panel testing with different gene panels may also be performed.
 選択された情報に対応する遺伝子パネルが、医療機関210から受け付けた解析依頼に含まれる遺伝子パネルと一致していない場合(ステップS203にてNO)には、情報選択部112は表示部16に、入力された遺伝子パネルが指定された遺伝子パネルと異なっている旨とともに、入力された遺伝子パネルを使用するか否かを問うメッセージを表示する(ステップS206)。入力された遺伝子パネルの使用の許可を求める旨の入力を受け付けた場合(ステップS207にてYES)には、情報選択部112は該入力を受け付ける。そして、情報選択部112は、表示部16に対し入力された遺伝子パネルが使用可能である旨のメッセージを表示する(ステップS204)。 If the gene panel corresponding to the selected information does not match the gene panel included in the analysis request received from the medical institution 210 (NO in step S203), the information selection unit 112 causes the display unit 16 to Along with the fact that the input gene panel is different from the designated gene panel, a message is displayed asking whether to use the input gene panel (step S206). When the input for requesting permission to use the input gene panel is received (YES in step S207), the information selection unit 112 receives the input. Then, the information selection unit 112 displays a message indicating that the gene panel input to the display unit 16 is usable (step S204).
 一方、入力された遺伝子パネルの使用の許可を求める旨の入力を受け付けた場合(ステップS207にてNO)には、情報選択部112は、情報選択部112は表示部16に、入力された遺伝子パネルが使用不可である旨のメッセージを表示し(ステップS205)、遺伝子解析装置1による解析を禁止する。 On the other hand, when the input for requesting permission to use the input gene panel is received (NO in step S207), the information selection unit 112 causes the information selection unit 112 to display the input gene in the display unit 16. A message indicating that the panel can not be used is displayed (step S205), and analysis by the gene analysis device 1 is prohibited.
 なお、遺伝子解析装置1が遺伝子パネル関する情報の入力を受け付ける場合に、図5に示す入力モードと図42に示す入力モードのいずれかを選択できる構成であってもよい。例えば、医療機関210から指定された遺伝子パネルを用いたパネル検査を行う場合であれば、図5に示す入力モードを選択することが好ましく、指定された遺伝子パネル以外の遺伝子パネルを用いて解析する場合には、図42に示す入力モードを選択することが好ましい。このように、遺伝子パネル関する情報の入力を受け付ける処理のモードを複数備えることにより、遺伝子解析装置1を使用するユーザは、用途に応じた入力モードを選択することができる。 In addition, when the gene analyzer 1 receives the input of the information regarding a gene panel, it may be the structure which can select either the input mode shown in FIG. 5 or the input mode shown in FIG. For example, in the case of performing a panel test using a gene panel designated by the medical institution 210, it is preferable to select the input mode shown in FIG. 5, and analysis is performed using a gene panel other than the designated gene panel In the case, it is preferable to select the input mode shown in FIG. As described above, by providing a plurality of processing modes for receiving input of information related to the gene panel, the user using the gene analysis apparatus 1 can select the input mode according to the application.
 〔実施形態5〕
 本発明の他の実施形態について、以下に説明する。なお、説明の便宜上、上記実施形態にて説明した部材と同じ機能を有する部材については、同じ符号を付記し、その説明を繰り返さない。
Fifth Embodiment
Other embodiments of the present invention are described below. In addition, about the member which has the same function as the member demonstrated in the said embodiment for convenience of explanation, the same code | symbol is appended, and the description is not repeated.
 本実施形態に係る遺伝子解析方法は、遺伝子パネルに関する情報を取得し、取得した遺伝子パネルに関する情報に基づいて、パネル検査の品質を評価する解析アルゴリズムを変更する。これにより、さまざまな遺伝子パネルを用いて種々の組合せの解析対象遺伝子を解析するにあたって、遺伝子パネルに応じた適切な品質管理を行うことが可能となる。 The gene analysis method according to the present embodiment acquires information on a gene panel, and changes an analysis algorithm for evaluating the quality of panel inspection based on the acquired information on the gene panel. Thus, when analyzing various combinations of analysis target genes using various gene panels, it is possible to perform appropriate quality control according to the gene panels.
 遺伝子パネルに応じて変更する品質評価の処理の一例としては、例えば、(1)パネル検査の品質評価に用いる品質評価指標を変更する、(2)同一の品質評価指標を用いた場合に、十分な信頼性があるかの判定に用いる基準を変更する、(3)パネル検査の品質評価に用いる品質評価指標の数を変更する、等が挙げられる。 As an example of the process of quality evaluation to be changed according to the gene panel, for example, (1) changing the quality evaluation index used for quality evaluation of panel inspection, (2) sufficient when using the same quality evaluation index And (3) changing the number of quality evaluation indexes used for the quality evaluation of panel inspections.
 品質評価指標としては、例えば、シーケンサー2が出力するリード配列情報に含まれる読み取り品質、複数の解析対象となる遺伝子に含まれる塩基のうちシーケンサー2で読み取られた塩基の割合、リード配列情報の読み取り深度(デプス)、リード配列情報の読み取り深度(デプス)のばらつき、品質管理試料に含まれる各標準遺伝子の変異が全て検出されたか否か、等の指標が挙げられる。 As the quality evaluation index, for example, the reading quality included in the read sequence information output by the sequencer 2, the ratio of the bases read by the sequencer 2 to the bases included in the plurality of genes to be analyzed, the reading of the read sequence information There are indicators such as the depth (depth), the variation in the reading depth of the lead sequence information (depth), and whether or not all mutations of each standard gene contained in the quality control sample are detected.
 (遺伝子解析装置1dの構成)
 ここでは、品質評価指標に基づいてパネル検査の品質を評価する機能を備える遺伝子解析装置1dについて、図43を用いて説明する。図43は遺伝子解析装置1dの構成の別の一例を示す図である。遺伝子解析装置1dは、パネル検査の品質の評価結果を含むレポートを作成することが可能である。なお、図43では、データの流れを矢印で示している。
(Configuration of Gene Analysis Device 1d)
Here, a gene analysis device 1 d having a function of evaluating the quality of panel inspection based on the quality evaluation index will be described with reference to FIG. FIG. 43 is a view showing another example of the configuration of the gene analysis device 1d. The gene analysis device 1d can create a report including the evaluation result of the quality of the panel test. In FIG. 43, the flow of data is indicated by arrows.
 遺伝子解析装置1dの解析実行部110dは品質管理部119をさらに備え、記憶部12dは品質評価基準データベース126をさらに備えている点で、図4に示す遺伝子解析装置1と異なっている。 The analysis execution unit 110 d of the gene analysis apparatus 1 d further includes a quality control unit 119, and the storage unit 12 d is different from the gene analysis apparatus 1 illustrated in FIG. 4 in that the storage unit 12 d further includes a quality evaluation reference database 126.
 品質評価基準データベース126には、パネル検査における解析結果の信頼性が一定の基準に達しているか否かを規定する基準値が記憶されている。ここで、一定の基準とは、例えば、パネル検査の解析結果を治療や診断に適用するために要求される信頼性を具備しているか否かの判断に用いられる。 The quality evaluation standard database 126 stores reference values that define whether the reliability of the analysis result in the panel inspection has reached a certain standard. Here, the certain standard is used, for example, to determine whether or not it has the reliability required to apply the analysis result of the panel test to treatment or diagnosis.
 本実施形態に係る情報選択部112は、入力部17から入力された遺伝子パネルに関する情報に基づいて、品質評価指標の基準値を変更する。 The information selection unit 112 according to the present embodiment changes the reference value of the quality evaluation index based on the information on the gene panel input from the input unit 17.
 (品質評価指標)
 測定に対して品質管理部119が生成する品質評価指標としては、例えば、シーケンサー2が出力するリード配列情報に含まれる読み取り品質、複数の解析対象となる遺伝子に含まれる塩基のうちシーケンサー2で読み取られた塩基の割合、リード配列情報の読み取り深度(デプス)、リード配列情報の読み取り深度(デプス)のばらつき、品質管理試料に含まれる各標準遺伝子の変異が全て検出されたか否か等の指標が挙げられる。
(Quality evaluation index)
As a quality evaluation index generated by the quality control unit 119 for measurement, for example, read quality included in the read sequence information output by the sequencer 2, read by the sequencer 2 among bases contained in a plurality of genes to be analyzed The index such as the ratio of the identified bases, the reading depth of the read sequence information (depth), the variation in the reading depth of the read sequence information (depth), and whether all mutations of each standard gene contained in the quality control sample were detected It can be mentioned.
 上記の品質評価指標の例について、詳細に説明する。 An example of the above-mentioned quality evaluation index will be described in detail.
 品質評価指標(1):クオリティスコア
 クオリティスコアは、シーケンサー2によって読み取られた遺伝子配列中の各塩基の正確さを示す指標である。
Quality Evaluation Index (1): Quality Score The quality score is an index indicating the accuracy of each base in the gene sequence read by sequencer 2.
 例えば、シーケンサー2からFASTQファイルでリード配列情報が出力される場合、クオリティスコアはリード配列情報に含まれている(図17参照)。なお、クオリティスコアの詳細については、実施形態1において説明されているため、ここではその説明を省略する。 For example, when the read sequence information is output from the sequencer 2 as a FASTQ file, the quality score is included in the read sequence information (see FIG. 17). The details of the quality score are described in the first embodiment, and thus the description thereof is omitted here.
 品質評価指標(2):クラスター濃度
 クラスター濃度は、シーケンサー2が出力するリード配列情報に含まれる読み取り品質を示す指標である。シーケンサー2は、フローセル上で多数の1本鎖DNA断片を局所的に増幅固定させて、クラスターを形成する(図14の9参照)。そして、蛍光顕微鏡を用いてフローセル上のクラスター群を撮像し、A、C、G、Tそれぞれに対応する異なる波長の蛍光を検出することによって配列を読み取る。クラスター密度は、フローセル上に形成された、各遺伝子のクラスターがどの程度近接し合っているかを示す指標である。
Quality Evaluation Index (2): Cluster Concentration The cluster concentration is an indicator indicating the read quality included in the read sequence information output by the sequencer 2. The sequencer 2 locally amplifies and fixes a large number of single-stranded DNA fragments on the flow cell to form a cluster (see 9 in FIG. 14). Then, the cluster group on the flow cell is imaged using a fluorescence microscope, and the sequence is read by detecting fluorescence of different wavelengths corresponding to A, C, G, and T, respectively. The cluster density is an index showing how closely the clusters of each gene formed on the flow cell are close to each other.
 例えば、クラスターの密度が過度に高くなり、クラスター同士が過度に近接したり重なり合ったりしてしまうと、フローセルを撮像した画像のコントラストすなわちS/N比が低くなるため、蛍光顕微鏡のフォーカスが取りにくくなる。それゆえ、蛍光を正しく検出することができなくなり、その結果、配列読み取り精度が低下するおそれがある。 For example, if the density of clusters becomes excessively high and clusters become too close to each other or overlap, the contrast of the image obtained by imaging the flow cell, that is, the S / N ratio, becomes low, making it difficult to obtain focus of the fluorescence microscope. Become. Therefore, fluorescence can not be detected correctly, which may result in reduced sequence reading accuracy.
 品質評価指標(3):シーケンサー2で読み取られた塩基配列のうちシーケンサー2で読み取られたターゲット領域の塩基配列の割合を示す指標
 この指標は、シーケンサー2により読み取られたターゲット領域以外も含む塩基のうち、どれだけのターゲット領域の塩基が読み取られたかを示す指標であり、読み取られた塩基の総数と、ターゲット領域の塩基の総数との比として算出される。
Quality evaluation index (3): an index indicating the ratio of the base sequence of the target area read by the sequencer 2 to the base sequence read by the sequencer 2 This index is a base of other than the target area read by the sequencer 2 Among them, it is an index indicating how many bases in the target area have been read, and is calculated as the ratio between the total number of bases read and the total number of bases in the target area.
 品質評価指標(4):リード配列情報の読み取り深度(デプス)を示す指標
 この指標は、解析対象となる遺伝子に含まれる各塩基について、その塩基を読み取ったリード配列の総数に基づく指標であり、読み取られた塩基のうちデプスが所定の値以上である塩基の総数と、読み取られた塩基の総数との比として算出される。
Quality evaluation index (4): index indicating the reading depth (depth) of lead sequence information This index is an index based on the total number of lead sequences from which the bases have been read for each base contained in the gene to be analyzed, Of the read bases, the ratio is calculated as the ratio between the total number of bases whose depth is greater than or equal to a predetermined value and the total number of read bases.
 なお、読み取り深度(デプス)とは、同一の塩基について読み取ったリード配列情報の総数を意味しており、被覆率、カバレッジ、デプス・オブ・カバレッジともいう。 The reading depth (depth) means the total number of pieces of read sequence information read for the same base, and is also called coverage, coverage, or depth of coverage.
 図45には、解析対象の遺伝子(図中の「標的遺伝子」)の全長がL塩基であり、読み取られた領域の塩基がt1塩基であった場合における、各塩基のデプスを示すグラフを示している。図45中のグラフの横軸は塩基の位置であり、縦軸は各塩基のデプスである。図45に示す例では、読み取られた領域のt1塩基のうち、デプスが所定の値(例えば100)以上の領域の総塩基数は(t2+t3)塩基である。この場合、品質評価指標(4)は、(t2+t3)/t1の値として生成される。 FIG. 45 shows a graph showing the depth of each base when the full length of the gene to be analyzed (“target gene” in the figure) is L bases and the base of the read region is t1 base. ing. The horizontal axis of the graph in FIG. 45 is the position of the base, and the vertical axis is the depth of each base. In the example shown in FIG. 45, of the t1 bases in the read area, the total number of bases in the area having a depth of a predetermined value (for example, 100) or more is (t2 + t3) bases. In this case, the quality evaluation index (4) is generated as a value of (t2 + t3) / t1.
 品質評価指標(5):リード配列情報の読み取り深度(デプス)のばらつきを示す指標
 この指標は、デプスの均一性を示す指標である。読み取られた領域のうちのある部分を読み取ったリード配列情報だけが極端に多い場合、デプスの均一性は低くなる。一方、読み取られた領域の全体にわたって万遍なくリード配列情報が存在している場合、デプスの均一性は高くなる。デプスの均一性は、例えば、四分位範囲(IQR)を用いて数値化することができる。IQRが高いほど均一性が低く、IQRが低いほど均一性が高いことを示す。
Quality evaluation index (5): index showing variation in reading depth (depth) of lead arrangement information This index is an index showing uniformity of depth. If the read sequence information obtained by reading a part of the read area is extremely large, the uniformity of the depth is low. On the other hand, when the read arrangement information is present all over the read area, the uniformity of the depth is high. Depth uniformity can be quantified, for example, using the interquartile range (IQR). The higher the IQR, the lower the uniformity, and the lower the IQR, the higher the uniformity.
 品質評価指標(6):品質管理試料に含まれる各標準遺伝子が有する変異が全て検出されたか否かを示す指標
 この指標は、被検体から採取した試料と併せて品質管理試料を測定した場合に、品質管理試料に含まれる各標準遺伝子が有する変異が検出され、正しく同定されたかを示す指標である。例えば、品質管理試料に含まれる各標準遺伝子が有する既知の変異の位置、変異種別などを正しく同定できたか否かを品質評価指標として用いる。品質管理試料は、複数の標準遺伝子を混合することにより調製される。
Quality evaluation index (6): Index indicating whether or not all mutations possessed by each standard gene contained in the quality control sample have been detected This index is used when the quality control sample is measured in combination with the sample collected from the subject , An indicator showing whether mutations possessed by each standard gene contained in the quality control sample were detected and correctly identified. For example, it is used as a quality evaluation index whether or not the position of a known mutation possessed by each standard gene contained in the quality control sample, the type of mutation, etc. were correctly identified. Quality control samples are prepared by mixing multiple standard genes.
 パネル検査の品質評価を行う処理の流れについて、図44を用いて説明する。図44は、遺伝子配列を解析するための処理の流れの一例を示すフローチャートである。 A flow of processing for performing quality evaluation of panel inspection will be described with reference to FIG. FIG. 44 is a flow chart showing an example of the flow of processing for analyzing gene sequences.
 まず図44のステップS31において、遺伝子配列を解析するための前処理が行われる。前処理には、試料に含まれるDNAなどの遺伝子を断片化して、断片化された遺伝子を回収するまでの処理が含まれる。ここで、品質評価を行うパネル検査における解析対象は、被検体から採取した試料であってもよいし、複数の標準遺伝子を混合することにより調製された品質管理試料であってもよい。 First, in step S31 of FIG. 44, preprocessing for analyzing gene sequences is performed. The pretreatment includes a process of fragmenting a gene such as DNA contained in the sample and recovering the fragmented gene. Here, the analysis target in the panel inspection for quality evaluation may be a sample collected from a subject, or a quality control sample prepared by mixing a plurality of standard genes.
 品質管理試料は、SNVを含む標準遺伝子、Insertionを含む標準遺伝子、Deletionを含む標準遺伝子、CNVを含む標準遺伝子、およびFusionを含む標準遺伝子のうち、少なくとも2つを含んでいる。例えば、品質管理試料は、標準遺伝子として、野生型に対して「SNV」を含む遺伝子Aの部分配列と、野生型に対して「Insertion」を含む遺伝子Bの部分配列を含む。 The quality control sample contains at least two of a standard gene including SNV, a standard gene including Insertion, a standard gene including Deletion, a standard gene including CNV, and a standard gene including Fusion. For example, the quality control sample contains, as standard genes, a partial sequence of gene A containing "SNV" to wild type and a partial sequence of gene B containing "Insertion" to wild type.
 次に、ステップS32において、シーケンサー2は、前処理された試料に含まれるDNAの塩基配列を読み取る。 Next, in step S32, the sequencer 2 reads the base sequence of DNA contained in the pretreated sample.
 続いて、ステップS33において、遺伝子解析装置1dの制御部11dは、入力部17に遺伝子パネルに関する情報をユーザに選択させるためのGUIを表示させる。GUIに対するユーザの入力操作に基づいて、遺伝子パネルに関する情報の取得を行う。遺伝子パネルに関する情報の取得は、GUIによるユーザの入力に限らず、例えば、遺伝子パネルに付されたバーコード等の識別子による取得でもよいし、インデックス配列を読み取ることにより識別してもよい。 Subsequently, in step S33, the control unit 11d of the gene analysis device 1d causes the input unit 17 to display a GUI for causing the user to select information on the gene panel. Information on the gene panel is acquired based on the user's input operation to the GUI. The acquisition of the information on the gene panel is not limited to the user's input by the GUI, but may be acquired by an identifier such as a barcode attached to the gene panel, or may be identified by reading the index sequence.
 遺伝子解析装置1dの制御部11dは、取得した遺伝子パネルに関する情報に基づいて、遺伝子パネルの種類を判定する。遺伝子解析装置1dは、取得した遺伝子パネルの種類に応じてパネル検査の品質管理を実行するように、解析アルゴリズムを変更する。 The control unit 11 d of the gene analysis device 1 d determines the type of gene panel based on the acquired information on the gene panel. The gene analysis device 1 d changes the analysis algorithm so as to execute the quality control of the panel inspection according to the type of the acquired gene panel.
 S34において、遺伝子解析装置1dは、遺伝子パネルの種類に応じて遺伝子配列を解析し、塩基配列中の変異の有無、変異の位置、変異の種別等を特定する。読み取られた遺伝子配列を解析することによって、検出された変異が同定される。 In S34, the gene analysis device 1d analyzes the gene sequence according to the type of gene panel, and specifies the presence or absence of a mutation in the base sequence, the position of the mutation, the type of mutation, and the like. By analyzing the read gene sequences, the detected mutations are identified.
 (品質管理部119)
 遺伝子解析装置1dは、生成した品質評価指標に基づいて、パネル検査の品質を評価する。品質管理部119は、クオリティスコア(品質評価指標1)およびクラスター濃度(品質評価指標2)を配列データ読取部111から取得する。また、シーケンサー2で読み取られたターゲット領域の塩基の割合(品質評価指標3)、リード配列情報の読み取り深度(品質評価指標4)およびリード配列情報の読み取り深度のばらつき(品質評価指標5)をデータ調整部113から取得する。さらに、品質管理試料に含まれる各標準遺伝子が有する変異が全て検出されたか否か(品質評価指標6)を変異同定部114から取得する。品質管理部119は、これらの品質評価指標の全てを取得する必要はなく、1つまたは複数の任意の指標を取得すればよい。
(Quality Management Department 119)
The gene analysis device 1d evaluates the quality of the panel inspection based on the generated quality evaluation index. The quality management unit 119 acquires the quality score (quality evaluation index 1) and the cluster concentration (quality evaluation index 2) from the array data reading unit 111. In addition, the ratio of bases in the target area read by the sequencer 2 (quality evaluation index 3), the reading depth of the read sequence information (quality evaluation index 4), and the variation of the reading depth of the read sequence information (quality evaluation index 5) It is acquired from the adjustment unit 113. Furthermore, it is acquired from the mutation identification unit 114 whether or not all the mutations possessed by each standard gene contained in the quality control sample have been detected (quality evaluation index 6). The quality control unit 119 does not need to acquire all of these quality evaluation indicators, and may acquire one or more arbitrary indicators.
 品質管理部119は、取得した品質評価指標と、品質評価基準データベース126に記憶される品質評価指標の基準値とを比較し、解析結果が十分な信頼性を具備しているか判定する。ここで、品質評価基準データベース126は、品質評価指標の基準値を、遺伝子パネルを特定する情報と関連づけて記憶している。 The quality management unit 119 compares the acquired quality evaluation index with the reference value of the quality evaluation index stored in the quality evaluation standard database 126, and determines whether the analysis result has sufficient reliability. Here, the quality evaluation standard database 126 stores the standard value of the quality evaluation index in association with the information specifying the gene panel.
 S35において遺伝子パネルの種類がAパネルであった場合、例えば、品質評価指標Aについて基準値aを用いて判定し、質評価指標Bについて基準値bを用いて判定する。一方、S35において遺伝子パネルの種類がBパネルであった場合、品質評価指標Aについて基準値cを用いて判定し、質評価指標Bについて基準値bを用いて判定する。このように、Aパネルの解析およびBパネルの解析においては、同一の品質管理指標Aを用いる一方、その評価の基準は異なるものを用いている。また、Aパネルの解析においては品質管理指標AおよびBを用いている一方、Bパネルの解析においては品質管理指標AおよびCを用いており、互いに異なる品質管理指標を用いている。 If the type of gene panel is A panel in S35, for example, the quality evaluation index A is determined using the reference value a, and the quality evaluation index B is determined using the reference value b. On the other hand, when the type of gene panel is B panel in S35, the quality evaluation index A is determined using the reference value c, and the quality evaluation index B is determined using the reference value b. Thus, in the analysis of the A panel and the analysis of the B panel, the same quality control index A is used, but different evaluation criteria are used. Also, while quality control indices A and B are used in the analysis of the A panel, quality control indices A and C are used in the analysis of the B panel, and mutually different quality control indices are used.
 また、S35において遺伝子パネルの種類がCパネルであった場合、品質評価指標Dについて基準値eを用いて判定する。このように、Aパネルの解析においては、品質評価指標AおよびBの2つの指標に基づいて品質評価を行っているが、Cパネルの解析においては、品質評価指標Dのみを用いて品質評価を行っている。このように、遺伝子パネルに応じて、用いる品質評価指標の数を変更してもよい。 When the type of gene panel is C panel in S35, the quality evaluation index D is determined using the reference value e. As described above, in the analysis of the A panel, the quality evaluation is performed based on the two indexes of the quality evaluation indicators A and B, but in the analysis of the C panel, the quality evaluation is performed using only the quality evaluation indicator D. Is going. Thus, depending on the gene panel, the number of quality evaluation indexes to be used may be changed.
 最後に、S36において、遺伝子解析装置1dは同定された変異、およびステップS34において判定されたパネル検査の品質の評価結果を含むレポートを作成する。 Finally, in S36, the gene analysis device 1d creates a report including the evaluation result of the identified mutation and the quality of the panel test determined in step S34.
 図46は、レポート作成部115によって作成されたレポートの一例を示す図である。この例に示すレポートの左上の部分には、被検体IDを示す「患者ID」、「患者の性別」、「患者の病名」、医療機関210において該被検体を担当する医師の名前である「担当医師名」、および医療機関名を示す「機関名」が記載されている。 FIG. 46 is a diagram showing an example of a report created by the report creation unit 115. As shown in FIG. In the upper left part of the report shown in this example, “patient ID” indicating “subject ID”, “patient's gender”, “patient's disease name”, and the name of the doctor in charge of the subject at the medical institution 210 “ The name of the doctor in charge and the name of the institution showing the name of the medical institution are described.
 その下には、遺伝子パネルに関する情報として、「Aパネル」という遺伝子パネル名も含まれている。さらに、パネル検査の品質に関する情報である品質評価指標「QC指標」が、レポートに出力されている。 Below that, the gene panel name "A panel" is also included as information on the gene panel. Furthermore, a quality evaluation index "QC index", which is information on the quality of panel inspection, is output in the report.
 なお、品質評価指標が所定の基準を下回った場合、検出された遺伝子変異に「*」を付すことができる。また、それに限らず、信頼性が低い旨を示すコメントを付すことができる。 In addition, when the quality evaluation index falls below a predetermined standard, "*" can be added to the detected gene mutation. In addition, it is possible to add a comment indicating that the reliability is low.
 本発明は上述した各実施形態に限定されるものではなく、請求項に示した範囲で種々の変更が可能であり、異なる実施形態にそれぞれ開示された技術的手段を適宜組み合わせて得られる実施形態についても本発明の技術的範囲に含まれる。 The present invention is not limited to the above-described embodiments, and various modifications can be made within the scope of the claims, and embodiments obtained by appropriately combining the technical means disclosed in the different embodiments. Is also included in the technical scope of the present invention.
 1、1a、1b、1c、1d 遺伝子解析装置
 2 シーケンサー
 3 管理サーバ
 4 ネットワーク
 11、11a、11b、11c、11d 制御部
 13 出力部
 16 表示部
 100 遺伝子解析システム
 121、121c 遺伝子パネル関連情報データベース
 122 参照配列データベース
 124 薬剤データベース
 125 リファレンスデータベース
1, 1a, 1b, 1c, 1d Gene Analysis Device 2 Sequencer 3 Management Server 4 Network 11, 11a, 11b, 11c, 11d Control Unit 13 Output Unit 16 Display Unit 100 Gene Analysis System 121, 121c Gene Panel Related Information Database 122 Sequence database 124 Drug database 125 Reference database

Claims (63)

  1.  遺伝子の配列情報を解析する遺伝子解析方法であって、
     シーケンサーにより読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得し、
     取得した前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の解析結果を出力する
     ことを特徴とする遺伝子解析方法。
    A gene analysis method for analyzing gene sequence information, comprising:
    Acquisition of read sequence information read by a sequencer and information on a gene panel including a plurality of genes to be analyzed,
    A gene analysis method comprising: outputting an analysis result of the lead sequence information based on the acquired information on the gene panel.
  2.  取得された前記遺伝子パネルに関する情報に基づいて、前記解析結果の出力対象となる遺伝子を変更する
     ことを特徴とする請求項1に記載の遺伝子解析方法。
    The gene analysis method according to claim 1, wherein a gene to be output target of the analysis result is changed based on the acquired information on the gene panel.
  3.  取得された前記遺伝子パネルに関する情報に基づいて、前記解析結果の出力対象となる遺伝子を解析するための解析アルゴリズムを変更する
     ことを特徴とする請求項1または2に記載の遺伝子解析方法。
    The gene analysis method according to claim 1 or 2, wherein an analysis algorithm for analyzing a gene to be an output target of the analysis result is changed based on the acquired information on the gene panel.
  4.  前記遺伝子パネルに関する情報を入力させるための入力画面を表示部に表示する
     ことを特徴とする請求項1から3のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 3, wherein an input screen for inputting information on the gene panel is displayed on a display unit.
  5.  複数の前記遺伝子パネルに関する情報から少なくとも1つの情報を選択させるための入力画面を表示部に表示する
     ことを特徴とする請求項1から4のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 4, wherein an input screen for selecting at least one piece of information from a plurality of pieces of gene panel information is displayed on a display unit.
  6.  試薬キット名を前記遺伝子パネルに関する情報として入力させるための入力画面を表示部に表示する
     ことを特徴とする請求項1から5のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 5, wherein an input screen for inputting a reagent kit name as information on the gene panel is displayed on a display unit.
  7.  解析対象となる複数の遺伝子名を前記遺伝子パネルに関する情報として入力させるための入力画面を表示部に表示する
     ことを特徴とする請求項1から6のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 6, wherein an input screen for inputting a plurality of gene names to be analyzed as information on the gene panel is displayed on a display unit.
  8.  解析対象となる疾患名を前記遺伝子パネルに関する情報として入力させるための入力画面を表示部に表示する
     ことを特徴とする請求項1から7のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 7, wherein an input screen for inputting a disease name to be analyzed as information on the gene panel is displayed on a display unit.
  9.  取得した前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の比較対象とすべき参照配列情報を選択し、
     前記リード配列情報と、選択された前記参照配列情報との比較に基づく前記解析結果を出力する
     ことを特徴とする請求項1から8のいずれか1項に記載の遺伝子解析方法。
    The reference sequence information to be compared with the read sequence information is selected based on the acquired information on the gene panel,
    The gene analysis method according to any one of claims 1 to 8, wherein the analysis result is output based on comparison of the lead sequence information and the selected reference sequence information.
  10.  取得された前記遺伝子パネルに関する情報に基づいて、変異配列が含まれた複数の参照配列情報から、前記リード配列情報に含まれる変異を特定するために比較対象とする参照配列情報を選択し、
     選択された前記参照配列に基づく前記解析結果を出力する
     ことを特徴とする請求項1から9のいずれか1項に記載の遺伝子解析方法。
    Based on the acquired information on the gene panel, reference sequence information to be compared is selected to specify a mutation included in the lead sequence information from a plurality of reference sequence information including the mutant sequence,
    The gene analysis method according to any one of claims 1 to 9, wherein the analysis result based on the selected reference sequence is output.
  11.  遺伝子パネルの解析対象とする遺伝子に関する情報を遺伝子パネル毎に記憶する遺伝子パネル関連情報データベースを用いて、前記リード配列情報の解析結果を出力する
     ことを特徴とする請求項1から10のいずれか1項に記載の遺伝子解析方法。
    11. The analysis result of the lead sequence information is output using a gene panel related information database that stores information on genes to be analyzed in the gene panel for each gene panel. The gene analysis method as described in a term.
  12.  選択された参照配列を参照配列データベースから読み出して、読み出した前記参照配列に対して前記リード配列情報をマッピングすることによりアライメントを行う
     ことを特徴とする請求項1から11のいずれか1項に記載の遺伝子解析方法。
    The selected reference sequence is read from the reference sequence database, and alignment is performed by mapping the read sequence information to the read reference sequence. Gene analysis method.
  13.  選択された参照配列を参照配列データベースから読み出して、前記参照配列と前記リード配列情報との一致度に基づいて、前記リード配列情報の位置を決定し、前記リード配列情報に含まれる変異を同定する
     ことを特徴とする請求項1から12のいずれか1項に記載の遺伝子解析方法。
    The selected reference sequence is read out from the reference sequence database, the position of the read sequence information is determined based on the degree of matching between the reference sequence and the read sequence information, and the mutation included in the read sequence information is identified. The gene analysis method according to any one of claims 1 to 12, characterized in that.
  14.  前記リード配列情報の解析によって同定された変異のうち、取得された前記遺伝子パネルに関する情報に対応付けられた変異に関する情報を含む解析結果を出力する
     ことを特徴とする請求項1から13のいずれか1項に記載の遺伝子解析方法。
    The analysis result including information on the mutation associated with the acquired information on the gene panel among the mutations identified by the analysis of the lead sequence information is output. The gene analysis method according to item 1.
  15.  取得された前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の解析結果として、前記リード配列情報の解析によって同定された変異に関連する薬剤情報を出力する
     ことを特徴とする請求項1から14のいずれか1項に記載の遺伝子解析方法。
    The method according to claim 1, characterized in that, based on the acquired information on the gene panel, drug information related to the mutation identified by the analysis of the lead sequence information is output as the analysis result of the lead sequence information. The gene analysis method according to any one of the above.
  16.  前記リード配列情報の解析によって同定された変異に基づいて、解析対象とする遺伝子の変異と、前記遺伝子パネルに関連する薬剤とを対応付けて記憶する薬剤データベースを検索する
     ことを特徴とする請求項1から15のいずれか1項に記載の遺伝子解析方法。
    Based on the mutations identified by the analysis of the lead sequence information, a drug database is stored that associates and stores mutations of genes to be analyzed and drugs related to the gene panel. The gene analysis method according to any one of 1 to 15.
  17.  前記薬剤データベースの検索において抽出された、前記リード配列情報の解析によって同定された変異に関連する薬剤のリストを生成する
     ことを特徴とする請求項16に記載の遺伝子解析方法。
    The gene analysis method according to claim 16, wherein a list of drugs related to the mutation identified by the analysis of the lead sequence information extracted in the search of the drug database is generated.
  18.  前記リード配列情報の解析結果として、薬剤の承認状況を含む薬剤情報を出力する
     ことを特徴とする請求項1から17のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 17, wherein drug information including a drug approval status is output as an analysis result of the lead sequence information.
  19.  前記リード配列情報の解析によって同定された変異に基づいて、解析対象とする遺伝子の変異と、前記変異に関連する参照情報とを対応付けて記憶するリファレンスデータベースを検索する
     ことを特徴とする請求項1から18のいずれか1項に記載の遺伝子解析方法。
    Based on the mutation identified by the analysis of the lead sequence information, a reference database is stored that associates and stores a mutation of a gene to be analyzed and reference information related to the mutation. The gene analysis method according to any one of 1 to 18.
  20.  前記リード配列情報の解析結果に基づいてレポートを作成し、
     前記レポートは、前記リード配列情報の解析によって同定された変異のうち、取得された前記遺伝子パネルに関連する情報に対応する変異に関する情報を含む
     ことを特徴とする請求項1から19のいずれか1項に記載の遺伝子解析方法。
    Create a report based on the analysis result of the lead sequence information,
    The said report contains the information regarding the mutation corresponding to the information relevant to the acquired said gene panel among the mutations identified by the analysis of the said lead sequence information, Any one of 1 to 19 characterized by the above-mentioned. The gene analysis method as described in a term.
  21.  同定されたすべての変異の中から、取得された前記遺伝子パネルに関する情報に対応する変異を、前記遺伝子パネルに関する情報に基づいて選択し、前記リード配列情報の解析結果として、選択された前記変異に関連する情報を出力する
     ことを特徴とする請求項1から20のいずれか1項に記載の遺伝子解析方法。
    Among all the identified mutations, a mutation corresponding to the acquired information on the gene panel is selected based on the information on the gene panel, and the mutation selected as the analysis result of the lead sequence information is selected. The gene analysis method according to any one of claims 1 to 20, which outputs related information.
  22.  前記レポートは、前記遺伝子パネルに関連する情報を含む
     ことを特徴とする請求項20に記載の遺伝子解析方法。
    The gene analysis method according to claim 20, wherein the report contains information related to the gene panel.
  23.  前記レポートは、薬剤のリストおよび参照情報との少なくともいずれか一方を含む
     ことを特徴とする請求項20または22に記載の遺伝子解析方法。
    The gene analysis method according to claim 20, wherein the report includes at least one of a drug list and reference information.
  24.  前記遺伝子の配列情報の解析状況に関する情報を管理サーバに送信する
     ことを特徴とする請求項1から23のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 23, wherein information related to an analysis state of sequence information of the gene is transmitted to a management server.
  25.  前記遺伝子の配列情報の解析状況に関する情報を、前記遺伝子パネルに関する情報毎に、管理サーバに送信する
     ことを特徴とする請求項1から24のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 24, wherein information on the analysis status of sequence information of the gene is transmitted to a management server for each information on the gene panel.
  26.  前記遺伝子の配列解析回数を、前記遺伝子パネルに関する情報毎に、管理サーバに送信する
     ことを特徴とする請求項1から25のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 25, wherein the number of times of sequence analysis of the gene is transmitted to a management server for each information related to the gene panel.
  27.  解析された前記遺伝子の数を、前記遺伝子パネルに関する情報毎に、管理サーバに送信する
     ことを特徴とする請求項1から26のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 26, wherein the number of analyzed genes is transmitted to the management server for each information related to the gene panel.
  28.  前記遺伝子の配列解析において処理されたデータ量に関する情報を、前記遺伝子パネルに関する情報毎に、管理サーバに送信する
     ことを特徴とする請求項1から27のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 27, wherein information on the amount of data processed in the sequence analysis of the gene is transmitted to the management server for each information on the gene panel.
  29.  前記リード配列情報と、取得した前記遺伝子パネルに関する情報に関連付けられた遺伝子パネルが解析対象とする遺伝子の配列情報とを比較した比較結果を、リード配列情報の解析結果として出力する
     ことを特徴とする請求項1から28のいずれか1項に記載の遺伝子解析方法。
    A comparison result of comparison between the lead sequence information and sequence information of genes to be analyzed by a gene panel associated with the acquired information on the gene panel is output as an analysis result of the lead sequence information. The gene analysis method according to any one of claims 1 to 28.
  30.  取得した前記遺伝子パネルに関する情報が登録済のものでなかった場合に、エラーを表示させる
     ことを特徴とする請求項1から29のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 29, wherein an error is displayed when the acquired information on the gene panel is not registered.
  31.  取得した前記遺伝子パネルに関する情報が医療機関から指定されたものでなかった場合に、エラーを表示させる
     ことを特徴とする請求項1から30のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 30, wherein an error is displayed when the acquired information on the gene panel is not designated from a medical institution.
  32.  エラーが表示された後に、ユーザから入力された遺伝子パネルの使用の許可を求める入力がされた場合に、遺伝子パネルの解析を許可する
     ことを特徴とする請求項30または31に記載の遺伝子解析方法。
    The gene analysis method according to claim 30 or 31, wherein analysis of the gene panel is permitted when an error is displayed and input for permission to use the gene panel is input from the user. .
  33.  取得した前記遺伝子パネルに関する情報が登録済のものでなかった場合に、遺伝子パネルの解析を禁止する
     ことを特徴とする請求項1から32のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 32, wherein analysis of the gene panel is prohibited when the acquired information on the gene panel is not registered.
  34.  取得した前記遺伝子パネルに関する情報が医療機関から指定されたものでなかった場合に、遺伝子パネルの解析を禁止する
     ことを特徴とする請求項1から33のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 33, wherein analysis of the gene panel is prohibited when the acquired information on the gene panel is not designated from a medical institution.
  35.  前記遺伝子パネルに関する情報を取得する工程には複数のモードがあり、前記複数のモードのうちのいずれかを選択可能である
     ことを特徴とする請求項1から34のいずれか1項に記載の遺伝子解析方法。
    35. The gene according to any one of claims 1 to 34, wherein there is a plurality of modes in the step of acquiring information on the gene panel, and any one of the plurality of modes can be selected. analysis method.
  36.  前記リード配列情報のうち、取得した前記遺伝子パネルに関する情報が示す遺伝子パネルが解析対象としない遺伝子の配列を含むリード配列情報が所定数以上である場合に、エラーを表示させる
     ことを特徴とする請求項1から35のいずれか1項に記載の遺伝子解析方法。
    An error is displayed when the number of pieces of lead sequence information including the sequences of genes not to be analyzed among the lead sequence information and the gene panel indicated by the acquired information on the gene panel is equal to or more than a predetermined number. The gene analysis method according to any one of Items 1 to 35.
  37.  前記リード配列情報には、前記遺伝子パネルに関する情報に関連付けられたインデックス配列が含まれている
     ことを特徴とする請求項1から36のいずれか1項に記載の遺伝子解析方法。
    The gene analysis method according to any one of claims 1 to 36, wherein the lead sequence information includes an index sequence associated with information on the gene panel.
  38.  前記インデックス配列は、遺伝子パネルに関する情報毎に異なっている
     ことを特徴とする請求項37に記載の遺伝子解析方法。
    The gene analysis method according to claim 37, wherein the index sequence is different for each information on a gene panel.
  39.  前記リード配列情報に含まれる前記インデックス配列と関連付けられた遺伝子パネルに関する情報が、取得した前記遺伝子パネルに関する情報と異なる場合に、エラーを表示させる
     ことを特徴とする請求項38に記載の遺伝子解析方法。
    The gene analysis method according to claim 38, wherein an error is displayed when the information on the gene panel associated with the index sequence contained in the lead sequence information is different from the acquired information on the gene panel. .
  40.  第1試料について、第1の解析対象遺伝子群を解析するための第1遺伝子パネルを用いて読み取られた第1リード配列情報を解析し、
     第2試料について、第2の解析対象遺伝子群を解析するための第2遺伝子パネルを用いて読み取られた第2リード配列情報を解析し、
     前記遺伝子パネルを特定する情報の選択を受け付けて遺伝子パネルに関する情報を取得し、
     前記第1リード配列情報を解析した解析結果、および前記第2リード配列情報を解析した解析結果を、選択された前記遺伝子パネルに関する情報に基づいて出力する
     ことを特徴とする請求項1から39のいずれか1項に記載の遺伝子解析方法。
    Analyzing a first read sequence information read using a first gene panel for analyzing a first analysis target gene group for the first sample;
    For the second sample, analyze the second read sequence information read using the second gene panel for analyzing the second analysis target gene group,
    Accepting selection of information specifying the gene panel and acquiring information on the gene panel;
    40. The analysis result obtained by analyzing the first read sequence information and the analysis result obtained by analyzing the second read sequence information are outputted based on the information on the selected gene panel. The gene analysis method according to any one of the above.
  41.  遺伝子パネル検査の品質を評価する工程をさらに含み、
     取得した前記遺伝子パネルに関する情報に基づいて、前記品質の評価結果を出力する
     ことを特徴とする請求項1から40のいずれか1項に記載の遺伝子解析方法。
    Further including the step of evaluating the quality of the genetic panel test,
    The gene analysis method according to any one of claims 1 to 40, wherein the evaluation result of the quality is output based on the acquired information on the gene panel.
  42.  前記遺伝子パネル検査の品質を評価する工程において、取得した前記遺伝子パネルに関する情報に基づいて、前記品質を評価する際に用いる品質管理指標を選択する
     ことを特徴とする請求項41に記載の遺伝子解析方法。
    The gene analysis according to claim 41, wherein in the step of evaluating the quality of the gene panel test, a quality control index to be used when evaluating the quality is selected based on the acquired information on the gene panel. Method.
  43.  前記遺伝子パネル検査の品質を評価する工程において、取得した前記遺伝子パネルに関する情報に基づいて、前記品質を評価する際に用いる品質管理指標の評価基準を選択する
     ことを特徴とする請求項41または42に記載の遺伝子解析方法。
    The method according to claim 41 or 42, wherein, in the step of evaluating the quality of the gene panel test, an evaluation standard of a quality control index used when evaluating the quality is selected based on the acquired information on the gene panel. The gene analysis method described in.
  44.  前記遺伝子パネル検査の品質を評価する工程において、取得した前記遺伝子パネルに関する情報に基づいて、前記品質を評価する際に用いる品質管理指標の数を選択する
     ことを特徴とする請求項41または42に記載の遺伝子解析方法。
    43. The method according to claim 41, wherein, in the step of evaluating the quality of the gene panel test, the number of quality control indicators to be used in evaluating the quality is selected based on the acquired information on the gene panel. Description method of gene analysis.
  45.  遺伝子の配列情報を解析する遺伝子解析装置であって、
     シーケンサーにより読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得する制御部と、
     出力部と、を備え、
     前記制御部は、取得した前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の解析結果を前記出力部に出力する
     ことを特徴とする遺伝子解析装置。
    A gene analyzer that analyzes gene sequence information, comprising:
    A control unit that acquires read sequence information read by a sequencer and information on a gene panel including a plurality of genes to be analyzed;
    And an output unit,
    The said control part outputs the analysis result of the said lead arrangement | sequence information to the said output part based on the information regarding the acquired said gene panel, The gene analyzer characterized by the above-mentioned.
  46.  前記制御部は、
     取得した前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の比較対象とすべき参照配列情報を選択し、
     前記リード配列情報と、選択された前記参照配列情報との比較に基づく前記解析結果を前記出力部に出力する
     ことを特徴とする請求項45に記載の遺伝子解析装置。
    The control unit
    The reference sequence information to be compared with the read sequence information is selected based on the acquired information on the gene panel,
    The gene analysis device according to claim 45, wherein the analysis result based on comparison of the lead sequence information and the selected reference sequence information is output to the output unit.
  47.  前記制御部は、前記リード配列情報の解析によって同定された変異のうち、取得された前記遺伝子パネルに関する情報に対応付けられた変異に関する情報を含む解析結果を前記出力部に出力する
     ことを特徴とする請求項45または46に記載の遺伝子解析装置。
    The control unit outputs, to the output unit, an analysis result including information on the mutation associated with the acquired information on the gene panel among the mutations identified by the analysis of the lead sequence information. The gene analyzer according to claim 45 or 46.
  48.  前記制御部は、取得された前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の解析結果として、前記リード配列情報の解析によって同定された変異に関連する薬剤情報を前記出力部に出力する
     ことを特徴とする請求項45ないし47いずれか1項に記載の遺伝子解析装置。
    The control unit outputs drug information related to a mutation identified by analysis of the lead sequence information as the analysis result of the lead sequence information based on the acquired information on the gene panel, to the output unit. The gene analysis device according to any one of claims 45 to 47, characterized by
  49.  前記制御部は、取得した前記遺伝子パネルに関する情報に基づいて、遺伝子パネル検査の品質の評価結果を前記出力部に出力する、請求項42に記載の遺伝子解析装置。 The gene analysis device according to claim 42, wherein the control unit outputs the evaluation result of the quality of the gene panel test to the output unit based on the acquired information on the gene panel.
  50.  遺伝子の配列解析を行うユーザを特定する情報と、使用された遺伝子パネルに関する情報と、配列情報の解析状況に関する情報とを含む情報と、を、遺伝子解析装置から受信する
     ことを特徴とする管理サーバ。
    A management server characterized by receiving, from a gene analysis device, information specifying a user who performs sequence analysis of a gene, information on a gene panel used, and information on an analysis state of the sequence information. .
  51.  前記遺伝子の配列情報の解析状況に関する情報を、前記遺伝子解析装置から受信する
     ことを特徴とする請求項50に記載の管理サーバ。
    51. The management server according to claim 50, wherein information related to the analysis status of sequence information of the gene is received from the gene analysis device.
  52.  前記遺伝子の配列情報の解析状況に関する情報を、前記遺伝子解析装置から前記遺伝子パネルに関する情報毎に受信する
     ことを特徴とする請求項50または51に記載の管理サーバ。
    52. The management server according to claim 50, further comprising: information on the analysis status of sequence information of the gene is received from the gene analysis device for each information on the gene panel.
  53.  前記遺伝子の配列解析回数を、前記遺伝子パネルに関する情報毎に、前記遺伝子解析装置から受信する
     ことを特徴とする請求項50から52のいずれか1項に記載の管理サーバ。
    The management server according to any one of claims 50 to 52, wherein the number of times of sequence analysis of the gene is received from the gene analysis device for each information related to the gene panel.
  54.  解析された前記遺伝子の数を、前記遺伝子パネルに関する情報毎に、前記遺伝子解析装置から受信する
     ことを特徴とする請求項50から53のいずれか1項に記載の管理サーバ。
    54. The management server according to any one of claims 50 to 53, wherein the number of analyzed genes is received from the gene analysis device for each information related to the gene panel.
  55.  前記遺伝子の配列解析において処理されたデータ量に関する情報を、前記遺伝子パネルに関する情報毎に、前記遺伝子解析装置から受信する
     ことを特徴とする請求項50から54のいずれか1項に記載の管理サーバ。
    The management server according to any one of claims 50 to 54, wherein information related to the amount of data processed in the sequence analysis of the gene is received from the gene analysis device for each information related to the gene panel. .
  56.  前記ユーザが前記遺伝子解析装置を用いて配列解析を行った場合の対価を、前記遺伝子の配列情報の解析状況に関する情報に基づいて計算する
     ことを特徴とする請求項50から55のいずれか1項に記載の管理サーバ。
    The value when the user performs sequence analysis using the gene analysis device is calculated based on information on the analysis status of sequence information of the gene according to any one of claims 50 to 55. Management server described in.
  57.  前記遺伝子パネルに関する情報の更新要求を、遺伝子解析装置から受信する
     ことを特徴とする請求項50から56のいずれか1項に記載の管理サーバ。
    57. The management server according to any one of claims 50 to 56, which receives an update request for information on the gene panel from a gene analyzer.
  58.  シーケンサーにより読み取られたリード配列情報および解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得する制御部と、前記制御部が取得した前記遺伝子パネルに関する情報に基づいた、前記リード配列情報の解析結果を出力する出力部と、を備える遺伝子解析装置と、
     遺伝子の配列解析を行うユーザを特定する情報と、使用された遺伝子パネルに関する情報と、前記遺伝子の配列の解析状況に関する情報とを含む情報を、遺伝子解析装置から受信する管理サーバと、を備える、
     ことを特徴とする遺伝子解析システム。
    A controller for acquiring the read sequence information read by the sequencer and information on a gene panel including a plurality of genes to be analyzed, and the information on the lead sequence information based on the information on the gene panel acquired by the controller A gene analysis device including an output unit that outputs an analysis result;
    A management server that receives, from a gene analysis device, information including information specifying a user performing gene sequence analysis, information on a gene panel used, and information on the analysis status of the gene sequence;
    Gene analysis system characterized by
  59.  前記ユーザが前記遺伝子解析装置を用いて配列解析を行った場合の対価を、前記遺伝子の配列情報の解析状況に関する情報に基づいて計算する
     ことを特徴とする請求項58に記載の遺伝子解析システム。
    The gene analysis system according to claim 58, wherein the value when the user performs sequence analysis using the gene analysis device is calculated based on the information on the analysis status of the sequence information of the gene.
  60.  遺伝子の配列情報を解析するプログラムであって、
     コンピュータに、
     シーケンサーにより読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得する工程と、
     取得した前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の解析結果を出力する工程と、
     を実行させるためのプログラム。
    A program that analyzes gene sequence information, and
    On the computer
    Acquiring read sequence information read by the sequencer and information on a gene panel including a plurality of genes to be analyzed;
    Outputting an analysis result of the lead sequence information based on the acquired information on the gene panel;
    A program to run a program.
  61.  請求項60に記載のプログラムを記録したコンピュータ読取り可能な記録媒体。 A computer readable recording medium recording the program according to claim 60.
  62.  シーケンサーにより読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得し、
     取得した前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の解析結果を出力する、遺伝子の配列情報を解析する遺伝子解析方法であって、
     取得した前記遺伝子パネルに関する情報が登録済のものでなかった場合に、エラーを表示させる
     ことを特徴とする遺伝子解析方法。
    Acquisition of read sequence information read by a sequencer and information on a gene panel including a plurality of genes to be analyzed,
    A gene analysis method for analyzing sequence information of a gene, which outputs an analysis result of the lead sequence information based on the acquired information on the gene panel,
    An error is displayed when the acquired information on the gene panel is not registered, a gene analysis method.
  63.  シーケンサーにより読み取られたリード配列情報と、解析対象となる複数の遺伝子を含む遺伝子パネルに関する情報とを取得し、
     取得した前記遺伝子パネルに関する情報に基づいて、前記リード配列情報の解析結果を出力する、遺伝子の配列情報を解析する遺伝子解析方法であって、
     取得した前記遺伝子パネルに関する情報が医療機関から指定されたものでなかった場合に、エラーを表示させる
     ことを特徴とする遺伝子解析方法。
    Acquisition of read sequence information read by a sequencer and information on a gene panel including a plurality of genes to be analyzed,
    A gene analysis method for analyzing sequence information of a gene, which outputs an analysis result of the lead sequence information based on the acquired information on the gene panel,
    An error is displayed when the acquired information on the gene panel is not designated from a medical institution.
PCT/JP2018/039963 2017-10-27 2018-10-26 Gene analysis method, gene analyzer, management server, gene analysis system, program and recording medium WO2019083024A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18869832.8A EP3702473A4 (en) 2017-10-27 2018-10-26 Gene analysis method, gene analyzer, management server, gene analysis system, program and recording medium
CN201880069344.4A CN111263964A (en) 2017-10-27 2018-10-26 Gene analysis method, gene analysis device, management server, gene analysis system, program, and recording medium
US16/855,239 US20200350035A1 (en) 2017-10-27 2020-04-22 Gene analysis method, gene analysis apparatus, management server, gene analysis system, program, and storage medium

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017-208651 2017-10-27
JP2017208651 2017-10-27
JP2018201317A JP7320345B2 (en) 2017-10-27 2018-10-25 Gene analysis method, gene analysis device, gene analysis system, program, and recording medium
JP2018-201317 2018-10-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/855,239 Continuation US20200350035A1 (en) 2017-10-27 2020-04-22 Gene analysis method, gene analysis apparatus, management server, gene analysis system, program, and storage medium

Publications (1)

Publication Number Publication Date
WO2019083024A1 true WO2019083024A1 (en) 2019-05-02

Family

ID=66247457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/039963 WO2019083024A1 (en) 2017-10-27 2018-10-26 Gene analysis method, gene analyzer, management server, gene analysis system, program and recording medium

Country Status (2)

Country Link
JP (1) JP2023139180A (en)
WO (1) WO2019083024A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112116955A (en) * 2019-06-19 2020-12-22 希森美康株式会社 Method and system for computer analysis of nucleic acid sequence of patient subject

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001243327A (en) * 1999-12-20 2001-09-07 Hitachi Ltd Method for guaranteeing quality of bio-product, and method for distributing bio-information
WO2004109551A1 (en) * 2003-06-05 2004-12-16 Hitachi High-Technologies Corporation Information providing system and program using base sequence related information
JP2010060431A (en) * 2008-09-03 2010-03-18 Toshiba Corp Automatic analyzer
JP2010273681A (en) * 2003-02-20 2010-12-09 Mayo Found For Medical Education & Res Method for selecting medications
JP2011040091A (en) * 2000-08-25 2011-02-24 Sysmex Corp Management method of clinical test device, server device, and management system of clinical test device
JP2017503258A (en) * 2013-12-12 2017-01-26 アビ−バイオティクス エス.エー. Method and system for providing personalized recommendations on drug use on a web basis with computer assistance and computer readable storage medium
JP2017067605A (en) * 2015-09-30 2017-04-06 高電工業株式会社 Specimen measurement device and specimen measurement method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001243327A (en) * 1999-12-20 2001-09-07 Hitachi Ltd Method for guaranteeing quality of bio-product, and method for distributing bio-information
JP2011040091A (en) * 2000-08-25 2011-02-24 Sysmex Corp Management method of clinical test device, server device, and management system of clinical test device
JP2010273681A (en) * 2003-02-20 2010-12-09 Mayo Found For Medical Education & Res Method for selecting medications
WO2004109551A1 (en) * 2003-06-05 2004-12-16 Hitachi High-Technologies Corporation Information providing system and program using base sequence related information
JP2010060431A (en) * 2008-09-03 2010-03-18 Toshiba Corp Automatic analyzer
JP2017503258A (en) * 2013-12-12 2017-01-26 アビ−バイオティクス エス.エー. Method and system for providing personalized recommendations on drug use on a web basis with computer assistance and computer readable storage medium
JP2017067605A (en) * 2015-09-30 2017-04-06 高電工業株式会社 Specimen measurement device and specimen measurement method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRONOBU MINAMI; YUMITSU KITAGAWA; KOHEI MIYAZONO: "Cancer Treatment Guidance Based on Gene Panel Tests Using Next-Generation Sequencers, Version 1.0", CANCER TREATMENT GUIDANCE BASED ON GENE PANEL TESTS USING NEXT-GENERATION SEQUENCERS, vol. i-viii, 11 October 2017 (2017-10-11), pages i-viii,1 - 5, XP009520371 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112116955A (en) * 2019-06-19 2020-12-22 希森美康株式会社 Method and system for computer analysis of nucleic acid sequence of patient subject

Also Published As

Publication number Publication date
JP2023139180A (en) 2023-10-03

Similar Documents

Publication Publication Date Title
US10937522B2 (en) Systems and methods for analysis and interpretation of nucliec acid sequence data
JP7067896B2 (en) Quality evaluation methods, quality evaluation equipment, programs, and recording media
JP7054133B2 (en) Sequence analysis method, sequence analysis device, reference sequence generation method, reference sequence generator, program, and recording medium
JP6891150B2 (en) Analysis method, information processing device, gene analysis system, program, recording medium
US20200350035A1 (en) Gene analysis method, gene analysis apparatus, management server, gene analysis system, program, and storage medium
JP2023139180A (en) Gene analysis method and gene analyzer
JP2019083011A5 (en)
JP7148681B2 (en) Method for creating report, information processing device, and program
JP6891151B2 (en) Analysis method, information processing device, gene analysis system, program, recording medium
US20210098075A1 (en) Method for managing test request by computer, management device, management computer program, and management system
EP3267347A1 (en) Electronic platform for providing methods for the interpretation of nucleic acid sequences
Hambuch et al. Whole Genome Sequencing in the Clinical Laboratory
Wygant Welcome Guest United States

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18869832

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018869832

Country of ref document: EP

Effective date: 20200527